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Abstract  
 
Introduction 
 
The assessment and management of rectal cancer is complex, involving clinicians 
from several specialities, with a broad and expanding range of therapeutic options. 
As oncological outcomes have improved, the preservation of functioning sphincters 
with avoidance of long-term functional problems, and the negative impact that these 
have on quality of life, is a priority in the management of rectal cancer.  
 
Aims and objectives  
 
This thesis aimed to discover what determines the ability to preserve functioning 
sphincters during the management of low rectal cancer. 
 
Objectives were (1) to systematically review the evidence base for treatment of rectal 
cancer (2) to determine the proportion of patients following anterior resection in the 
UK with low anterior resection syndrome (LARS) and identify risk factors (3) to 
determine ability of measures derived from diffusion-weighted MRI (DWI) to 
predict and assess response to neoadjuvant chemoradiotherapy (CRT) in rectal 
cancer (4) to identify microRNA targets with potential as predictive biomarkers of 
response to CRT and (5) to define altered sphincter function following anterior 
resection and CRT using high-resolution anorectal manometry (HRAM).  
 
Methods 
 
Objective 1: A systematic review of the current literature. Objective 2: A prospective 
epidemiological cohort study using LARS and QLQ-C30 quality of life 
questionnaires. Objective 3: A retrospective cohort study of patients undergoing 
DWI for rectal cancer. Objective 4: A retrospective MicroRNA profiling using pre-
treatment rectal cancer biopsies.  Objective 5:  A prospective cohort study of rectal 
cancer patients undergoing HRAM.  
 
Results  
 
A review of the literature showed that there is data on oncological outcomes 
following sphincter preserving rectal cancer surgery, but data on functional 
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outcomes is limited. 1093 participants completed the LARS questionnaire, 22% had 
minor LARS and 41% major LARS. The risk factors for LARS identified by the study 
were neoadjuvant radiotherapy, defunctioning stoma, female gender and younger 
age. The DWI study included 39 patients and found that use of DWI was feasible and 
that measures derived from DWI show potential as non-invasive biomarkers for 
predicting and assessing response to CRT in rectal cancer. The laboratory study 
confirmed that analysis of microRNA expression from rectal biopsy tissue from 28 
patients was feasible and that, with further study, microRNAs could possibly act as 
predictive biomarkers for response to neoadjuvant therapy. 51 patients underwent 
HRAM, which showed potential for being a tool to help improve assessment and 
understanding of pre and post treatment sphincter function in patients with rectal 
cancer.  
 
Conclusions 
 
Patients undergoing sphincter-preserving surgery for rectal cancer are at risk of 
developing LARS. This has a long-term impact on quality of life. Neoadjuvant 
therapy significantly increases risk of LARS. Imaging and laboratory studies 
confirmed that DWI and microRNA analysis are feasible approaches to the 
identification of potential biomarkers; with further study these could meet the aim of 
individualised therapy and limit use of neoadjuvant therapy to preserve anorectal 
function where possible. The exact pathophysiology behind LARS remains 
unexplained; HRAM can be used as an investigative tool to improve this 
understanding with the aim to preserve function. Multicentre prospective studies 
incorporating all of these methods are required. 
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Chapter 1. Introduction  
 
1.1 Epidemiology  
 
1.1.1 Epidemiology of rectal cancer  
 
Colorectal cancer (CRC) is the fourth most common cancer in the UK behind lung, 
breast and prostate, and is the third most common cancer in both men and women1. 
Incidence is linked strongly to age; with 94% of cases occurring in people aged over 
50 1. Even though incidence is stable, overall 5-year survival rates continue to 
improve, having almost reached 55%. Despite this, CRC remains the second biggest 
cause of cancer deaths in the UK. Rectal cancer makes up around 28% of CRCs, with 
a further 7% at the rectosigmoid junction1; Figure 1.1 shows the distribution of 
cancers throughout the colon. The incidence of rectal cancer is 23 per 100,000 people 
per year in the UK, this translates into over 14,000 new cases of rectal cancer 
annually and incidence of rectal cancer is higher in men, making up over 60% of 
cases1.  
 
Figure 1.1 Percentage distribution of bowel cancer cases in the UK 2010-2012, for 
men and women1. 
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1.1.2 Epidemiology of sphincter preservation 
 
Several developments in recent years have facilitated a move towards sphincter-
preserving surgery for low rectal cancer. These include: an appreciation of the need 
for total mesorectal excision; technological improvements in stapling equipment and 
an improved understanding of pathology, leading to gradual reductions in the 
minimum acceptable distal margin2,3. Despite the resulting fall in rates of 
abdominoperineal excision of the rectum (APER), 20-30% of patients undergoing 
surgery for rectal cancer are still left with a permanent stoma4.  
 
In the 2018 National Bowel Cancer Audit (NBCA) report, 26% of patients undergoing 
a major resection for rectal cancer had an APER with formation of a permanent 
stoma5. Sphincter-preserving procedures were more common with 9% having a 
Hartmann’s procedure and 63% an anterior resection5. However, even a proportion 
of patients undergoing sphincter-preserving surgery may still be left with a stoma. A 
study looking at the reversal rates following Hartmann’s procedure in England has 
shown that for patients who undergo this procedure for cancer, only 8.3% are 
subsequently reversed6. The NBCA report shows that 77% of patients having an 
anterior resection had a temporary ileostomy created5. At 18 months, 28% of those 
having an anterior resection still had a stoma5. This reflects research findings that 
show that up to 25% of these ‘temporary’ stomas are never reversed7. Overall, of 
patients undergoing a major resection for rectal cancer, 52% had a stoma at 18 
months. Rates of stoma at 18-months were highly variable across the UK NHS 
Trusts, ranging from between 42-63%5.  
 
 
1.2 Applied rectal anatomy 
 
The rectum is the most distal part of the colon and is usually 12 to 15cm in length. 
The rectum begins at the rectosigmoid junction where the taenia coli of the colon 
coalesce from 3 distinct bands into a single longitudinal muscle layer8. The rectum is 
mostly extraperitoneal although anteriorly a thin layer of visceral peritoneum covers 
the front and sides of the rectum down to the peritoneal reflection8. Endoscopically, 
the most important landmarks are the rectal valves (the circular valves of Houston), 
these are rectal folds that can be variable in position but roughly divide the rectum 
into upper, middle and lower thirds9 (see Figure 1.2). The rectum dilates slightly 
below the middle fold and this area is known as the rectal ampulla10. Other 
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landmarks that have been used to define the rectum include the level of the sacral 
promontory or the peritoneal reflection but these can be variable11. Rectal length can 
also be variable and is affected by several factors including body size, pelvimetry 
and gender10.  
 
Figure 1.2 Rectal anatomy (adapted from12) 
 
 
 
The distal limit of the rectum can be defined as either the muscular anorectal ring or 
the dentate line13. The dentate line marks an important transition point, partly 
because it is visible but also because it delineates the point at which the blood supply 
and innervation change to those of the anal canal9. The most distal part of the rectum 
lies within the pelvic floor musculature; this section of the rectum, which varies 
considerably in length, has been termed the rectal ‘no man’s land’ and can be 
difficult to resect via an abdominal approach14.  
 
Distal to the rectum, the anal canal extends from the anorectal junction to the anal 
verge. The anal canal also varies in length. The anal sphincter is formed from 2 
muscles, the internal and external anal sphincters. The internal sphincter is made up 
of smooth muscle and is the continuation of the inner circular smooth muscle layer of 
the rectum. The external muscle is skeletal and although it is in a constant state of 
tonic contraction, it is also under voluntary control9.  
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1.3 Definitions used in rectal cancer surgery 
 
1.3.1 Rectal cancer 
 
Rectal cancer can be classified in several different ways, including high vs. low, early 
vs. late and ‘locally advanced’. Due to the variable definitions of the rectum itself, 
there is also variation in what is defined as a rectal cancer. A recent review of 
National and International guidelines on rectal cancer found that four guidelines 
described this as ‘any cancer within 15cm of the anal verge’, and two used ‘12cm 
from the anal verge’ as the limit. However, even the method used to measure this 
distance varied, with six guidelines using rigid proctoscopy and two using tumour 
height on MRI15. A study of 123 surgeons from 28 countries assessed their agreement 
with the different definitions given for the rectum and found that only 50% agreed 
with a definition of ‘15cm from the anal verge’, with others preferring measurement 
from the dentate line16.  
 
1.3.2 Low rectal cancer 
 
As described above, the rectum can be divided into three parts, with the low rectum 
defined as 0-6cm from the anal verge, the mid rectum 7-11cm and the upper rectum 
12-15cm10. This certainly corresponds with the definition of low rectal cancer used by 
LOREC – the Low Rectal Cancer Development programme, which is: “an MRI-based 
anatomical definition where the mesorectum tapers at the origin of the levators, at 
the pelvic sidewall. This usually corresponds to a measurement of within 6 
centimetres of the anal verge”17.  
 
Rullier et al. have proposed a classification of low rectal tumours into 4 groups based 
on the location of the tumour in relation to the anal sphincter (illustrated in Figure 
1.3)18. They advise different treatment strategies for tumours in each group. This 
classification avoids some of the issues with definition outlined above, as by 
referencing the tumour to the sphincter mechanism, problems with variation in anal 
canal length are avoided18. This system has also been shown, by the same authors, to 
be identifiable and reproducible on MRI19.  
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Figure 1.3 The classification of low rectal tumours proposed by Rullier and 
colleagues. AR: anal ring; DL: dentate line; AV: anal verge. The dotted line indicates 
the plane of surgical dissection required18.  
 
 
 
1.3.3 Early rectal cancer 
 
Early rectal cancer has been defined as, “invasive adenocarcinoma, spreading into, 
but not beyond, the submucosa, that is a T1 tumour in the tumour node metastasis 
(TNM) classification”20. However, others have included T2N0 tumours within the 
definition of early rectal cancer21. The issue with using TNM staging within the 
definition is that this information is only available following histological excision and 
is not useful when deciding which tumours may be locally excised. Because of this, 
the European Association for Endoscopic Surgery have recently defined early rectal 
cancer as, “a rectal cancer with good prognostic features that might be safely 
removed preserving the rectum and that will have a very limited risk of relapse after 
local excision”22. 
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1.3.4 Locally advanced rectal cancer 
 
The EURECA-CC2 European Rectal Cancer Consensus Conference defined locally 
advanced tumours as, “neoplasms extending beyond the rectal wall with 
unresectable infiltration to surrounding organs or structures, and/or perforation of 
the visceral peritoneum (T4 N0–2 M0)”23. However, the term is more widely used, 
particularly in a research setting, to include all stage II tumours (T3 or T4) and all 
stage III tumours (node positive), even by authors who participated in the consensus 
conference24. The proportion of tumours referred to as locally advanced is increasing 
and confusion over which tumours are classified by this term hinders discussions on 
treatment25.  
 
 
1.4 Clinical assessment of rectal cancer  
 
1.4.1 Presentation 
 
The most common presenting symptoms of rectal cancer include: rectal bleeding; 
tenesmus; change in bowel habit; weight loss and symptoms of anaemia. The 
majority of patients presenting with rectal cancer are referred by their GP and seen in 
the outpatient clinic within 2 weeks according to NHS guidelines26. 20% of patients 
with CRC present as an emergency and for those undergoing emergency surgery, 
prognosis is much worse than for elective patients5. The NHS Bowel Screening 
Programme was introduced in 2006, screening patients every 2 years from the ages 
of 60-74 using faecal occult blood testing27. Between 2006 and 2010, 5% of patients 
undergoing resection for CRC presented via this route26, this proportion had 
increased to 10% in the most recent NBCA report5. 
 
1.4.2 Diagnosis 
 
The use of digital rectal examination (DRE) depends on the height of the tumour. In 
palpable tumours it can be used to determine fixation of the tumour, sphincter 
involvement, location within the rectum and an accurate assessment of tumour 
height28. It has limited use for the determination of depth of invasion, showing only 
65% agreement with histological assessment29. This study also demonstrated the 
limitations of DRE for assessing rectal cancers as 24% of patients had tumours that 
were too high or found examination too painful. A further study did find that 
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identification of a non-fixed tumour on DRE was a significant predictor of good 
response to neoadjuvant chemoradiotherapy (CRT) 30. Rigid sigmoidoscopy is often 
used in an outpatient setting to confirm the precise location of the tumour within the 
rectum and assess tumour height from the anal verge. This has been shown to 
produce significantly different measurements to those on MRI, which is partly due to 
the straightening of the rectum that occurs during sigmoidoscopy31.  
 
Routine blood tests are usually done to assess general fitness and in preparation for 
treatment. Carcinoembryonic antigen (CEA) is used as a tumour marker in CRC. It is 
detectable in serum and is used during diagnosis, monitoring treatment effect and in 
follow-up. Use of CEA in the detection of CRC is stage-dependent, with CEA > 
2.5ng/ml having a sensitivity of 36% and specificity of 87% for stage I and II cancers, 
a sensitivity of 74% for stage III and 83% for stage IV tumours32. CEA can be raised in 
smokers, in inflammatory conditions and in a range of other cancers; these issues in 
combination with the low sensitivity in early CRC make it an unsuitable test for 
population screening33. A study of 98 patients undergoing neoadjuvant CRT for 
rectal cancer showed that pre-treatment CEA <3.0ng/ml was a significant predictor of 
good pathological response to treatment30.  
 
Colonoscopy allows direct inspection of the mucosal surface of the large bowel and 
is usually the first line investigation for all patients with suspected CRC. The location 
of the tumour can be assessed and biopsies taken to allow histological diagnosis. 
This also allows for identification of any polyps or synchronous lesions in the 
remainder of the colon. In patients who are less fit to undergo this invasive test, they 
may undergo virtual colonoscopy using 3D reconstruction of images taken with CT. 
This has good specificity and sensitivity for polyps and tumours over 1cm in size but 
is less accurate for smaller lesions and does not permit biopsy34.  
 
1.4.3 Staging  
 
The aim of the staging investigations is to determine the location and extent of the 
tumour, along with nodal, vascular or neural infiltration. This allows classification of 
the patient into a low, medium or high risk category, which in turn determines 
which treatment route will be followed35.  
 
Staging of rectal cancer is classified according to the TNM system as described by the 
American Joint Committee on Cancer36. This internationally recognised system 
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allows reproducible and consistent staging. Tumours can also be grouped into stages 
I to IV (as shown in Table 1.1), which predicts prognosis and dictates management 
strategies. Dukes’ staging was traditionally used in the UK prior to the introduction 
of the AJCC system and is occasionally referred to; it fits with AJCC staging as 
shown in Table 1.1 below37. Some variables, which are used in decision-making 
regarding neoadjuvant therapy, and have a bearing on outcomes in rectal cancer, are 
not currently included in the TNM system, most importantly involvement of the 
circumferential resection margin (CRM) and vascular invasion. 
 
Table 1.1 TNM staging of rectal cancer. Taken from AJCC 7th ed36.  
 
Primary Tumour (T) 
T0 No evidence of primary tumour 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades through the muscularis propria into pericolorectal tissues 
T4a Tumor penetrates to the surface of the visceral peritoneum 
T4b Tumor directly invades or is adherent to other organs or structures 
Regional Lymph Nodes (N) 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N2 Metastasis in 4 or more regional lymph nodes 
Distant Metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
Stage Grouping 
 T N M Dukes staging 
Stage I T1 - T2 N0 M0 A 
Stage II T3 - T4b N0 M0 B 
Stage III T1 - T4b  N1 - N2 M0 C 
Stage IV Any T Any N M1 - 
 
 
1.4.4 Staging investigations  
 
Magnetic resonance imaging (MRI) is the gold standard for local staging in rectal 
cancer in the UK and facilitates surgical planning and selection of patients for 
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neoadjuvant therapy. Guidelines for the Management of Cancer of the Colon, 
Rectum and Anus from the Association of Coloproctologists of Great Britain and 
Ireland (ACPGBI) and Guidelines on Colorectal Cancer from the National Institute 
for Health and Care Excellence (NICE) state that all patients with rectal cancer 
should undergo MRI unless there is any contraindication to this38,39. The most recent 
NBCA data shows that 85% of patients with rectal cancer in the UK had an MRI5. For 
tumours ≥T2, MRI is the most useful imaging modality for assessing depth of 
invasion of the primary tumour and determining involvement of the CRM40. It has a 
shorter learning curve than other imaging modalities and findings can easily be 
demonstrated, making it useful for a multi-disciplinary team (MDT) setting28. Data 
from the MERCURY study group have shown the accuracy of MRI in predicting a 
clear CRM to be as high as 91%41. They have also shown that MRI is accurate to 
within ±0.5mm in assessing the distance of extra-mural invasion compared with 
histological analyses41.  
 
MRI staging can be used to accurately predict those who do not need CRT even with 
a T3 tumour. Features on MRI shown to be prognostic of good outcome include: 
cancer <5mm from the muscularis propria (i.e. early T3); CRM >1mm and absence of 
extramural vascular invasion42,43. Using these criteria to determine management, 
patients who underwent surgery without neoadjuvant therapy showed a low 
recurrence rate of 3%42.  
 
MRI is not so sensitive and specific for the assessment of nodal involvement 
although this is a problem that affects all imaging modalities used in rectal cancer 
staging44. A meta-analyses of imaging techniques in rectal cancer found the overall 
sensitivity of MRI to detect metastatic lymph nodes was 66%, with specificity of 
76%45. Lymph node size has been identified as the most reliable parameter to predict 
nodal involvement on MRI46 but there is a lack of consensus about the exact size 
criteria to use, and studies have used various size cut-offs from 3 – 10mm47. There is 
also considerable overlap in size between normal and metastatic nodes48 and some 
studies have found nodal size to be an unreliable indicator of lymph node 
metastases49. Nodal size is certainly not the only determinant of involvement and 
other features, including regularity in the shape of the node and signal intensity, are 
also important50. A study assessing involvement of lymph nodes on MR showed that 
the presence of a spiculated or irregular border showed specificity of 100%, although 
sensitivity was still low at 45 and 36%47. The presence of a mottled heterogeneous 
appearance showed sensitivity of 50% and specificity of 100%47.  
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Standard T2 weighted MRI imaging has some limitations in the restaging of rectal 
cancer following neoadjuvant therapy, it overcalls based on peri-tumoral 
inflammation, ulceration, fibrosis and proctitis47. The restaging of lymph nodes in the 
mesorectum is affected by similar changes47. In the MERCURY study data, the 
accuracy of CRM involvement on restaging MRI scans dropped to 77%50. A meta-
analysis has shown the accuracy of restaging scans for predicting T stage to vary 
from 34 to 82% with an overall value of 52%51. T0 and T1 tumours were frequently 
overstaged51. Overall accuracy for restaging of nodal involvement was higher at 72%, 
ranging from 60 to 88% in individual studies51. A prospective study analysing data 
from 5 large prospective databases showed similar results, demonstrating poor 
accuracy for the prediction of N and T stage as well as inability to predict complete 
pathological response or discriminate T4 disease52.  
 
As a result of these problems in the interpretation of standard MRI images following 
neoadjuvant therapy, a technical evolution is occurring in MRI with the development 
of new modalities including diffusion-weighted MRI, perfusion MRI and lymph-
node specific contrast agents28.  
 
Diffusion weighted imaging (DWI) MRI is a functional imaging technique, which 
utilises the way in which different tissues affect the dynamics of water molecule 
diffusion, to provide detailed information about tumours and peri-tumoral changes 
such as necrosis, fibrosis and inflammation53. Use of DWI is increasing but the 
evidence base is incomplete; potential benefits in terms of predicting clinical 
outcomes and determining response to neoadjuvant therapy are not yet fully 
established53. 
 
Endo-rectal ultrasound (ERUS) is more commonly used in the staging of rectal 
cancer in the USA and Europe, but less so in the UK. It is more accurate for early 
stages of rectal cancer, specifically the diagnosis of T1 and T2 lesions. A meta-
analysis has shown ERUS to have sensitivity of 90% for assessing perirectal tissue 
involvement, significantly higher than that of MRI at 82%45. ERUS has some benefits; 
it can be used in an outpatient setting by a variety of health professionals to provide 
rapid information about a tumour. However, drawbacks include that it is user 
dependent with inter-observer variation of up to 15%54 and has a longer learning 
curve than other modalities55. ERUS has poorer sensitivity and specificity for nodal 
assessment than for T stage, with a sensitivity of 67% and specificity of 78% on meta-
analyses, comparable to results for MRI45. However, ERUS is unable to define the 
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involvement of the CRM and since that plays a major role in pre-operative planning, 
it is often used alongside MRI.  
 
For restaging, ERUS shows highly variable accuracy for T stage assessment, ranging 
from 26 to 93% with an overall value of 65%51. Inaccuracy can arise due to difficulty 
differentiating tumour from desmoplastic reactions and peri-tumoral fibrosis28. 
Showing a similar pattern to MRI, overall accuracy for restaging of nodal 
involvement was higher than for T stage, at 73%51.   
 
Contrast-enhanced CT of the chest, abdomen and pelvis is currently used in the UK 
to assess distant nodal and metastatic disease. Thoracic CT is of increased 
importance in the staging of rectal cancer as rectal tumours spreads preferentially to 
the lungs not the liver due to the rectal blood supply bypassing the portal system35. 
Retrospective studies have confirmed this increased risk of lung metastases, showing 
a frequency of 9 to 18% in patients with rectal cancer56,57. CT has limited accuracy for 
local staging and the potential for replacing this modality with early whole body 
MRI, which would incorporate local and distant staging, is currently being 
investigated58. Repeat CT scanning is usually carried out as part of restaging, 
following neoadjuvant therapy and prior to surgery, although there are no 
guidelines on this. A small study assessing whether this interval CT made any 
difference found that a change in treatment strategy due to new findings on CT 
occurred in 12% of patients59.  
 
Positron emission tomography (PET) CT scanning is primarily used in the 
assessment of distal nodal involvement and metastatic disease rather than in primary 
staging. It cannot provide detailed anatomical information and is limited to 
identifying lesions over 5mm60. It therefore has limited use in assessing T stage. It 
also has a low sensitivity for detecting nodal involvement, again because many 
affected nodes will be smaller than 5mm and also because the effect of the primary 
lesion masks nearby nodes60. Despite this, a number of studies have shown that 
including PET-CT in the protocol for the staging of rectal cancer leads to upstaging 
or downstaging and a subsequent change of management in up to 38% of patients61-
63. 
 
PET-CT has also been investigated for the assessment of response to neo-adjuvant 
therapy and ability to predict complete pathological response to therapy. A recent 
meta-analysis showed good accuracy for assessment of response with pooled 
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sensitivity of 73% and specificity of 77%64. Individual studies have shown even 
greater accuracy when data is combined from PET-CT scans before, during and after 
neoadjuvant treatment65. Results from a prospective trial of observation following 
complete clinical response to neoadjuvant therapy show that PET-CT findings 
compared with clinical and pathological findings resulted in a sensitivity of 93% and 
specificity of 53% to predict complete response66. The advantages and disadvantages 
of ERUS, MRI and PET-CT are summarised in Table 1.2.  
 
Table 1.2 Advantages and disadvantages of different imaging techniques for 
staging and restaging of rectal cancer ERUS: Endo-rectal ultrasound; MRI: magnetic 
resonance imaging; PET-CT: Positron emission tomography-computed tomography; 
CRM: circumferential resection margin (adapted from28). 
 
 Staging Restaging 
 Pros Cons Pros Cons 
ERUS High accuracy 
and specificity for 
early rectal cancer 
Poor N staging 
Operator 
dependent  
Learning curve 
High accuracy 
for persistent 
nodal 
involvement  
Low accuracy 
for T restaging 
MRI CRM evaluation 
High accuracy in 
advanced 
tumours 
Best tool for 
selecting patients 
for neoadjuvant 
therapy 
Low accuracy for 
lymph node 
involvement 
Good prediction 
of CRM 
involvement 
Poor accuracy 
in predicting 
T0 and N0 
PET-
CT 
Confirmation of 
M and N at 
distant sites 
Low accuracy for 
T staging 
Detection of 
progression at 
distant sites 
Lack of 
standardisation 
in assessing 
response 
 
 
 
1.5 Multi-disciplinary team approach to rectal cancer management  
 
The NICE and ACPGBI Guidelines38,39 advise that all patients with CRC should be 
discussed at an MDT. This process was introduced following two reports, the 
Calman Hine report67 and Guidance on Commissioning Cancer Services68. These two 
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documents led to significant changes in delivery of care, from an individual 
approach, to a multi-disciplinary team (MDT) based approach. The ACPGBI 
guidelines also specify the core members of an MDT; these recommendations are 
shown in Box 1.138. The guidelines also recommend that the core MDT team should 
have regular liaison with surgeons from a liver MDT and thoracic MDT as required38.  
 
Box 1.1 Core members of the multi-disciplinary team from the ACPGBI 
Guidelines for the Management of Cancer of the Colon, Rectum and Anus. MDT: 
multi-disciplinary team38. 
 
MDT data in the UK is intrinsically linked to data provided for the National Bowel 
Cancer Audit. It is mandatory for all patients to be included in both processes and 
the Audit therefore works to ensure all patients are discussed at MDT69. 
Unfortunately it is not possible from the data to determine what proportion of 
patients are left out of the MDT/NBCA data but it is likely to be a low percentage.  
 
Core members of the MDT team: 
• Specialist surgeons (at least 2) 
• Clinical oncologist 
• Medical oncologist 
• Diagnostic radiologist with gastrointestinal expertise 
• Histopathologist 
• Colonoscopist (surgeon, physician or specialist nurse) 
• Clinical nurse specialist (CNS) 
• Clinical trials co-ordinator or research nurse 
• Palliative care specialist (doctor or nurse) 
• MDT co-ordinator 
• Administrative support (including data manager) 
 
The extended MDT members should include: 
• Gastroenterologist 
• Liver surgeon 
• Thoracic surgeon 
• Interventional radiologist 
• Dietician 
• Liaison psychiatrist/clinical psychologist 
• Social worker 
• Clinical geneticist 
• Specialist screening practitioner (SSP) 
• Clinician with expertise in colonic stenting 
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Patients with rectal cancer tend to be discussed at two or three distinct time points. 
Firstly, at the time of diagnosis, to discuss histopathology information from biopsies, 
review staging investigations and consider patient variables as outlined above. At 
this point a team decision would be made about the requirement for neoadjuvant 
therapy and which regime should be used. If the plan is for the patient to have 
surgery only, then the patient may only be discussed twice. Similarly if they undergo 
neoadjuvant SCRT with a five-day course followed by immediate surgery, then they 
would only be discussed twice. However, those that undergo neoadjuvant 
chemoradiotherapy usually have restaging investigations following this treatment. 
 
This allows the response to therapy to be assessed and determines whether there has 
been any systemic spread of disease in the interim since previous imaging. Their case 
is then re-discussed prior to planning surgery if indicated. Following surgery all 
cases are discussed again to review histopathology results and decide whether 
adjuvant therapy is required. During the follow-up period should there be any need 
for further discussion, for example to review imaging or decide on the best 
management for metastatic disease or local recurrence, then the case would be 
discussed again. For patients who have a clinical complete response to neoadjuvant 
therapy and decide against operative intervention, instead following a watch and 
wait policy, their imaging and clinical evaluation results may be discussed multiple 
times during the course of their follow-up. Figure 1.4 shows these possible time 
points of discussion in diagrammatic form.  
 
The multiple modalities and treatment approaches available for patients with rectal 
cancer have made decision making increasingly complex for the healthcare 
professionals involved in the care of these patients70. The improvements seen in 
survival in recent years have only been possible through an MDT approach to 
treating rectal cancer28.  
 
There are both benefits and drawbacks of the MDT process. Despite the widespread 
implementation of MDT discussions for all cancers, including rectal cancer, there is a 
lack of evidence for benefit in terms of patient outcomes. The widespread adoption 
of the system and the corresponding change in mindset of the professionals involved 
means it would now be impossible to conduct a randomised trial to assess the 
benefits of MDT discussion71. Discussing patients at MDT has been shown to increase 
the length of time to treatment72; it also has a considerable cost in terms of the 
protected time required from all of the professionals who participate.  
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Although there have not been any trials conducted, a team in the UK who conducted 
a retrospective audit, have shown that MDT discussion, based on MRI with 
implementation of neoadjuvant therapy, reduced CRM positivity rates compared to 
patients from the preceding two years who had not been discussed at MDT73. 
Another similar audit has shown an increase in the proportion of patients 
undergoing adjuvant therapy74. A further study analysed data from the Swedish 
Rectal Cancer Registry to show that those patients with stage II or III cancer who 
were discussed at MDT were significantly more likely to undergo neoadjuvant 
radiotherapy even when results were corrected for comorbidity and age75. Other 
suggested benefits of the MDT system include76,77: 
• Patients who are discussed at MDT are more likely to be involved in a clinical 
trial 
• Improved communication and collaboration between the professionals 
involved  
• The MDT provides an educational opportunity for trainees and for the 
professionals involved 
• It provides support from colleagues 
• Improves consistency of management across and between teams with the aim 
of improving outcomes 
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Figure 1.4 Diagram illustrating time points at which patients undergoing surgery for rectal cancer may be discussed at MDT meeting. 
MDT: multi-disciplinary team; SCRT: Short course radiotherapy; LCRT: Long course chemoradiotherapy. 
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1.6 Surgical approaches to sphincter preservation 
 
Rectal cancer surgery is technically challenging for a number of reasons. The position 
of the rectum, low down within the pelvis, leads to inherent problems with difficult 
access. The necessary plane of dissection runs very close to autonomic nerves. Poor 
visualisation and inadequate control of the distal segment at the time of anastomosis 
can be a particular problem. Partly because of these reasons, local recurrence rates 
following rectal cancer surgery are much higher than those for colon cancer. Also 
because of these problems, the rate of surgical innovation, with the development of 
new equipment and new approaches is also increased in rectal cancer.  
 
1.6.1 History of sphincter-preserving surgery 
 
Traditionally, excision of the rectum and anus en bloc, via an APER was the historical 
gold standard operation for rectal cancer as described by Ernest Miles in 1908 78. His 
proposals were based on a combination of anatomical and biological principles, with 
a surgical technique based on an understanding of the lymphatic spread of cancer2. 
In 1910, the American surgeon Donald Balfour described the first ‘anterior resection’ 
with anastomosis between the colon and rectum79. This technique initially showed 
high mortality rates due to frequent anastomotic leaks80. In 1948, Claude Dixon of the 
Mayo Clinic established the safety of sphincter preservation via anterior resection by 
publishing his series showing a mortality rate of 2.6% and overall 5-year survival of 
64%81. Despite this, APER remained the most frequently carried out operation for 
rectal cancer. Sir Alan Parks established a further development in 1972 with his 
description of a pull-through technique and hand-sewn coloanal anastomosis, 
facilitating sphincter preservation even for low rectal cancers82. Surgical techniques 
evolved further with the development of circular stapling equipment in the 1970s80. 
These staplers were designed to get low down into the pelvis to facilitate a low 
anastomosis.  
 
From the first descriptions of anterior resection until the 1970s, the blunt pelvic 
dissection used resulted in high local recurrence rates of 30-40%; this in turn led to 
poor overall survival83. In 1982, Professor Bill Heald published the first description of 
rectal resection with a total mesorectal excision (TME)84. The description of this 
approach led to a marked change in rectal cancer surgery outcomes and has been 
universally adopted as the gold standard method for resection. A TME approach 
utilises sharp dissection through embryological avascular plane between the visceral 
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and parietal pelvic fascia, using anatomical principles, with resection of the 
mesorectum and the lymph nodes contained within it84. The rectum is then removed 
en bloc alongside the blood supply and lymphovascular drainage84. Dissection 
outside of this plane may lead to autonomic nerve injury with resulting bladder and 
sexual dysfunction resulting from damage to the superior hypogastric plexus & 
bilateral hypogastric nerves, which join the sacral parasympathetic complex85.  
 
TME is used for the mid and lower rectum, for tumours in the upper rectum it is 
acceptable to resect 5cm of mesorectum distally84. For upper rectal tumours a TME 
would create a lower than necessary anastomosis with a subsequent negative effect 
on functional outcome. TME dramatically reduced the rates of local recurrence to 
less than 10%86. As a consequence of this, 5-year survival also improved, for example 
Heald et al. were able to achieve 80% 5-year survival86. TME has also been shown to 
reduce post-operative bladder and sexual dysfunction87.  
 
Until the 1980s it was believed that a 5cm distal margin was required when carrying 
out a resection for rectal cancer. This was initially based on Miles’ belief that rectal 
cancer spreads distally via the lymphatic supply2. In the early 1980s it was 
established that Miles had overestimated the distal spread of rectal cancer and that a 
distal margin of 2cm was sufficient88,89. Williams et al. demonstrated that distal 
spread >1cm occurred in a low proportion of rectal cancers and was associated with 
poor outcome despite surgery88. Subsequent studies demonstrated that for distal 
tumours an even smaller distal margin of 1cm was sufficient90 and more recent 
results have suggested than even this margin may be greater than required91,92. In 
1986, the importance of circumferential resection margin (CRM) positivity in 
predicting local recurrence and poor survival was first described93. This has now 
replaced distal margin as the more important predictor of outcome in rectal cancer 
surgery. In a meta-analysis of clinico-pathological predictors of local recurrence, 
CRM was shown to be the strongest predictive factor94. These developments have all 
facilitated increased rates of sphincter preservation.  
 
There has been debate in recent years about whether oncological outcomes following 
APER are inherently worse than those following anterior resection95. This resulted 
from high rates of CRM involvement and local recurrence in some published 
series96,97. A number of explanations have been proposed to explain these findings. 
Tumours that require an APER were more likely to be distal in the rectum, locally 
advanced, poorly differentiated, and have poor response to neoadjuvant therapy98. 
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Other commentators have suggested that surgical technique may be responsible; as 
the mesorectum narrows at the level of the pelvic floor, it is possible that inadequate 
circumferential clearance occurs with so-called ‘waisting’ of the specimen95. With 
meticulous technique for APER, avoiding CRM positivity and tumour perforation, 
equivalent oncological outcomes to those for anterior resection have been 
demonstrated by some studies, with local recurrence rates around 5%99-101. There 
have also been recent moves to amend technique for APER back to the original 
described principles, with increasing use of extralevator APE (ELAPE)102.  
 
A number of options are available for configuration of anastomoses following an 
anterior resection (Figure 1.5). These have been investigated predominantly to try 
and reduce the impact of rectal resection on post-operative function. This is 
discussed later in the chapter. The most important criteria for any anastomosis are a 
lack of tension and ensuring adequate vascular supply to the created join.  
 
Morbidity is frequently experienced following TME, with major trials reporting up to 
45% of patients undergoing complications103. Anastomotic leak following anterior 
resection remains one of the most serious causes of morbidity and mortality104, 
leading to post-operative death from sepsis, reoperation, stoma, prolonged hospital 
stay and poor quality of life104. A further negative outcome from anastomotic leak is 
that it delays the use of adjuvant therapy. Reported rates vary widely, partly due to 
inconsistent definition but large prospective databases show the overall rate to be 
around 10%105,106. The main risk factor for anastomotic leak is height of the 
anastomosis from the anal verge, with anastomoses <7cm at highest risk107. Other risk 
factors include neoadjuvant therapy, male gender and smoking106. 
 
A defunctioning stoma, which may be a transverse colostomy but is more usually a 
loop ileostomy, is often created to protect against the negative clinical sequelae of an 
anastomotic leak. A number of meta-analyses of studies randomising patients to 
undergo defunctioning stoma have shown that a temporary stoma reduces the 
clinical consequences of anastomotic leakage and reduces the risk of reoperation, 
although it does not appear to reduce mortality109-112. Whether the benefit of a 
defunctioning stoma remains in an era of enhanced recovery from surgery has been 
questioned113. Rates of defunctioning are highly variable between countries and 
centres. As discussed above, audit data and retrospective studies have demonstrated 
that up to 25% of temporary stomas are not reversed7. Delay of closure beyond 6 
months has been shown to increase the complications resulting from closure114 but 
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the effect that delayed closure may have on post-operative bowel function is 
unknown.   
 
Figure 1.5 Options for anastomotic configuration following anterior resection: A) 
Straight coloanal anastomosis; B) Colopouch-rectal anastomosis and C) Coloplasty-
anal anastomosis108.  
 
 
 
Concern about anastomotic complications and poor post-operative function, may 
lead surgeons to carry out a Hartmann’s procedure for rectal cancer. Although these 
stomas are labelled as temporary, many of them are created with no intention to 
reverse them. There is considerable morbidity related to reversal of a Hartmann’s 
procedure and less than 10% of Hartmann’s procedures carried out for cancer in 
England are reversed6.   
 
1.6.2 Laparoscopic surgery 
 
Over the last 20 years, laparoscopic resection has been widely adopted for the 
resection of colorectal tumours. A number of randomised trials have examined the 
role of laparoscopic surgery in the resection of rectal cancer and have shown 
conflicting results regarding the effect on pathological and oncological outcomes. 
The UK Medical Research Council trial was one of the first studies of conventional 
versus laparoscopic assisted surgery in colorectal cancer115. It showed a conversion 
rate of 34%, comparable morbidity and mortality, and no difference in recurrence 
rates or survival115. In the initial results there were concerns raised over the rates of 
CRM positivity in the laparoscopic anterior resection group, 12% vs. 6% in the open 
group115. However long-term results continue to show equivalent oncological 
outcomes in terms of comparable overall and disease free survival116.  
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The more recently reported European COLOR II randomised trial of laparoscopic vs. 
open surgery for rectal cancer included 1044 patients and showed similar results, 
with comparable morbidity, mortality, recurrence rates and 3-year survival117; the 
conversion rate was lower at 16%. Following this, a Cochrane review of laparoscopic 
versus open total mesorectal excision for rectal cancer concluded that there was 
moderate evidence that laparoscopic and open surgery have similar long term 
survival outcomes, and that laparoscopic surgery may have benefits for short-term 
recovery118.  
 
The ALaCaRT randomised clinical trial studied the effect of laparoscopic-assisted 
resection versus open resection on pathological outcomes in rectal cancer119. This 
multicentre study was carried out in Australia and New Zealand and included 475 
patients. A composite end point of adequate surgical resection was used and this was 
defined as (1) complete total mesorectal excision, (2) a clear circumferential margin 
(<1 mm), and (3) a clear distal resection margin (<1 mm). The study failed to establish 
the non-inferiority of laparoscopic resection. The CRM negative rate was 93% in the 
laparoscopic group vs. 97% in the open group and complete TME rate was 87% in 
the laparoscopic group vs. 92% in the open group119. The conversion rate from 
laparoscopic to open surgery was 9%. Recently published results show no difference 
in 2-year local recurrence, overall survival or disease free survival between the open 
and laparoscopic groups120.  
 
The ACOSOG Z6051 trial was a study of 486 patients from the USA and Canada with 
a similar design to ALaCaRT, looking again at pathological outcomes in rectal cancer 
following open or laparoscopic resection121. It used a similar composite end-point 
including the same three criteria as ALaCaRT and also failed to establish non-
inferiority of the laparoscopic approach121. Successful resection occurred in 81.7% of 
laparoscopic cases and 86.9% of open cases121. The 2-year local recurrence and 
disease free survival rates for the Z6051 trial have also been recently published, and 
similarly show no difference between the laparoscopic and open resection groups122. 
  
Authors from both the ALaCaRT and Z6051 studies advised that the results do not 
support routine use of laparoscopic resection for all patients119,121, although neither 
study was powered to demonstrate the superiority of either an open or laparoscopic 
approach, and both show similar mid-term oncological outcomes for laparoscopic 
and open surgery120,122. The validity of the composite endpoint used in these studies 
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has also been questioned, and suggested as a possible reason for the conflicting 
results when compared with the COLOR II trial123.  
 
As is the practice during many of their surgical approaches, surgeons in Japan 
practise extended lymphadenectomy during TME surgery, carrying out en bloc 
excision of lateral pelvic lymph nodes as their standard approach124. The incidence of 
metastasis in these lateral pelvic nodes has been shown to be around 15%125 and has 
been linked to increased rates of local recurrence126. Retrospective studies have not 
shown any survival benefit from routinely carrying out lateral nodal dissection125, 
although comparisons with Western surgical results and recurrence rates are 
hindered by differing anatomical definitions127. A large multicentre randomised trial 
of TME vs. TME with lateral lymph node dissection showed no significant difference 
in 5-year recurrence-free survival but significantly higher local recurrence with TME 
alone128. Although it may therefore seem that lateral dissection may provide benefit, 
the results of this study are not necessarily applicable to the UK population as none 
of the patients received neoadjuvant therapy129.  
 
1.6.3 Robotic-assisted laparoscopic surgery  
 
Robotic-assisted laparoscopic surgery was first developed in the 1990s and was 
initially used by urological surgeons for prostatectomy130. The more advanced 
robotic surgical platforms that are used currently have been designed for multi-
quadrant surgery and offer theoretical advantages for pelvic surgery including the 
use of a 3-dimensional view of the operative field, finer dissection with the freely 
articulating EndoWristTM equipment, intuitive instrument handling and precise 
movements aided by tremor filtration130. This improved visualisation and precision 
in dissection could theoretically facilitate improved preservation of autonomic 
nerves in the pelvis during TME, and could possibly lead to a higher rate of 
sphincter preservation and improved functional outcomes130. Studies assessing 
functional outcomes following robotic surgery have so far used non-randomised 
approaches and only have a very small number of patients included130. The largest 
randomised study of robotic surgery for rectal cancer, the ROLARR trial, did not 
show any short-term benefit for robotic-assisted surgery131. However, the primary 
end point of the ROLARR study was conversion rate to open surgery and longer-
term oncological and functional outcomes are not yet reported.  
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1.6.4 Sphincter preserving techniques  
 
Recent developments mean that a range of surgical options is now available for 
sphincter preservation.  
 
In selected cases of rectal cancer, local excision may be considered as an alternative to 
radical resection. There are several different techniques used for local excision, of 
which the most frequently studied is transanal endoscopic microsurgery (TEM)132. 
This technique was initially pioneered by Gerhard Buess who first described the 
technique in 1983 133 and was further investigated in patients who were considered 
unfit to withstand the morbidity and mortality associated with a major resection132. 
Local excision has subsequently been investigated in early tumours and the most 
difficult aspect of this surgery remains selecting appropriate patients132,134. The 
principle of local excision involves excision of the rectal tumour with a full-thickness 
excision of the rectal wall but no removal of local nodes28. Recurrence rates were 
initially very high and have remained the major concern about the adoption of this 
technique135. The majority of T1 and T2 tumours will be node negative but the 
assessment of nodal involvement is not completely accurate, as has been covered 
above. A subset of the patients who undergo TEM will, therefore, have positive 
nodes left behind, leading to the increased rates of local recurrence seen in these 
patients136.   
 
A meta-analysis of outcomes following TEM in patients with T1 tumours showed 
that TEM was safer than undergoing a major resection, with 0% mortality, lower 
morbidity and shorter hospital stay137. Local recurrence following TEM was 
significantly higher than that following radical resection but there was no difference 
in survival at five years137. For T2N0 tumours, the use of local excision is more 
controversial. A recent study showed local recurrence rates of 29% in local R0 
excision of low-risk T2 tumours138. A pooled analysis has shown increasing risk of 
recurrence with increasing T stage, with recurrence rates of 0% for T0, 2% for T1 and 
between 6 and 20% for T2 tumours139. Risk factors for recurrence have been analysed 
and include depth of invasion, tumour diameter, lymphovascular invasion and poor 
differentiation140.  
 
A further recent meta-analysis has shown, however, that in patients undergoing 
neoadjuvant chemoradiotherapy, the local recurrence rates, disease free and overall 
survival were equivalent between those undergoing CRT and local excision and 
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those having CRT followed by radical resection141. The most frequent complications 
following TEMs are suture line dehiscence, bleeding and urinary retention136. 
Inadvertent entry into the peritoneal cavity occurs in 5.8% of cases142. Patients 
undergoing neoadjuvant CRT followed by local excision are more likely to develop 
wound related complications including dehiscence143.  
 
A number of clinical trials have investigated the role of local excision. The American 
College of Surgeons Oncology Group (ACOSOG) Z6041 study was a single-arm 
study to assess the safety of local excision for T2N0M0 tumours144. There was a high 
rate of complete pathological response (44%) and high rates of negative resection 
margins144. Also, the rate of complications during CRT and following local excision 
was higher than anticipated at 39%; long-term oncological outcomes are awaited144. 
The recently published Chemoradiation therapy for rectal cancer in the distal rectum 
followed by organ-sparing transanal endoscopic microsurgery (CARTS) study was a 
non-randomised study including patients with T1-T3/N0 tumours145. A flow chart 
from this complex study is shown in Figure 1.6. The results of the study showed that, 
in half of the patients with rectal cancer, following this protocol enabled them to 
achieve organ preservation. Toxicity to therapies was again a major issue: 42% of 
patients experienced toxicity to chemoradiotherapy and 28% had complications from 
surgery post TEM145.  
 
The GRECCAR 2 study randomised T2-T3/N0 patients with a good response to 
neoadjuvant chemoradiotherapy to local excision vs. TME146. The results of the study 
showed no significant difference in survival, local recurrence or morbidity between 
the two groups. However, 35% of the local excision group underwent a completion 
anterior resection and the investigators acknowledged that this made the results 
difficult to interpret146. 
 
Ongoing studies, the results of which will further inform the debate surrounding the 
use of local excision, include: 
• TEM and Radiotherapy in Early Rectal Cancer (TREC)147: a randomised trial 
of TME vs. neoadjuvant short course radiotherapy followed by delayed local 
excision at 8 to 10 weeks, for T1/T2N0 tumours. 
• The study groups from TREC and CARTS have now combined their 
protocols to undertake a trial that randomises patients between 3 arms. The 
STAR-TREC will randomise to: standard TME; short course radiotherapy 
with TEM; and long course chemoradiotherapy with TEM142. 
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Figure 1.6 Protocol from the CARTS study (Chemoradiation therapy for rectal 
cancer in the distal rectum followed by organ-sparing transanal endoscopic 
microsurgery)145. CRT: chemoradiotherapy; TEM: transanal endoscopic 
microsurgery.  
 
 
 
The use of the anterior perineal plane to resect the distal rectum was initially 
described by Cuneo in 1908 and published in a French surgical textbook in 1926 148 as 
quoted in a paper from France in 1988 149. The French surgeons went on to utilise the 
procedure themselves, publishing a large case series149. It is unclear why there was 
no further uptake of the procedure following this report. Use of the anterior perineal 
approach to perform a rectal anastomosis has been reported intermittently since 
then150.  
 
Intersphincteric dissection to facilitate removal of low rectal tumours is a procedure 
that developed from methods used in surgery for inflammatory bowel disease151,152. 
The procedure involves a transanal approach with dissection into the 
intersphincteric plane (see Figure 1.7) and either partial or total excision of the 
internal anal sphincter usually followed by a hand-sewn anastomosis151. Rullier et al. 
have used this procedure for type II juxta-anal and type III intra-anal lesions in the 
classification, which they proposed (shown in Figure 1.3) and have demonstrated 
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that with use of this procedure, it is possible to avoid a permanent colostomy for the 
majority of patients with low rectal cancer153.  
 
Systematic reviews show outcomes comparable to those of other techniques for low 
rectal cancer with low operative mortality of 0.8 to 1.6%, rates of anastomotic leakage 
of 10.5%, local recurrence of 6.7 to 9.5% and 5-year survival rates of up to 86%151,154. 
There have been concerns about the effect that this procedure is likely to have on 
functional outcomes and proponents agree that patients need to have good pre-
operative function and be motivated to deal with ensuing continence issues151. 
Meaningful comparisons between the functional results of sphincter-preserving 
procedures have been hindered by a lack of validated outcome measures155. 
Bretagnol et al. compared functional outcomes with those following a hand-sewn 
coloanal anastomosis (which would be the only feasible sphincter-preserving 
alternative for many of the patients undergoing this surgery)156. The results showed 
higher rates of faecal incontinence following intersphincteric resection with some 
effect on quality of life; there was no difference in other measures including stool 
frequency and urgency156.  
 
Figure 1.7 Plane of dissection (indicated by dotted line) for intersphincteric 
resection with subtotal excision of the internal anal sphincter157.  
 
 
 
Transanal TME (sometimes known as transanal minimally invasive surgery – 
TAMIS) evolved from a combination of technologies including transanal endoscopic 
microsurgery (TEM); endoscopic mucosal resection (EMR); single incision 
laparoscopic surgery (SILS) and natural orifice transluminal endoscopic surgery 
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(NOTES)158. This approach to resection can be used with a transanal approach only 
or as a combined approach with initial transanal dissection followed by a standard 
abdominal approach which is then extended distally to join up the resection159. The 
transanal approach is used predominantly for tumours within 5cm of the dentate 
line and starts with the definition of a tumour-free distal margin159. It is believed to 
best suit patients in whom an abdominal approach alone would be very difficult and 
would limit the ability to carry out a sphincter-preserving resection; these include 
male patients, obese patients and those with a narrow pelvis159. With the 
development of equipment designed for this procedure, early problems with port 
dislodgement, maintenance of a pneumoperitoneum and achieving adequate 
exposure are gradually being resolved.  
 
The first report from the International transanal TME registry reported on 720 cases 
and shows results equivalent to those for standard TME in terms of operative time, 
complete resection and good macroscopic quality of the TME specimen as well as 
short-term morbidity and mortality160. 32% of cases in this series used two teams 
operating simultaneously from transanal and abdominal approaches; the abdominal 
part of the TME was conducted laparoscopically for 82% of cases160. Long-term 
oncological and functional results following this procedure are not yet reported; the 
International registry aims to report initial findings at three years. There is also an 
ongoing randomised trial of laparoscopic vs. transanal TME for mid/low rectal 
cancer, the COLOR III trial, which should provide further data on outcomes161.  
 
Proponents of perineal approaches believe that these techniques will be widely 
adopted and are the next major development to advance the practice of rectal cancer 
surgery162. A randomised trial of abdominal vs. perineal approach for distal rectal 
dissection in 100 patients with low rectal cancer was carried out with a primary 
endpoint of surgical quality, and showed significantly lower rates of CRM positivity 
in the perineal group (4 vs. 18%), with no difference in morbidity163. Critics feel the 
studies that have been carried out so far have been done on patients with early 
favourable tumours, that many complications are unreported, and that case selection 
bias is an issue in the majority of publications of this method. There is undoubtedly a 
steep learning curve, during which care must be taken to avoid complications164. It is 
likely that the rectal cancer surgeon needs to be aware of all these available 
approaches and techniques which could be used in difficult cases to help minimise 
the poor outcomes associated with an involved CRM.  
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1.7 Tumour biology, patient factors and molecular biomarkers 
 
1.7.1 Tumour biology 
Over 95% of tumours that arise in the colon and rectum are adenocarcinomas165. A 
proportion of carcinomas are sub-classified as either mucinous adenocarcinoma, 
where over 50% of the tumour volume is composed of extracellular mucin or signet-
ring cell carcinomas, defined by the presence of > 50% of tumour cells with 
prominent intracytoplasmic mucin166. Early histological analysis allows confirmation 
of the diagnosis of adenocarcinoma and rules out other rarer tumour types, which 
include squamous cell carcinomas, adenosquamous carcinomas, neuroendocrine 
carcinomas, sarcomas, lymphomas, carcinoid tumours, melanomas and 
gastrointestinal stromal tumours165,166.  
CRC arises via a sequence from adenoma through to carcinoma due to genetic and 
epigenetic alterations in cell growth, differentiation, proliferation and apoptosis167. 
This process is partly controlled by the action of oncogenes and tumour suppressor 
genes167. Mutations in the adenomatous polyposis coli (APC) gene are an early step 
and have been demonstrated in over 70% of sporadic CRCs168.   
Sporadic CRC progresses by two different pathways of genomic destabilisation: 
chromosomal instability (CIN) and microsatellite instability (MSI)169. MSI results 
from defects in the DNA mismatch genes leading to the accumulation of insertion 
and deletion errors in microsatellite repeat sequences170. This abnormality is found in 
about 15% of sporadic CRCs and a much higher proportion of hereditary cases170. 
These tumours are more often located in the proximal colon, are more often 
mucinous, are less frequently associated with metastases and have a better 
prognosis171-174. CIN cancers make up around 45% of CRCs and are defined by 
chromosomal abnormalities175. The remaining 30-40% of sporadic cancers have been 
classified as microsatellite and chromosome stable (MACS)176.  
 
Genetic susceptibility to CRC due to hereditary factors is believed to account for 
around 5 to 15% of cases177. These hereditary factors, affecting relatives of those with 
CRC are mainly composed of polymorphisms with combinations of gene variations 
resulting in increased risk178. Mendelian familial syndromes involving an identified 
single gene defect make up around 2 to 6% of CRC cases and therefore affect a 
minority of patients179. These syndromes are usually divided into polyposis and non-
polyposis syndromes. Polyposis syndromes include familial adenomatous polyposis 
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(FAP) with mutation of the APC gene; MYH-associated polyposis (MAP) with 
mutation of the MYH gene; and Peutz–Jeghers syndrome with mutations of the 
STK11 gene179. Hereditary non-polyposis colon cancer (HNPCC), now called Lynch 
Syndrome (LS) is an autosomal dominant syndrome resulting in early CRCs. LS is 
caused by defective DNA mismatch repair genes, MLH1, MSH2, PMS2 and MSH6, 
and CRCs arising as a result of HNPCC are characterised by MSI179.  
 
Chronic inflammatory bowel problems, ulcerative colitis (UC) and Crohn’s disease 
also increase the risk of CRC180. Longstanding inflammatory changes lead to 
dysplasia, which in turn leads to carcinogenesis180. For UC, the risk of CRC is 2.4x 
that of the normal population, with male patients and those diagnosed at a young 
age, as well as individuals with extensive colitis, having the highest risk181.  
 
1.7.2 Pathological factors affecting outcome 
 
Several histopathological tumour characteristics have been shown to have an 
important bearing on outcome in rectal cancer. Grading of rectal cancer is based on 
the predominant degree of differentiation in the primary tumour and has been 
shown to affect recurrence rates and survival182,183. A number of studies have 
investigated the possible effect of tumour location circumferentially within the 
rectum184,185, these have shown conflicting results and this lack of effect has been 
confirmed by further research186. However, tumour height within the rectum has 
consistently been shown to affect outcome with increased recurrence rates and 
poorer survival for lower rectal tumours187,188.  
 
Lymph node involvement has an impact on recurrence and survival in rectal cancer, 
therefore justifying its inclusion in the staging classification187,188. However, the 
number of lymph nodes resected in patients undergoing surgery also has prognostic 
significance189, mainly because this number acts as a surrogate marker of surgical and 
pathological excellence189.  The ACPGBI guidelines for CRC indicate that resection 
specimens should include at least 12 nodes38 although it is widely accepted that 
neoadjuvant therapy reduces the lymph node yield190. According to the principles of 
TME surgery, if the nodes are taken along with the rectum en bloc then involvement 
of lymph nodes should not have such prognostic significance and other factors, 
particularly involvement of the CRM, should have greater significance191. For these 
reasons guidelines advise that the quality of the TME specimen should be included 
in pathology reporting and this data is included in reporting proformas38. The CR07 
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trial of pre-operative short course radiotherapy vs. post-operative long course 
chemo-radiotherapy showed that the quality of the TME specimen has a bearing on 
recurrence. In patients with an involved CRM and a poor quality specimen, 
recurrence was 12%, falling to 4% in those with a mesorectal plane of dissection192.  
 
The presence of extramural venous invasion (EMVI) either on MRI or on 
pathological assessment has been shown to lead to significantly higher rates of local 
recurrence and significantly poorer disease free survival188,193. Similarly, identification 
of extramural perineural invasion on pathological review also increases the rate of 
recurrence and worsens disease free survival194-196.    
 
Current protocols for locally advanced rectal cancer include neoadjuvant therapy 
with chemo- and radiotherapy. The evidence for this treatment and the different 
regimes used will be discussed further below. The response of individual tumours to 
chemo- and radiotherapy is variable and unpredictable. Some tumours fail to 
respond at all and in fact progress during neoadjuvant therapy. The optimal 
response is pathological complete response (pCR), with total regression of the 
tumour. This occurs in 10-30% of cases and can facilitate sphincter preserving 
surgery or even organ preservation by avoiding surgery altogether. The ability to 
predict the response of a tumour to neoadjuvant therapy would allow treatment to 
be tailored on an individual basis. For patients who would not benefit, they could 
avoid the time, cost and toxicity of these therapies. For patients with highly 
radiosensitive and chemosensitive tumours, the neoadjuvant regime could actually 
be intensified with the aim of avoiding surgical intervention and following a 
treatment protocol more akin to that for anal carcinoma.  
 
1.7.3 Patient factors affecting outcome 
 
Making decisions about patients undergoing low rectal surgery with respect to 
sphincter preservation is complex and takes into account several different factors 
relating to the patient. Some of these such as age, current bowel function, neo-
adjuvant treatment and obstetric history relate to their likely functional outcomes. 
Others, such as smoking status, nutritional state and co-morbidities relate to their 
likelihood of complications following the surgery. In individual decision-making, the 
wishes of the individual patient may determine the decision made about the type of 
surgery.  
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The gender, body mass index (BMI) and body shape of a patient all affect their pelvic 
anatomy. The narrow male pelvis makes sphincter-preserving surgery technically 
challenging; this in combination with a high BMI may lead to reconsideration of the 
operative approach, for example prompting a change to a transanal technique197. 
Obesity is associated with increased perioperative morbidity198. Despite the potential 
effect it could have on outcome, it has previously been poorly recorded but BMI has 
now been included in the NBCA dataset (from 2013-14 onwards), which should 
improve routine recording5. In the first round of the data collection, this variable was 
recorded in 36.5% of those undergoing major surgery199.  
 
The age of a patient is always a consideration but physiological age is much more 
important to fitness to undergo major surgery than numerical age. In recognition of 
this, the routine assessment of performance status and cardiovascular fitness has 
become normal practice. Cardio-pulmonary exercise testing (CPEX) was traditionally 
used prior to oesophago-gastric and hepatobiliary and pancreatic surgery. At some 
NHS Trusts it is used for selected high-risk patients who are considered to need 
assessment prior to colorectal resection. This decision is sometimes made by the 
surgical team and sometimes advised by the MDT. As for BMI, CPEX status has 
recently been included as a variable within the NBCA dataset, unlike BMI however, 
this data was poorly recorded with only 2.5% of those undergoing major surgery 
being included in first round of data collection199. It is possible that this reflects a low 
percentage of patients undergoing CPEX or that this data is not available to the MDT 
for recording within the audit data. Performance status, which has been routinely 
used by oncologists for many years as a measure of fitness for adjunctive therapy, 
was much better recorded, at over 80%5. These variables have been included in an 
effort to better understand the potential reasons why some patients do not undergo 
surgery199.  
 
A patient’s comorbidities are also important to their ability to undergo treatments for 
rectal cancer including chemotherapy, radiotherapy and surgery. The effect of 
medications needs to be considered and management of any coexisting conditions 
may need to be optimised prior to surgery. Information relating to their social 
circumstances should also be recorded and can be useful in an MDT setting when 
discussing what support the patient may need as they progress through treatment.  
 
Baseline anorectal function should also be included within the history for all patients 
with rectal cancer. This needs to be differentiated from any effect the rectal tumour 
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has had on function200. Details may include any pre-existing symptoms such as 
incontinence, urgency, or rectal evacuatory dysfunction; prior obstetric injury; 
anorectal surgery or neuromuscular problems. If there are any concerns over pre-
treatment sphincter function, then formal assessment may be carried out with 
anorectal manometry, rectal sensory testing, endo-anal ultrasound and 
proctography.  
 
1.7.4 Assessing response to therapy 
 
The response of a tumour to neoadjuvant therapy can be assessed in different ways. 
Tissue regression grading (TRG) systems stratify response based on the effects of 
radiotherapy, with the grade determined on pathological analysis by the ratio of 
fibrosis to tumour201. Many different TRG classifications have been proposed; they 
have all been shown to have association with outcome but there is no consensus 
about which system should be used202. Mandard initially proposed the classification 
for oesophageal cancer; this scale and variations on it remain the most widely used 
TRG scoring system202. The Mandard score goes from TRG 1 indicating complete 
response through to TRG 5 indicating no regression203. The Mandard score was 
subsequently modified by Dworak et al. for use in assessing rectal cancer response204 
and has subsequently been modified and adapted several times202. The descriptions 
within the scoring systems overlap considerably but an extra layer of confusion is 
added because in some systems low numbers reflect good response and others run 
the opposite way with high TRG grades reflecting the best response (see Table 1.3). A 
recent study comparing the accuracy of the different systems found the four-tier 
system approved by the AJCC to most accurately predict recurrence202. The ACPGBI 
Guidelines on CRC provide a dataset for pathology reporting which endorses and 
recommends the system described in the Royal College of Pathologists Guidelines 
(see Table 1.3)38.  
 
Downstaging in TNM stage following neoadjuvant therapy is also used as a marker 
of tumour response. This is hindered by the limitations in the imaging modalities 
themselves (see above discussion), particularly with regard to nodal assessment. 
Despite this, downstaging has been shown to significantly predict good outcomes205 
and is frequently used in the assessment of response.    
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Table 1.3 Comparison between different tissue regression grading systems 202 AJCC: American Joint Committee on Cancer; MSKCC: 
Memorial Sloan-Kettering Cancer Center; TRG: tissue regression grade. 
Tier Mandard203 AJCC 36 Dworak204 Rödel206 MSKCC207 American 
College of 
Pathologists208 
The Royal 
College of 
Pathologists209 
TRG 0  
No residual 
tumour cells 
No regression No regression   
No viable cancer 
cells 
 
TRG 1 
No residual 
cancer  
Single cell or 
small groups of 
cells 
Predominantly tumor 
with significant 
fibrosis and/or 
vasculopathy  
Minor regression (dominant 
tumor mass with obvious 
fibrosis in 25% or less of the 
tumor mass) 
100% Tumor 
response 
Single cells or 
small groups of 
cancer cells 
No viable tumour 
cells (fibrosis or 
mucus lakes only) 
TRG 2 
Rare residual 
cancer cells 
Residual cancer 
with 
desmoplastic 
response 
Predominantly fibrosis 
with scattered tumor 
cells  
Moderate regression 
(dominant tumor mass with 
obvious fibrosis in 26% to 
50% of the tumor mass) 
86%-99% 
Tumor 
response 
Residual cancer 
outgrown by 
fibrosis 
Single cells or 
scattered small 
groups of cancer 
cells 
TRG 3 
Fibrosis 
outgrowing 
residual 
cancer 
Minimal 
evidence of 
tumor response 
Only scattered tumor 
cells in the space of 
fibrosis with/without 
acellular mucin 
Good regression (dominant 
fibrosis outgrowing the 
tumor mass; i.e., more than 
50% tumor regression) 
≤85% Tumor 
response 
Minimal or no 
tumor kill; 
extensive residual 
cancer 
Residual cancer 
outgrown by 
fibrosis 
TRG 4 
Residual 
cancer 
outgrowing 
fibrosis 
 
No viable tumor cells 
detected  
Total regression (no viable 
tumor cells, only fibrotic 
mass) 
  
Minimal or no 
regression 
(extensive residual 
tumour)  
TRG 5 
Absence of 
regressive 
changes 
      
1.7.5 Molecular biomarkers 
 
To identify potential predictive biomarkers of response to neoadjuvant therapy, 
work has concentrated on histological and molecular assessment of pre-treatment 
biopsies201. There are currently no reliable biomarkers available to stratify patients 
although many markers have been investigated and the findings from these studies 
are discussed below. Response to therapy is complex, involving multiple pathways 
and, as such, it is unlikely that any one marker can entirely predict response in all 
cases210. There are also only a limited number of studies that look at panels of 
markers with cohorts of sufficient numbers. Investigations are often retrospective, 
underpowered with far too few patients, and do not include both technical and 
independent validation211. Further problems with reproducing the results of previous 
studies arise from a lack of consistency between treatment regimes and because the 
assessment of response is carried out using a variety of systems (see above).  
 
One of the main factors accounting for the differing sensitivity of individual tumours 
to radiotherapy is tumour hypoxia. Hypoxia is a hallmark of solid tumours and 
plays an important role in tumour growth and progression. It arises due to 
angiogenesis being insufficient to supply the needs of the rapidly proliferating 
tumour cells and their increased consumption of oxygen212. As the tumour outgrows 
the local blood supply, adaptation towards hypoxia allows it to continue to grow. 
Cellular adaptations to hypoxia are mediated by genes activated by transcription 
factors known as hypoxia-inducible factors (HIFs)213. Hypoxic tumours are more 
resistant to radiotherapy since oxygen free radicals are required for the generation of 
DNA damage, such as DNA double strand breaks, caused by ionizing radiation213. 
Hypoxic tumours are also resistant to chemotherapy via a number of mechanisms. 
Some chemotherapeutic agents depend on cellular oxygenation for their mechanism 
of action; others act on tumour cells during DNA synthesis and are made less 
effective by the slow cell cycling occurring as a result of hypoxia212. Because of these 
links between hypoxia and response to CRT, markers of hypoxia may be useful as 
biomarkers of response to CRT. 
 
A further line of investigation into the mechanisms behind resistance to therapy is 
the behaviour of cancer stem cells. These cells within a tumour are able to self renew 
and differentiate into different cancer cell types accounting for the heterogeneity 
seen within tumours214 If the cancer stem cells are not all killed by radiotherapy then 
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repopulation between treatments or at the end of therapy may reduce overall 
sensitivity of the tumour to radiotherapy215.  
 
p53 is a tumour suppressor gene, frequently mutated in CRC (~50% of cancers), 
which has been widely investigated with possible links to response201. Often referred 
to as the guardian of the genome, it acts by mediating cell cycle arrest and apoptosis 
in damaged or mutated cells216. Direct sequencing has been used to show that mutant 
p53 genotype is significantly associated with radioresistance217 and is more 
frequently found in non-responders218. A recent meta-analysis identified 30 studies 
investigating the relationship between p53 status and response to neoadjuvant 
therapy in rectal cancer219. The overall conclusion was that wild-type p53 status is 
predictive of good response and increased rates of complete response219.  
 
The p21 protein has a key functional role in the p53 signalling pathway201. Its 
expression is mainly controlled by p53 and p21 is upregulated by p53 activation 
secondary to DNA damage (as occurs during radiotherapy), leading in turn to cell 
cycle arrest220. As a result, p21 has been investigated as a marker of radioresistance. 
p21 can act as both a tumour suppressor and oncogene; its induction and effects on 
the cell cycle can be mediated via p53-dependent and p53-independent 
mechanisms221. Increased p21 expression has been shown to link to poor response to 
neoadjuvant therapy222,223 and worse disease free survival224,225. Some studies show no 
association between p21 expression and outcomes and there has not yet been any 
attempt at meta-analyses of the studies226. Others suggest a more complicated 
relationship between p53 and p21 expression and the situation is likely to be 
complex227.  
 
Epidermal Growth Factor Receptor (EGFR) is expressed in cancers and is linked to 
aggressive tumours, radioresistance and poor prognosis228. It is involved in many 
cellular pathways including differentiation, proliferation and apoptosis229. Giralt et al. 
have shown that EGFR expression is less likely in patients with pCR, more likely in 
those with poor response and predicts poor disease-free survival230. A further study 
of 183 patients with rectal cancer undergoing neoadjuvant therapy demonstrated on 
logistic regression that the significant predictive factor of tumour downstaging was a 
low level of EGFR expression231.  
 
Cyclooxygenase-2 (COX-2) mediates tumour invasiveness and metastasis232. It is an 
enzyme mediating conversion of arachidonic acid to prostaglandins, which tumour 
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cells use to protect against radiotherapy induced cell death211. Patients with 
overexpression are more likely to demonstrate poor response232.  Further studies 
have shown that COX-2 overexpression is associated with poor TRG233, increased risk 
of nodal positivity and significantly shorter survival time234. Clinical studies have 
investigated the potential of drugs that inhibit COX-2 including aspirin and non-
steroidal anti-inflammatories. Selective COX-2 inhibitors, such as celecoxib and 
etoricoxib, have additionally been investigated for the chemoprevention of CRC235.  
 
A number of other markers have also been investigated. Bcl-2 and bax are proteins 
involved in cell apoptosis and survival201. Bcl-2 is linked to cell survival and 
expression has been shown to link to increased rates of complete response201. Loss of 
bax function has been linked to chemoresistance and higher levels of expression have 
been linked to improved response236. Ki67 is a marker for proliferation237; Jakob et al. 
have shown that rectal cancers with low expression have better response to 5-
fluorouracil (5-FU) based therapy238. This marker has also been looked at extensively 
in relation to response to neoadjuvant therapy in other cancers, particularly breast 
cancer239.  
 
Thymidylate synthase is involved in DNA synthesis and is the main intracellular 
target of the chemotherapy drug 5-FU and its derivatives211. This explains the finding 
that overexpression is linked to 5-FU resistance240,241. Other markers investigated 
include circulating tumour cells210, Cyclin D1211, Survivin and dihydropyrimidine 
dehydrogenase211.  
 
Multiple studies have looked at the association between pre-treatment CEA levels in 
serum and response to neoadjuvant therapy; these are summarised in Table 1.4 
below. A number of studies have also shown that a reduction in CEA levels 
following neoadjuvant therapy is also associated with a better response to therapy242-
245. Raised preoperative CEA has also been shown to be a predictor of decreased 
overall survival246. 
 
Several studies have attempted to identify a gene expression profile associated with 
response to neoadjuvant therapy. Ghadimi et al. identified a panel of 54 genes, which 
were able to predict response in terms of tumour downstaging253. Rimkus et al. have 
conducted a similar study with similar results, however there was no crossover in 
the genes identified by these different studies254. A further study identified an 
expression profile, which showed 84% accuracy for predicting pCR, and even greater 
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Table 1.4 Summary of studies into CEA as a predictor of response to neoadjuvant 
therapy. CEA: Carcinoembryonic antigen; ng/ml: nanogram per millilitre; pCR: 
pathological complete response. No.: number of participants; TRG: tissue regression 
grade; 5-FU: 5-fluorouracil. 
 
Author No.  CEA 
level 
Treatment Endpoint Comment 
Park247 141 5 ng/ml 45 Gray and 
5-FU or 
doxifluridine 
Nodal status 
TRG 
CEA >5 ng/ml 
associated with 
increased nodal 
infiltration and poor 
response 
Das248 562 2.5 
ng/ml 
45 Gray and  
5-FU or 
capecitabine  
Downstaging 
pCR rates 
CEA > 2.5 ng/ml was 
associated with 
reduced pCR and 
lower downstaging 
rates 
Moureau-
Zabotto249 
 
168 5 ng/ml 45 Gray and  
5-FU 
pCR rates 
Downstaging 
CEA <5 ng/ml 
associated with pCR 
and increased 
downstaging 
Perez250 170 5 ng/ml 50.4 Gray 
and  
5-FU with 
folinic acid 
pCR rates 
Disease stage 
CEA <5 ng/ml 
associated with 
earlier stage and 
increased pCR rates 
Wallin251 530 5 ng/ml 45 Gray + 5.4 
Gray boost 
and 5-FU 
pCR rates CEA <5 ng/ml 
associated with 
increased pCR rates 
Restivo252 260 5 ng/ml 45 Gray + 9 
Gray boost 
and 5-FU or 
capecitabine  
pCR rates CEA <5 ng/ml 
associated with 
increased pCR rates 
 
accuracy on a separate validation set255. These studies show potential but the 
complexity of the data produced makes replication and clinical application difficult.  
 
MicroRNAs are small non-coding RNAs that function as regulators of gene 
expression; it is believed that up to 30% of human genes are microRNA targets256. 
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Their regulatory function over oncogenes, tumour suppressor genes and other 
processes including differentiation, invasion and adaptations leading to resistance to 
CRT, gives them potential as biomarkers and therapeutic targets. In rectal cancer, 
microRNAs have been shown to have potential as biomarkers of response to neo-
adjuvant CRT. Previous studies using expression arrays on tumour samples from 
responders and non-responders have identified a number of possible microRNA 
targets, but these show little overlap and have not been externally validated257-259. 
 
 
1.8 Neoadjuvant and adjuvant therapies    
 
The use of adjunctive therapy for rectal cancer began with studies in the 1980s into 
the use of chemotherapy and/or radiotherapy to reduce the risk of local recurrence 
and prolong survival260. The use of neoadjuvant and adjuvant therapy has 
continually evolved since that time and the choice of therapy for individual patients 
remains one of the most complex decisions to be made by the MDT. The treatment 
chosen for each patient remains dependent on staging modalities and is therefore 
subject to the limitations of these modalities, which has been discussed above. The 
unpredictable response of each individual tumour to these therapies also continues 
to be a further issue. Studies of adjunctive therapy have focussed on answering a 
series of questions: 
1) Should we give chemotherapy or radiotherapy or both? 
2) Should we give these therapies before or after surgery? 
3) If we give radiotherapy should this be short course or long course and what 
dose is optimal? 
4) If we give chemotherapy which agent or agents should we use and at which 
dose? 
5) Can rates of sphincter-preserving surgery be increased by the use of 
adjunctive therapies? 
 
1.8.1 Chemotherapy agents 
 
Chemotherapy drugs inhibit tumour growth by targeting rapidly dividing cells. The 
evolution of chemotherapy for the treatment of colorectal and rectal cancer began 
with the development of 5-FU in 1957261. 5-FU is administered intravenously and acts 
by inhibiting thymidylate synthase, which in turn prevents pyrimidine nucleotide 
synthesis. This affects the ability of cells to synthesise DNA and leads to cell cycle 
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arrest and apoptosis262. It was established early after the development of 5-FU that it 
acts as a radiosensitiser261.  
 
Leucovorin, also known as Folinic acid, is a folic acid derivative, which is sometimes 
given alongside 5-FU because it potentiates 5-FU’s inhibition of thymidylate 
synthase262. 5-FU has been shown to be more effective for the treatment of CRC when 
given via a continuous infusion rather than as a series of bolus deliveries263. 
Capecitabine is a pro-drug of fluoropyrimidine, which is given orally making the 
delivery of chemotherapy more convenient210. Capecitabine, like 5-FU, also acts as a 
radiosensitiser264.  
 
In randomised trials comparing 5-FU and capecitabine, no difference has been seen 
in pCR, local recurrence or survival rates265,266. Both 5-FU and capecitabine can cause 
an inflammatory skin reaction on the palms and soles, known as Palmar-Plantar 
Erythrodysesthesia or hand-foot syndrome; studies have shown that this occurs 
more frequently with capecitabine than with 5-FU267.  
 
A further chemotherapy drug used in rectal cancer, oxaliplatin, is a platinum agent 
which forms cross links in DNA, thereby preventing DNA replication, resulting in 
cell death268. Oxaliplatin acts synergistically with 5-FU and also acts as a 
radiosensitiser269. Despite its theoretical benefits, in the neoadjuvant setting, clinical 
trials in rectal cancer have failed to show any benefit in terms of recurrence rates or 
survival from adding oxaliplatin to 5-FU or capecitabine270,271. However, in the 
adjuvant setting, oxaliplatin is routinely used with capecitabine. This partly results 
from the MOSAIC trial, which has shown improvement in overall and disease free 
survival with oxaliplatin, in patients with stage III colon and rectal cancer272. 
Oxaliplatin, like other platinum agents, can lead to peripheral neuropathy and the 
studies have shown greater toxicity in the groups who received oxaliplatin270-272.  
 
Irinotecan is an inhibitor of topoisomerase I, which leads to inhibition of DNA 
replication and transcription273. Like oxaliplatin it has been shown to have theoretical 
benefits when given alongside 5-FU. Retrospective studies have suggested possible 
improvement survival benefits274,275, however results from clinical studies have so far 
been disappointing276,277. A randomised study in the UK, the ARISTOTLE trial is 
aiming to definitely answer the question of whether irinotecan provides benefit, this 
is now completed, but not yet reported278.  
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1.8.2 Radiotherapy 
 
Radiotherapy is used to treat tumours via the delivery of ionising radiation, causing 
direct damage to DNA, leading to loss of reproductive capability of the cell and 
eventually cell death. Radiotherapy for rectal cancer has traditionally been delivered 
via two regimes. Short course radiotherapy (SCRT) is made up of 25 Grays (Gy) 
delivered in 5 fractions of 5 Gy over a one-week course. Long-course radiotherapy 
usually consists of 45-50 Gy delivered in 25-28 fractions; this is normally delivered 
over a five-week period. It is normally combined with chemotherapy and given as 
long course chemoradiotherapy (LCRT). There have been recent developments in 
radiotherapy for rectal cancer; these include reducing the field size, improvements in 
mapping techniques and more targeted delivery of radiation. The primary aim of 
these developments is to anatomically sculpt delivery of the radiotherapy dose and 
minimise collateral damage to surrounding tissue279.  
 
The response of a tumour to radiotherapy is dose dependent; ideally the dose given 
would be elevated to achieve maximum local control. With the external delivery of 
radiotherapy the dose escalation is limited because of concerns about damage to 
surrounding tissue280. Due to these limitations, the use of brachytherapy, with 
internal delivery of radiotherapy, has been of increasing interest in recent years. 
There are three methods of delivery for brachytherapy280: 
• Contact radiotherapy, also known as Papillon 
• High dose rate (HDR) intra-luminal rectal brachytherapy 
• Interstitial rectal brachytherapy implant 
 
Contact radiotherapy has a number of potential benefits. It is delivered to the tumour 
under direct vision and there is limited absorption by surrounding tissues. Very high 
doses can, therefore, be given in a short time and treatment is usually given every 
two weeks280. This technique has been used selectively for many years in patients 
who were unfit for surgery. More recently, the potential for adding this in to the 
neoadjuvant regime has been explored; this would be given as a boost to the tumour 
bed with the aim of increasing pCR rates.  
 
The Lyon R96-02 trial included patients with T2 or T3 low-risk tumours, 
randomising them to either standard neoadjuvant radiotherapy (39 Gy in 13 
fractions) vs. the same standard regime with an additional contact radiotherapy 
boost (85 Gy in 3 fractions). Patients in the contact radiotherapy group showed 
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significantly higher rates of pCR (24% vs. 2%) and of sphincter preservation (76% vs. 
44%)281. There was no difference in local recurrence, disease-free or overall survival 
at 10 year follow-up282. Trials are currently being set up to investigate the role of 
contact radiotherapy in combination with TEM for early tumours, facilitating organ 
preservation for more patients.  
 
1.8.3 Theoretical benefits of neoadjuvant therapy 
 
There are a number of theoretical benefits of giving chemotherapy and/or 
radiotherapy pre-operatively rather than following surgery. These include: 
• Treatment is delivered to intact tissue planes with an intact blood supply and 
therefore oxygenation optimises the susceptibility of the tumour to these 
therapies 
• ‘Sterilisation’ of lymphatics within the mesorectum reducing dissemination of 
the tumour during dissection  
• Exclusion of the small bowel from the pelvis by the rectum 
• Downsizing/downstaging may improve operability of tumour 
• Improved compliance with treatment 
• Post-operative radiotherapy could have a greater effect on neorectal function 
 
1.8.4 Clinical trials of neoadjuvant and adjuvant therapy in rectal cancer 
 
Table 1.5 summarises the main trials of neoadjuvant and adjuvant therapies in rectal 
cancer. These are discussed in more detail below. 
 
The first trials in this area set out to establish the role of adjuvant therapy in 
improving survival from rectal cancer. The Gastrointestinal Tumor Study Group 
carried out a 4-arm study between 1975 and 1980. Patients were randomised to 
surgery alone, adjuvant radiotherapy, adjuvant chemotherapy, or adjuvant 
chemoradiotherapy283. The chemoradiotherapy group showed significantly better 
disease-free and overall survival283. The National Surgical Adjuvant Breast and 
Bowel Project (NSABP) R-01 study then compared 3 groups: surgery alone, surgery 
with adjuvant radiotherapy and surgery with adjuvant chemotherapy260. It found 
that local recurrence was significantly lower in the radiotherapy group (25% vs. 16%) 
compared to surgery alone260. Disease free survival and overall survival were better 
in the chemotherapy group than the surgery alone group260. The NSABP R-02 trial 
then compared adjuvant chemotherapy to adjuvant chemoradiotherapy and showed 
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a reduction in local recurrence in the chemoradiotherapy group284. These studies 
established the important role of adjuvant therapies in improving outcomes285.  
 
The Swedish rectal cancer trial, which ran from 1987 to 1990, was one of the earliest 
randomised trials to attempt to determine the potential benefits of neoadjuvant 
therapy. Patients with resectable rectal cancer were randomised to pre-operative 
radiotherapy with 25 Gy in 5 fractions followed by surgery vs. surgery alone286. Pre-
operative radiotherapy led to a significant reduction in local recurrence (27% vs. 
11%) and a 10% improvement in 5-year overall survival (58% vs. 48%). These results 
were maintained in a long-term follow-up at a median of 13 years287. A separate 
analysis of late gastrointestinal effects showed that patients in the radiotherapy 
group had an increased risk of late small bowel obstruction and abdominal pain, and 
that these effects depended on the radiotherapy dose given288.  
 
The high recurrence rates and poor survival seen in the Swedish trial reflect its 
historical nature; it was conducted prior to the use of MRI for staging, with no 
assessment of CRM involvement and before the concept of TME surgery had been 
widely adopted286. The next study to assess the use of radiotherapy did specify (and 
assess) TME as the surgical approach used. The Dutch TME trial randomised 
patients to pre-operative radiotherapy with 25 Gy in 5 fractions followed by TME vs. 
TME alone289. The rate of local recurrence was significantly lower in the group 
receiving radiotherapy (2.4% vs. 8.2%)289. Toxicity was similar in the 2 groups 
although the irradiated patients who underwent APER had a higher risk of perineal 
complications103. At long-term follow up the beneficial effect of radiotherapy in 
reducing local recurrence was maintained but there was no difference between the 
groups in overall survival293. 
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Table 1.5 Summary of the main trials of neoadjuvant and adjuvant therapy in rectal cancer. DFS: Disease-free survival; OS: Overall Survival; 
CRM: circumferential resection margin; CRT: chemoradiotherapy; RT: radiotherapy; chemo: chemotherapy; pCR: pathological complete 
response; Gy: Gray. 
 
Trial Period Patients TME  Treatment arms  Outcomes Results 
Gastrointestinal 
Tumor Study 
Group283 
1975-1980 227 
Dukes B2 and C 
No Surgery alone 
Adjuvant RT 
Adjuvant chemo 
Adjuvant CRT 
DFS 
OS 
 
DFS & OS improved in adjuvant 
CRT group 
NSABP R-0260 1977-1986 555 
Dukes B and C 
No Surgery alone 
Adjuvant chemo (5-FU, 
vincristine & semustine) 
Adjuvant RT 
DFS 
OS 
Local recurrence 
Local recurrence was lower in the 
RT group vs. surgery alone 
DFS & OS were improved in the 
chemo group vs. surgery alone 
NSABP R-02284 1987-1992 694 
Dukes B and C 
No Adjuvant chemo 
Adjuvant CRT 
DFS 
OS 
Local recurrence 
Local recurrence was lower in the 
CRT group. No difference in DFS or 
OS 
Swedish rectal 
cancer trial286 
1987-1990 1168 
Resectable rectal 
cancer 
No Surgery alone 
Neoadjuvant RT (25Gy) 
Mortality 
Local recurrence 
DFS, OS  
Local recurrence reduced and 
DFS/OS improved in RT group. 
Mortality equivalent. 
Dutch TME trial289 1995-1999 1861 
Resectable rectal 
cancer 
Yes Surgery alone 
Neoadjuvant RT 
Local recurrence 
OS 
Local recurrence was lower in the 
RT group. No difference in OS 
German Rectal 
Cancer Study 
Group290 
1995-2002 823 
Stage II or III 
Yes Neoadjuvant CRT 
Adjuvant CRT + boost RT 
Local recurrence 
DFS, OS 
Sphincter 
preservation 
Local recurrence was lower & 
sphincter preservation improved in 
the neoadjuvant CRT group. No 
difference in DFS/OS 
Polish Rectal 
Cancer trial291 
1999-2002 312 
Stage II or III 
Yes Neoadjuvant CRT 
Neoadjuvant RT 
CRM positivity, 
pCR, sphincter 
preservation, 
DFS, OS 
CRT group had increased toxicity 
but lower CRM positivity rates, 
increased pCR. No difference in 
DFS, OS or sphincter preservation.  
MRC CR07 292 1998-2005 1350 
Resectable rectal 
cancer 
No Neoadjuvant RT 
Selective adjuvant CRT if 
CRM positive 
Local recurrence 
DFS, OS 
Local recurrence was lower and 
DFS better in the neoadjuvant RT 
group. No difference in OS 
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The Medical Research Council CR07 study was a randomised trial comparing short-
course pre-operative radiotherapy (25 Gy in 5 fractions) with post-operative 
chemoradiotherapy (45 Gy in 25 fractions with concurrent 5FU) for those with a 
positive CRM292. This study showed that preoperative radiotherapy decreased local 
recurrence rates (4.4% vs. 10.6%) and led to increased disease free survival. There 
was no difference between the groups in overall survival. A later analysis looked at 
the effect of pre-operative SCRT on patients’ quality of life. SCRT led to increased 
rates of male sexual dysfunction and faecal incontinence294. Other retrospective 
studies have confirmed the link between preoperative SCRT and faecal 
incontinence295,296, as well as increased rates of urinary incontinence295. These results 
have led some to argue for a more selective use of preoperative radiotherapy in the 
UK, arguing that the CR07 was carried out before the routine use of MRI staging and 
the added staging information that this provides297,298.  
 
The German rectal cancer study was a trial randomising patients with stage II or III 
rectal cancer to pre-operative or post-operative chemoradiotherapy. The regime used 
was 50.4 Gy in 28 fractions with 5-FU; the post-operative group received the same 
regime with an added 5.4 Gy boost to the tumour bed299. Rates of local recurrence 
were reduced in the pre-operative group (6% vs. 13%)299. For patients judged at 
diagnosis to need an APER, the rate of sphincter preservation was more than 
doubled after pre-operative chemoradiotherapy299. Toxicity was lower and quality of 
life was improved in the pre-operative group299. There was no difference seen in 
disease free or overall survival299. At long-term follow-up there was a persisting 
reduction in local recurrence rates in the pre-operative group, with still no difference 
in survival299. As a result of this study, pre-operative chemoradiotherapy replaced 
adjuvant therapy as the standard of care for locally advanced rectal cancer; despite 
the details of the regime used varying from that in the study300.  
 
A further randomised trial carried out in Korea utilised a similar protocol for 
patients with stage II or III cancer, randomising to pre-operative or post-operative 
chemoradiotherapy with 50 Gy in 25 fractions with capecitabine rather than 5-FU. 
Results showed no difference between the groups in local recurrence, disease free 
survival or overall survival301. However, the primary outcome of the trial was disease 
free survival and it was not powered to detect a difference in local recurrence301. For 
patients with distal tumours (<5cm), those undergoing pre-operative therapy were 
significantly more likely to undergo a sphincter-preserving procedure301.  
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There have been two randomised studies of pre-operative LCRT vs. SCRT. The 
Polish study randomised patients to pre-operative chemoradiotherapy with 50.4 Gy 
in 28 fractions with 5-FU and leucovorin followed by TME at 6-8 weeks or pre-
operative radiotherapy with 25 Gy in 5 fractions followed by surgery within 7 
days291. Chemoradiotherapy increased acute toxicity but decreased CRM 
involvement (4% vs. 13%) and increased complete response291. There was no 
difference seen in sphincter preservation, local recurrence and disease-free or overall 
survival. The trial was powered to detect a 15% difference in sphincter preservation 
and was therefore, once again, underpowered to detect a difference in local 
recurrence. There was a trend towards significance with crude incidence of local 
recurrence of 9.0% in the chemoradiotherapy group vs. 14.2% in the short course 
radiotherapy group (p=0.170) and it is possible that a larger study might have 
detected a difference. There was no difference seen in quality of life (measured via 
the validated QLQ-C30) or anorectal and sexual function (measured with an 
unvalidated questionnaire)302.  
 
The second study, conducted in Australia by the Trans-Tasman Radiation Oncology 
Group (TROG), randomised patients to preoperative chemoradiotherapy with 50.4 
Gy in 28 fractions with 5-FU followed by surgery at 4-6 weeks or preoperative 
radiotherapy with 25 Gy in 5 fractions followed by early surgery303. Both groups also 
received adjuvant chemotherap303. The study was powered to detect a 10% difference 
in local recurrence at 3 years. There was no difference seen between the two groups 
in local recurrence, survival or toxicity303. However, there was once again a trend 
towards a difference in recurrence with 3-year rates of 4.4% in the 
chemoradiotherapy group vs. 7.5% in the short course radiotherapy group 
(p=0.24)303. For distal tumours <5cm, the difference in local recurrence was even 
greater, with 3.2% in the chemoradiotherapy group vs. 12.5% in the SCRT group 
(p=0.21). Criticisms were made of this study, including the fact that it was 
underpowered, there was a lack of inclusion of MRI staging or TME (neither of 
which was standard care in Australia at the time) in the protocol and no reporting of 
CRM positivity or the quality of mesorectal excision, making it hard to judge the 
surgery conducted304.  
 
Overall the evidence does not show a clear benefit for neoadjuvant 
chemoradiotherapy over SCRT, or vice versa. Both the studies described included 
patients with T3/4 ‘resectable’ lesions; it is unclear whether these included those with 
an involved CRM or not; both studies were underpowered and failed to show a 
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meaningful difference between the two treatments. Use of chemoradiotherapy or 
SCRT for locally advanced rectal cancer remains variable with Northern European 
and Scandinavian countries using SCRT and the USA and Southern European 
countries preferring LCRT305. Within the UK the trend has been away from the use of 
SCRT but this depends on individual centres and does not appear to be evidence 
based. Theoretically some prefer LCRT as it delivers systemic chemotherapy earlier. 
There have also been concerns raised about operative complications following SCRT, 
although this has been shown to only be a problem when surgery is delayed beyond 
5 days306. An ongoing trial may provide further evidence; the Berlin rectal cancer trial 
is aiming to randomise 760 patients to neoadjuvant LCRT vs. SCRT, with a primary 
outcome of local recurrence307. However, since they are including T2/3 patients there 
may, once again, be problems of applicability to the real-world use of these therapies.  
 
Whether neoadjuvant therapy improves rates of sphincter preservation has been 
debated extensively197. There is no evidence that neoadjuvant short course 
radiotherapy can improve rates of sphincter preservation197. For neoadjuvant 
chemoradiotherapy, the situation is more complex. As mentioned above, individual 
trials including the German rectal cancer study have shown a benefit for neoadjuvant 
chemoradiotherapy in reducing the requirement for APER290. A number of 
prospective, non-randomised studies have also demonstrated rates of sphincter 
preservation of >70% in patients receiving neoadjuvant LCRT who were deemed to 
require an APER at diagnosis308-310. However, two meta-analyses on this topic, the 
first in 2006 including 10 trials and the second in 2012 including 17 trials have failed 
to show any improvement in rates of sphincter preservation with neoadjuvant 
chemoradiotherapy311,312. It is more likely to be the improvements in neoadjuvant 
therapy, in combination with the surgical developments described above, which has 
led to improvements in overall rates of sphincter preservation28.  
 
Another aspect of therapy for rectal cancer, which is under investigation, is the 
timing of surgery following neoadjuvant therapy. Traditionally, surgery has been 
timed at 6 weeks post completion of long-course radiotherapy. This was based on the 
results of the Lyon R90-01 trial, published in 1999, which compared intervals of 2 
and 6 weeks, showing improved clinical and pathological downstaging after 6 
weeks, with no increase in morbidity313. In recent years, a number of retrospective 
analyses began to establish that leaving a longer period between neoadjuvant 
therapy and surgery was not detrimental to outcome and that shorter periods may 
be linked to increased complications314-316. A randomised trial investigating the 
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possibility of lengthening this interval, the 6 vs. 12-week study led by the Royal 
Marsden Hospital, has shown that waiting 12 weeks leads to improved rates of 
downstaging and pCR317. These results have been presented in abstract form and are 
not yet formally reported. A small prospective single-arm study explored the 
possibility of administering further chemotherapy in the interval between 
neoadjuvant chemoradiotherapy and surgery, showing high tolerability and 
acceptable toxicity318. Larger prospective trials are needed to further assess this 
approach.  
 
When given following surgery, adjuvant therapy most commonly uses 
chemotherapy, particularly 5-FU based therapy. Many studies have tried to 
determine the benefit of this; these have mostly concentrated on those who have not 
undergone neoadjuvant therapy and have had surgery alone319. The European 
Organization for Research and Treatment of Cancer (EORTC) 22921 trial was a 
multicentre European study, including patients with resectable T3 and T4 cancers, 
which compared four treatment options320:  
• Preoperative radiotherapy;  
• Preoperative chemoradiotherapy;  
• Preoperative radiotherapy with adjuvant chemotherapy 
• Preoperative chemoradiotherapy with adjuvant chemotherapy  
 
This study showed no benefit for adjuvant chemotherapy on overall or disease-free 
survival321 and this lack of effect remains on the latest follow-up after 10 years322. 
Despite this, the trial failed to change practice because there were problems with 
adherence to adjuvant chemotherapy with only 43% of patients receiving the 
planned dose without delay320. Reasons for this included post-operative 
complications, disease progression, patient refusal and toxicity from preoperative 
therapies320. Such problems reflect the frequent difficulties with the use of adjuvant 
therapy.  
 
A Cochrane systematic review carried out in 2012 included studies randomising to 
adjuvant chemotherapy following surgery vs. no further treatment319. The meta-
analysis showed that adjuvant therapy improved overall survival by 17% and 
disease-free survival by 25%, as well as reducing recurrence by 25%319. However, this 
review showed significant heterogeneity between the included chemotherapy 
regimes and did not include studies with patients who had undergone neoadjuvant 
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therapy, commenting that there remains a lack of evidence for adjuvant therapy in 
this group of patients319.  
 
A number of randomised trials have been established with the aim of examining the 
use of adjuvant therapy in patients who have had neoadjuvant therapy but have 
closed early due to poor accrual and failed to demonstrate any benefit. These include 
the high profile PROCTOR-SCRIPT and CHRONICLE studies323,324. Problems with 
the studies that have been carried out so far include slow accrual, premature closure, 
inadequate power and poor compliance with the treatment protocols324. It also 
appears that clinicians and patients have a lack of equipoise on this issue, which has 
a further negative effect on study accrual325. A recent systematic review has shown 
no benefit for the use of adjuvant therapy following preoperative CRT in terms of 
recurrence or survival rates326. The use of chemotherapy in this setting remains 
controversial and a recent consensus meeting to develop European guidelines for 
rectal cancer failed to reach consensus in this area23, advising that decisions be made 
on an individual patient basis by experienced MDTs.  
 
A number of alternative regimes for the treatment of locally advanced rectal cancer 
are also being investigated. The US based PROSPECT study is assessing induction 
chemotherapy with FOLFOX, (5-FU, oxaliplatin and leucovorin)327. The Dutch 
RAPIDO study is randomising patients to SCRT followed by pre-operative 
chemotherapy and then TME vs. standard chemoradiotherapy with TME328.  
 
1.8.5 Monoclonal antibodies 
 
Monoclonal antibodies are a targeted biological therapy used in cancer to target 
antigens on cancer cells, reducing tumour growth and proliferation by a number of 
mechanisms including enhancing the immune system mediated destruction of cells 
or by blocking growth signals from the tumour. A number of these therapies have 
been used in the treatment of rectal cancer including cetuximab and panitumumab, 
which are both epidermal growth factor receptor (EGFR) inhibitors and 
bevacizumab, which is a vascular endothelial growth factor (VEGF) inhibitor329. 
These new therapies have been most widely explored in combination with standard 
chemotherapy agents for use in locally advanced and metastatic rectal cancer. 
Clinical use has been limited by the costs of these therapies and limitations on their 
use from the National Institute for Health and Care Excellence330. At the current time, 
both cetuximab and panitumumab are recommended as treatment options for 
metastatic colorectal cancer.  
 
 66 
1.8.6 Complete response to neoadjuvant therapy 
 
Surgery, with or without the use of neoadjuvant or adjuvant therapies, has always 
been the principle treatment for rectal cancer. As the use of neoadjuvant 
chemoradiotherapy has become widespread, it has been noted that a proportion of 
those undergoing this treatment have a complete response and when they 
subsequently undergo surgery there is no evidence of remaining tumour seen on 
histological assessment; this is known as a pathological complete response (pCR). A 
pooled analysis of 484 patients who had a pCR shows that these patients have 
improved long-term outcomes with lower recurrence and better survival331. These 
findings, in combination with the recognised morbidity and mortality risks of 
surgery, has led some investigators to consider the possibility of following a non-
operative approach for those who appear to have had a clinical complete response 
(cCR).  
 
This so-called ‘watch and wait’ strategy has the potential to preserve not only the 
sphincters but also the rectum itself. Angelita Habr-Gama and colleagues in Sao 
Paulo, Brazil have intensively studied this strategy. They followed a policy for many 
years of intensifying the neoadjuvant regime, using 50.4-54 Gy with 5-FU-based 
chemotherapy to try and achieve maximal rates of cCR. In their latest series, 49% of 
patients achieved an early cCR332. High local recurrence rates have always been the 
concern with this approach and in this series, 31% of patients developed recurrence 
at a median time point of 60 months332. The majority of these recurrences were 
endorectal, occurring with the lumen of the retained rectum332. This type of 
recurrence has been shown to be more amenable to curative resection than 
recurrence occurring outside of the rectum333. In keeping with this, Habr-Gama et al. 
found >90% were amenable to successful salvage surgery, with an overall local 
control rate of 94%332.  
 
The International Watch & Wait Database was established in 2014 with the aim to 
determine outcomes following cCR and surveillance334. The first report of outcomes 
from the database included 880 patients with a median follow-up time of 3.3 years334. 
The 2 year incidence of local recurrence was 25.2%, distant metastases occurred in 
8%, 5-year overall survival was 85% and 5-year disease-specific survival was 94%334. 
 
A systematic review of results from all studies using this strategy included 9 studies 
with 650 patients but was limited in its conclusions by the lack of randomised studies 
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or control groups, inconsistent definition of cCR and heterogeneity in terms of the 
regimes used, patients included and follow-up strategies335. The studies identified 
included patients with earlier stage and smaller tumours than the majority of cancers 
currently treated with neoadjuvant therapy, making it unlikely that the high cCR 
rates seen could be reproduced in usual practice335.  
 
Part of the difficulty in uniting the results of studies to reach an overall assessment of 
outcomes is the heterogeneity of different approaches all labelled under the ‘watch 
and wait’ label. Some studies include patients who are unfit for major resection and 
undergo CRT with contact radiotherapy boost as the initial treatment plan; others 
such as Habr-Gama et al. have deliberately intensified the chemoradiotherapy 
regime, setting out to achieve maximal cCR rates and avoid surgery. A third group 
of, mainly retrospective, studies have collected data from patients who are given 
routine neoadjuvant regimes, happen to have a cCR and do not undergo surgery for 
a number of reasons including adverse events or patient choice335.  
 
Accurately assessing complete clinical response to predict those who have had pCR 
and facilitate a policy of ‘watching and waiting’ has always been a major concern 
regarding this strategy and has limited widespread adoption336. A recent review has 
shown that no single method can conclusively be used for assessment of cCR336. 
Multiple strategies and protocols for the follow-up of these patients have been 
published, utilising a variety of methods including clinical, endoscopic and imaging 
modalities, including ERUS, MRI, DWI and PET-CT336. Biopsies taken from the site of 
the apparently completely regressed tumour have limited value in ruling out 
residual cancer337. This has led Habr-Gama et al. to publish their definitions of clinical 
and endoscopic criteria for evaluating cCR with illustrated examples338.  
 
A survey of British and Irish colorectal surgeons has shown that widespread 
adoption of this strategy is still some way off. 58% stated they would not consider 
conservative management in patients with a cCR and 69% said they would not even 
discuss this option with a patient who was fit for resection339. Over 70 different 
combinations of investigations to define cCR were given by respondents339. 
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1.8.7 Management protocols in early and locally advanced rectal cancer 
 
Treatment protocols in rectal cancer have traditionally differentiated between early 
tumours and those that are locally advanced. Standard therapy for early rectal cancer 
has been resection with a TME followed by adjuvant chemotherapy in selected 
patients38. This remains the most frequently used treatment for these cancers. The 
NICE Guidelines on Colorectal Cancer published in 2011 and revised in 2014 
recommend that all stage I tumours are discussed at an ‘early rectal cancer’ MDT and 
advises that patients should be informed of the lack of evidence comparing treatment 
strategies in these cases and offered participation in a trial where appropriate39. The 
NICE CRC treatment pathway offers the options of contact brachytherapy or surgical 
resection for these cancers. The most recent European consensus guidelines go 
further and advise options of local excision or TME for T1 lesions; advising TME as 
the only option for T2 cancers340.   
 
Standard treatment for locally advanced rectal cancer has been neoadjuvant SCRT or 
LCRT followed by surgery +/- adjuvant chemotherapy; this is the treatment advised 
by the ACPGBI 2017 Guidelines38. Recent guidelines reflect improvements in staging 
modalities, which have allowed improved differentiation between different types of 
locally advanced cancer. The outcomes for a T3aN0 cancer with a clear CRM and no 
EMVI are very different to those for a T4N2 lesion with an involved CRM and EMVI 
present; more recent guidelines have begun to take these considerations into account. 
The division of rectal cancer into three distinct risk categories has been termed ‘the 
good, the bad and the ugly’ classification, as shown in Figure 1.8341. Recent studies 
have suggested that because of resulting toxicity and lack of benefit from 
neoadjuvant treatment in T3a tumours where the CRM is not involved (<10% 
recurrence with TME alone), good outcomes may be achieved using surgery alone in 
selected T3N0 cases297,342. Similar findings have been shown on retrospective analysis 
of large databases343,344.  
 
The NICE Guidelines separate rectal cancers into low, moderate and high risk as 
shown in Table 1.6. Neoadjuvant therapy is not recommended for tumours in the 
low-risk group. SCRT is advised for those in the moderate group with LCRT used for 
those that are on the borderline between moderate and high and those in the high-
risk group39. The European guidelines provide similar advice but give equal 
weighting to options of SCRT or LCRT for neoadjuvant therapy in T3N1-2 tumours23. 
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Figure 1.8 Management according to the ‘The Good, The Bad and The Ugly’ classification of rectal cancer 341. MRF: mesorectal fascia; LR: 
local recurrence; TME: total mesorectal excision.  
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Table 1.6 Risk of local recurrence for rectal tumours as predicted by MRI. From the 
NICE Colorectal Cancer Pathway39.  
 
Risk of local 
recurrence 
Characteristics of rectal tumours predicted by MRI 
Low • T1 or T2 or T3a and 
• No lymph node involvement 
Moderate • Any T3b or greater, in which the potential surgical margin 
is not threatened or 
• Any suspicious lymph node not threatening the surgical 
resection margin or 
• The presence of extramural vascular invasion 
High • A threatened (<1 mm) or breached resection margin or 
• Low tumours encroaching onto the inter-sphincteric plane 
or with levator involvement 
 
It is likely in the future that options of dose escalation of neoadjuvant therapy with 
the aim of achieving cCR to facilitate organ preservation may be introduced but there 
is a lack of evidence for the routine use of this option. The adverse impact that dose 
escalation could have on the bowel function of patients who end up undergoing 
surgery remains unclear. Many questions remain unanswered including which 
patients would be chosen for this approach and how response in best assessed; as 
such current advice is to use this strategy only in the setting of a clinical trial345. 
 
 
1.9 Functional outcomes 
 
It has been recognised for some time that a large proportion of patients undergoing 
anterior resection for rectal cancer have alteration of their bowel habit following 
surgery. Symptoms vary and can include incontinence, urgency, frequency, 
obstructed defaecation, constipation and lack of predictability346. This combination of 
symptoms following surgery has become known as ‘anterior resection syndrome’ 
(ARS)347. 
 
Multiple descriptions and definitions of ARS exist, but a pragmatic definition is 
‘disordered bowel function after rectal resection, leading to a detriment in quality of 
life’348. The different descriptions and definitions of ARS and the many different 
symptoms which patients experience, have led to considerable difficulties in 
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establishing just how common the problem is. Many small retrospective studies have 
assessed function following rectal resection, sometimes comparing this with 
functional outcomes from other procedures. The results vary considerably with the 
incidence of incontinence ranging from 3-79% of patients, urgency 0-69% and 
incomplete evacuation 2-85%155. 
 
These figures are taken from the only meta-analysis of long-term functional 
outcomes following anterior resection, the results of which were significantly limited 
by the heterogeneity of the primary data155. 65% of studies identified did not use a 
validated assessment tool, with lack of consistency and transparency of reporting. 
Inconsistencies were also noted in the prognostic factors and outcomes described 
and in definitions used to assess severity155.  
 
ARS following surgery for rectal cancer has been shown to have a considerable 
impact on post-operative quality of life (QOL)349,350. Two meta-analyses have been 
unable to find any difference in quality of life following anterior resection when 
compared with abdominoperineal excision of the rectum351,352. It is likely that poor 
function following anterior resection removes some of the benefit to patients from 
carrying our sphincter-preserving surgery; this needs to be better understood and 
predicted in order to improve individual patient counselling. A qualitative study 
questioning patients about their symptoms shows that they experience fear, 
embarrassment and vulnerability about their unpredictable bowel habit and that 
although ARS is a physical problem, its effects on patients are predominantly 
psychosocial353.  
 
Many studies have examined the possible causes for ARS and undoubtedly it is a 
multifactorial condition with a contribution from several different mechanisms354. 
These include direct damage to the anal sphincters during surgery355,356, autonomic 
nerve disruption357,358, reduced rectal reservoir359, impaired neo-rectal compliance360, 
abnormal motility of the neorectum361, altered rectoanal inhibitory reflex362 and a 
hyperactive postprandial response363.  
 
The configuration of the anastomosis has been considered as a possible determinant 
of post-operative function, with several comparisons between straight end-to-end 
anastomosis and colonic J-pouch shape anastomoses. A systematic review was 
unable to show any difference between the techniques364, whereas a Cochrane review 
with meta-analysis showed that pouch configuration might provide better functional 
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outcome but that benefit is not likely to be maintained beyond 18 months365. Studies 
have confirmed that symptoms relate to length of time since surgery with 
improvement over the first year366,367 and then stabilisation of symptoms following 
that. This is likely due to permanent anatomical and physiological changes347. 
 
Risk factors for developing ARS include neoadjuvant radiotherapy155,368, adjuvant 
chemoradiotherapy369 and the level of the anastomosis370,371. The impact of age on 
functional outcome after surgery for rectal cancer is unclear. No effect was found in 
the meta-analysis155 or the one study specifically designed to answer this question372 
(although other studies have shown that age is a factor in outcome373,374). 
 
The different measurement tools that have been used to assess post-operative 
function have led to inconsistent assessment and have not been specifically designed 
for LARS. Most of the scoring systems commonly in use are designed to measure 
incontinence and do not take into account other symptoms including urgency375. The 
authors of the meta-analysis of long-term functional outcomes, described above, 
criticised investigators for continually developing new scoring systems despite the 
existence of established validated scores, thus making reliable assessment of 
outcomes and comparison between populations impossible155. Use of a common 
scoring system would also facilitate testing of interventions in a meaningful way348.  
 
To combat these problems two validated scoring systems, specifically for ARS, have 
recently been developed. The Memorial Sloan-Kettering Cancer Center Bowel 
Function Instrument contains eighteen questions and was developed and validated 
in New York376. The Low Anterior Resection Syndrome (LARS) score contains five 
questions and was developed and validated by a group of researchers in Denmark375. 
It has also been validated in a European study including Swedish, Spanish and 
German patients373. This score is simple to complete, short and a high level of 
compliance was found during the validation studies already carried out. It is more 
suitable for use in clinical practice, in an outpatient setting, than the longer Memorial 
Sloan-Kettering score. The LARS score is ideally suited to establishing the prevalence 
of LARS and has recently been validated in the UK population377.  
 
In addition to effects on bowel function, rectal cancer surgery can have other 
detrimental effects for patients, including sexual dysfunction, difficulty voiding and 
bladder incontinence. Rates of these problems following surgery are difficult to 
assess as they depend on adequate recording and reporting of these problems. In a 
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similar way to problems with bowel function, patients may not volunteer this 
information unless specifically asked and it is likely that the incidence is 
underestimated. Urinary dysfunction with symptoms including urgency, 
incontinence, and incomplete emptying affects up to a third of patients after rectal 
resection; the main cause of this is nerve damage during surgery378. Reported rates of 
sexual dysfunction rates range from 23% to 69% in men and 19% to 62% in women379. 
During the Dutch TME trial, data on sexual dysfunction was recorded preoperatively 
and at each follow-up visit378. Overall, 76% of men and 62% of women reported 
either new symptoms or deterioration of pre-existing symptoms. Risk factors for 
sexual dysfunction included nerve damage (as recorded in operation notes), 
anastomotic leakage and preoperative radiotherapy378. 
 
 
1.10 Survivorship and long-term quality of life 
 
1.10.1 Patient preferences 
 
The priorities in the surgical management of rectal cancer are to achieve oncological 
clearance whilst balancing this with optimising bowel function and long-term 
quality of life. The views of the patient must be an important consideration during 
the decision-making process and some would prefer to accept a less than perfect 
functional outcome in order to achieve their goal of sphincter-preservation.  
 
Current treatment strategies in rectal cancer are designed to achieve the maximal 
reduction in local recurrence, as documented above. When healthy volunteers were 
presented with data about the treatment schedule, functional and sexual outcomes 
following surgery alone vs. chemoradiotherapy with surgery, 54% would only accept 
chemoradiotherapy if it led to a 10% or greater benefit in terms of reducing the risk 
of local recurrence380.  
 
A questionnaire study looking at the beliefs of patients who have undergone surgery 
for rectal cancer, showed that most would be willing to accept some degree of 
incontinence in order to avoid an APER381. A further study in Australian patients 
looked at physician and patient preferences and found that patients’ strongest 
preference was avoidance of a stoma and that 65% of the group would trade a mean 
of 34% of their remaining life expectancy to achieve this goal382. The views of 
surgeons and oncologists in this study were markedly different, in terms of 
preferences: surgeons appeared to be averse to radiotherapy382. In the same study, 
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when asked to choose between negative outcomes in order of acceptance, surgeons 
were more likely to accept a permanent colostomy than either patients or 
oncologists382. This may be because of their familiarity with stomas and their 
experience of patients coping with this option. This finding has implications because 
surgeons may underestimate the importance of this outcome to patients382.  
 
Part of the difficulty with these studies is that they have been carried out on patients 
who have already undergone treatment, which clearly affects their views on the 
treatments received. The team looking after them will have taken their preferences 
into account when deciding on the treatment options that they have received; any 
complications sustained will also affect their views. The importance placed on 
avoidance of permanent stoma; incontinence or sexual dysfunction differs greatly 
between individual patients and these small studies may not reflect the views of all 
patients. Although patients do have preferences, they often look for guidance on this 
complex decision from the professionals involved in their care. When asked, prior to 
surgery, about their preference for procedure, almost two thirds of patients would 
defer this decision to their surgeon, whilst 30% would opt for anterior resection and 
only 5% for APER383. One of the major difficulties in counselling patients about the 
likely outcomes following different surgical options is the lack of evidence about 
functional outcomes following surgery for rectal cancer, along with our inability to 
predict which patients will develop problems.  
 
Taking into account patient preferences should be considered an integral part of the 
informed consent process. Following the landmark Montgomery case the guidance 
on informed consent has recently changed towards a patient-centred perspective 
with the Royal College of Surgeons reinforcing the need for surgeons to inform 
patients about all risks material to them and to provide information about alternative 
treatments384. This has particular relevance in rectal cancer surgery, where treatment 
options and pathways can be complex, and the long-term outcomes for some recent 
options including ‘watch and wait’, local excision or transanal TME surgery, may be 
unclear. Decisions can be difficult particularly where modest improvements in 
survival may potentially equate to significant effects on QOL385. 
 
Patients now, rightly, expect to be involved in shared decision-making386 and this 
should cover potential risks, benefits and likely outcomes as well as the long-term 
sequelae of treatment including bowel, bladder and sexual dysfunction and their 
potential impact on QOL386. The majority of rectal cancer surgeons agree that shared 
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decision-making is important in rectal cancer surgery but it is still poorly utilised in 
practice387. Time pressures are one of the greatest barriers to shared decision making 
identified by clinicians388 and because of this, the consent process may necessitate 
several discussions with a patient, and often their family, over multiple 
appointments. Increased discussion time has been identified as an important factor 
for improved comprehension389. 
 
Patient recall of discussions around informed consent and retention of information is 
poor and patients want more information on functional results and long-term QOL 
than clinicians may anticipate385. Decision support aids such as written information, 
videos or relevant online information may be helpful385, but are not widely used390. A 
specific Rectal Cancer Patient Decision Aid has been shown to improve knowledge, 
understanding and reduce decisional conflict391. This may also help to adjust 
expectations so that patients are better able to deal with symptoms following 
treatment, or know where to seek help about them if they do occur.  
 
1.10.2 Quality of life  
 
Assessing quality of life (QOL) following surgery for rectal cancer is difficult due to a 
number of reasons. QOL is not only affected by the surgical treatment but by a 
number of other factors including other therapies and ongoing toxicity from these as 
well as any complications that may have arisen and the effect of any resulting further 
procedures. QOL is not static and is likely to change over time, being particularly 
affected by the time that has elapsed since treatment392. Individual studies have often 
failed to take into account the time needed for problems with bowel function to settle 
down following anterior resection95. Comparing QOL in those who have undergone 
anterior resection and those who have had an APER needs to take into account that 
the patient’s preferences about these two procedures has usually played a part in 
decision making and patients in each group are therefore already more likely to 
prefer the option they have undergone. These two groups are often not comparable 
in terms of age, pre-operative function or tumour location in the rectum, which can 
all affect QOL. It is not possible to conduct a study randomising patients between 
APER and anterior resection because of the lack of equipoise in clinicians and 
patients, and the fact that permanent colostomy is generally considered an 
unfavourable outcome and would be avoided whenever possible. The problems that 
might arise when dealing with a permanent stoma are different to those of living 
with functional problems, and this subtlety is often missed using generic QOL scales.   
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Two systematic reviews of studies measuring QOL following anterior resection and 
APER have not shown any difference between the two groups351,352. The Cochrane 
review, published in 2012 included 35 studies, all of them were observational and 
non-randomised and there was also marked heterogeneity; for these reasons meta-
analysis was not conducted351. This review suggested the need for large prospective 
cohort studies in which patients’ QOL measurements are recorded both pre- and 
post-operatively351. An earlier systematic review, published in 2007, included 11 
studies with 1443 patients in a meta-analysis and showed no difference in global 
health scores352. There were differences seen between the groups in different aspects 
of QOL with anterior resection patients showing higher levels of physical function 
and sexual function352. APER patients showed higher cognitive and emotional 
function scores352.  
 
1.10.3 Selection of outcomes  
 
Making decisions about patients with rectal cancer based on evidence from available 
studies needs to take into account the outcomes that these studies have measured 
and the relevance of these. The majority of the studies described above, which 
comprise the current evidence base for rectal cancer treatment, have local recurrence 
(or measures of surgical quality used as a surrogate measure for this) as their 
primary end point393. Despite all the developments that have occurred in 
neoadjuvant therapy and surgical technique, leading to low levels of local 
recurrence, 20 to 40% of patients with rectal cancer develop metastases and 
ultimately die from systemic disease393.  
 
Overall survival is the primary aim of cancer treatments and the most important 
outcome for patients. Using survival as an end point for trials is problematic because 
the time lag between start and end of the study means that the methods tested are 
often out-dated by the time results are available393. What should replace this as the 
end point in clinical studies is not an easy decision. As described above, what 
matters most to clinicians and patients is not always the same. Surgical trials may use 
a range of end points such as downstaging, TRG or even pCR rates, which although 
measurable, have little meaning to the lives of the patients treated. Other outcomes, 
which are often not well measured, may be important to patients, these include 
overall quality of life, functional outcomes, and toxicities resulting from therapy as 
well as the emotional and financial costs of treatment.  
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A recent survey of CRC survivors in England set out to use patient reported outcome 
measures (PROMs) for the first time in a National study to capture the patient 
experience. The tools used included the EQ-5D quality of life measure, FACT Items 
(Functional Assessment of Cancer Therapy) and SDI (Social Difficulties Inventory)394. 
This identified a wide range of lifestyle issues affecting the patients including 
problems with appetite, tiredness, reduced sleep, embarrassment, social distress, 
financial concerns, difficulty travelling, mood swings, difficulty concentrating and 
fear of cancer returning394. ‘Frequently occurring challenges’ identified by patients 
included394:  
• The emotional impact of cancer and treatment 
• On-going social and financial problems 
• Long-term and age-related illnesses that could exacerbate, or be exacerbated 
by, problems associated with cancer treatment 
• Unpleasant physical side-effects of treatment 
 
This study has shown the wide range of effects that cancer and its treatments can 
have on patients. These outcomes have, in the past, been poorly recorded and 
viewed as having secondary importance to clinically defined outcomes such as 
recurrence. PROMs are becoming increasingly recognised within the NHS as a vital 
tool to measure the impact that treatment is having on patients. It is likely that future 
studies will be required to include this type of instrument in addition to traditionally 
used end points.  
 
 
1.11 Conclusions 
 
Achieving the optimum oncological outcome is the primary aim of rectal cancer 
treatment. Maximising rates of sphincter preservation is also a key goal but it is 
meaningless if the functional outcomes are poor, affecting quality of life. What we 
ideally need to achieve is maximal rates of functioning sphincters wherever this is 
possible. Surgically, the limits of what is technically feasible continue to expand. 
Patient preferences are important but it is crucial to ensure that patients are 
counselled appropriately, and have realistic and accurate expectations of whatever 
treatment choice is decided on95.  
 
Over-treatment and under-treatment of rectal cancer can both have detrimental 
effects for patients395; unfortunately a judgement as to whether either of these has 
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occurred can usually only be made at the completion of therapy. Failing to achieve 
adequate local control of disease can have a detrimental effect on survival and clearly 
this needs to be avoided. On an individual level, patients might therefore be willing 
to accept over-treatment to ensure survival, opting to deal with the later 
consequences of this once they are through the initial treatment. When the whole 
population of rectal cancer patients is considered, over-treatment becomes a 
problem; as more people live for many years following treatment it is important that 
treatment for cancer does not lead to detrimental effects on long-term QOL. 
 
The range of options for therapy in rectal cancer is broad and multifaceted; it is likely 
to keep expanding. All of this means increasingly complex discussions with patients 
and often their family members. This involves different members of the MDT and 
usually needs multiple discussions, with time for the patient to consider information 
between them. There is a balance to be reached between achieving treatment in a 
timely way to permit maximum benefit whilst allowing the patient the time 
necessary to negotiate the decisions that need to be made, often based on incomplete 
evidence about the likely outcomes.   
 
It is increasingly likely that in the future the focus will move away from achieving 
maximal rates of sphincter preservation and towards achieving organ preservation 
by avoiding resection of the rectum for as many patients with rectal cancer as 
possible.  Although treatment protocols are useful for guiding therapy decisions; 
ultimately these need to be made based on individual patient circumstances and 
preferences; the goal in the future would be for them to also be based on individual 
tumour biology.  
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Chapter 2. Aims and objectives 
 
2.1 Research question 
 
The introductory chapter has outlined the progress that has been made over recent 
years in the delivery of treatment for rectal cancer, with developments in many areas 
including neoadjuvant therapy and minimally invasive surgery. Treatment 
pathways for rectal cancer are complex and involve the whole multidisciplinary 
team. The developments that have been made have focussed on improving 
oncological outcomes but there has been comparatively little interest in functional 
outcomes.  
 
Across the whole of cancer care, there has been a move towards recognition of the 
importance of patient centred outcomes, and an emphasis on survivorship. 
Clinicians and researchers have recognised the potential impact that cancer therapies 
can have on long-term quality of life and begun to explore ways to limit the long-
term negative impacts of cancer treatment. For rectal cancer specifically, there has 
been a clear paradigm shift in the last few years. The focus is no longer necessarily 
on sphincter preservation, but on preservation of acceptable anorectal function. 
 
The overall research question asked in this thesis is: 
• What determines the ability to preserve functioning sphincters during 
management of low rectal cancer?  
This overall research question can be broken down into these further questions: 
• How many patients have a poor functional outcome and what determines this? 
• Can we find biomarkers to help us rationalise treatments that we know have a 
potential negative impact on functional outcome? 
• What tools can help us to understand the physiological changes that underlie 
poor functional outcomes?  
We currently have only an estimate of the number of patients who develop Low 
Anterior Resection Syndrome (LARS), which indicates a poor functional outcome 
following anterior resection (the current gold standard surgical option for rectal 
cancer). In order to improve functional outcomes, we need to know how many 
patients are affected by LARS. We also need to better understand the factors that 
might determine whether a patient develops LARS.   
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Neoadjuvant chemoradiotherapy is known to be a major risk factor for poor 
functional outcome. Response to this treatment is variable and we cannot currently 
predict this on an individual level. It is possible that we could limit the negative 
effects by using it only in those patients who would respond to it and derive 
oncological benefit from this treatment. The ability to predict who would respond 
would allow us to stratify and individualise care but in order to achieve this 
predictive biomarkers are needed.  
 
Anorectal physiology has been studied for many years using standard anorectal 
manometry. Despite this, we do not fully understand the alterations in structure or 
function of the anorectum following rectal cancer treatment and why some patients 
that develop these changes experience LARS and others are asymptomatic. High 
resolution anorectal manometry (HRAM) is a newly developed investigative method 
that converts manometry readings into colour contour pressure topography plots, 
this allows appreciation of the anorectum as a functional unit and can show dynamic 
changes. The potential for HRAM as a tool to better understand the physiological 
changes underlying functional change following treatment for rectal cancer has not 
yet been explored.  
 
 
2.2 Aims and objectives 
 
The overall aim of thesis was to explore the factors that determine the ability to 
preserve functioning sphincters during management of low rectal cancer. The 
following specific objectives will be met by each chapter: 
  
1. To determine the proportion of patients having undergone anterior resection in 
the UK who have LARS (chapter 3).  
2. To identify risk factors for LARS and to confirm the link between LARS and 
quality of life (chapter 3). 
3. To determine the potential ability of measures derived from diffusion weighted 
MRI to predict and assess response to neoadjuvant LCRT for rectal cancer 
(chapter 4).  
4. To identify microRNA targets with potential use as predictive biomarkers of 
response or non-response to neoadjuvant CRT in rectal cancer (chapter 5).  
5. To define the changes in anal sphincter function following anterior resection and 
chemoradiotherapy using HRAM (chapter 6).  
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Chapter 3. Anterior resection syndrome following sphincter-
preserving resection in the UK population  
 
3.1 Introduction  
 
Over the last 25 years, developments in the treatment of rectal cancer, outlined in the 
introductory chapter, have led to dramatically improved outcomes and, in particular, 
improved survival. Overall 5-year survival from rectal cancer has now reached 54%, 
with 10-year survival being only slightly lower1. Similar improvements in care have 
also been seen in many other cancers. This rise in the number of survivors has led to 
a change in emphasis in cancer therapy and improved awareness that these patients 
will need to live with the long-term effects of their treatments. Survivors from 
colorectal cancer have identified unpleasant physical side-effects from their 
treatment as a particular problem2.  
 
In the early years following the advent of sphincter preserving surgery for rectal 
cancer, there was already interest in the functional outcomes for patients3. 
Investigations into physiological changes following rectal resection began during the 
1980s4. From the 1990s onwards the term “anterior resection syndrome” (ARS) 
became widely used to describe dysfunction following anterior resection5. 
Alternatives to anterior resection, particularly those that facilitate resection of very 
low rectal cancers, have been shown to have an even greater effect on long-term 
function6.  
 
Anterior resection syndrome can be defined as “disordered bowel function after 
rectal resection, leading to a detriment in quality of life”7. Symptoms include flatus 
and faecal incontinence, altered frequency, urgency, clustering, fragmentation and 
evacuatory dysfunction7,8. It essentially leads to unpredictable bowel habit, which 
can cause distress and feelings of vulnerability9. Although it is a physical condition, 
the effects are frequently psychosocial and have a detrimental impact on quality of 
life8,10. Rectal cancer survivors are more likely than those surviving from other 
colorectal cancers to suffer from ‘social distress’ experiencing difficulties relating to 
family, social activities, finances and work2. 
 
Anterior resection syndrome is a complex multifactorial condition with different 
mechanisms contributing in individual patients. The physiological reasons that have 
been proposed for these symptoms are discussed in more detail in chapter 6. 
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Intuitively it makes sense that loss of the rectum, with its sophisticated ability to 
control defaecation would lead to dysfunction. This is partly confirmed by the 
finding that those undergoing partial mesorectal excision (PME) with retention of the 
most distal rectum have less likelihood of developing symptoms than those 
undergoing TME with the entire rectum removed11.  
 
Several risk factors have been identified for ARS including neoadjuvant 
radiotherapy, height of anastomosis, total as opposed to partial mesorectal excision 
and younger age11-13. Other risk factors have been suggested by smaller studies but 
have yet to be confirmed, including temporary stoma14, anastomotic configuration15 
and obstructive presenting symptoms16. The main limiting factor in determination of 
risk factors is that they overlap and confound each other. For example, a patient with 
an advanced tumour is more likely to undergo neoadjuvant therapy, more likely to 
have a technically challenging operation and more likely to require a defunctioning 
stoma. This makes analysis of the contributing factors more difficult.  
 
It has long been recognised that following anterior resection, bowel related 
symptoms are most troubling during the initial 12-month period, this has been 
confirmed by a number of studies17,18. However, it was previously believed that with 
additional time post surgery, symptoms would continue to improve and this has 
recently been questioned11,13. The symptoms of ARS are now considered to be long 
lasting and reflect the permanent changes in anatomy and physiology following 
surgery19. Detailed physiological studies have suggested that the situation may be 
more complicated with symptoms of urgency and tenesmus improving as 
compliance improves, but incontinence worsening with time as the rectoanal 
inhibitory reflex returns20.  
 
There has been uncertainty about the proportion of patients that suffer from these 
problems for many years. A meta-analysis of long-term functional outcomes 
following anterior resection, published in 2011 showed that results in individual 
studies vary considerably21. This is shown by the very wide range of proportions 
reported by primary studies within this analysis, for example the proportion of those 
with incontinence ranged from 3-79% and urgency 0-69%. Further analysis was done 
to determine the cause of the variation. The authors found significant heterogeneity 
of the primary data; 65% of studies identified did not use a validated assessment 
tool, with lack of consistency and transparency of reporting. The pooled proportions 
suffering from each symptom were as follows: incontinence 35%; incomplete 
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evacuation 55%; urgency 35% and clustering 59%, indicating that a considerable 
percentage of patients will experience one or more symptoms.  
 
The Scheer meta-analysis also found that 65% of the studies identified did not use a 
validated assessment tool to measure symptoms. Many of the studies that have 
assessed functional outcomes have utilised study groups from other trials, for 
example the Dutch TME trial, and have not, therefore, been designed to assess 
functional outcomes22. Other studies have used non-validated tools18,23 and where 
they have used validated tools, these have been designed to solely measure 
incontinence e.g. the Wexner score, and do not include other symptoms24,25.  
 
The Low Anterior Resection Syndrome (LARS) score was developed to resolve the 
lack of measurement tool. It contains five questions and is easily completed in 
clinical practice, showing a high level of patient compliance26. The original 
development of the score was carried out in Denmark26 and it was validated in a 
European study including Swedish, Spanish and German patients27. It has 
subsequently been validated in the UK population28. The LARS score has also been 
used, by the same study group, to assess quality of life (QOL) in the Danish 
population8. Results from the validation studies suggest LARS is a much greater 
clinical problem than anticipated previously12 but prevalence in the UK population 
has not been independently verified.  
 
Over recent years, there has been an uptake of minimally invasive surgery in the UK 
with 58% of colorectal cancer resections now carried out laparoscopically29. As 
outlined in the introductory chapter, there is conflicting evidence about the 
oncological long-term outcomes following laparoscopic vs. open surgery. Similarly, 
there is a lack of evidence about the likely impact laparoscopic surgery will have on 
functional outcomes and the possible effect of further developments including 
robotic surgery and transanal approaches. There is also an increasing recognition of 
the potential effect that the sequelae of cancer treatments can have on patients’ long-
term quality of life2. All these developments make this is an ideal time for an 
exploration of the impact of current practice on functional outcomes following rectal 
cancer surgery in the UK.  
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3.2 Aims 
 
The primary aim of this study was to determine the proportion of patients having 
undergone anterior resection in the UK who have anterior resection syndrome.  
 
The secondary aims were to identify risk factors for anterior resection syndrome and 
to determine the link between LARS and QOL. 
 
 
3.3 Methods 
 
3.3.1 Study design 
 
This was a UK based epidemiological questionnaire-based cohort study. The study 
had a single site, Queen Mary University London, but used multiple Participant 
Identification Centres (PICs) to identify eligible participants.  
 
3.3.2 Outcomes 
 
The primary outcome was the proportion of participants with no LARS (score 0-20 
on LARS questionnaire), minor LARS (score 21-29) and major LARS (score 30-42). 
 
The secondary outcomes were the relationship between LARS and QOL and the risk 
factors for LARS including: gender, age (above and below median), neoadjuvant 
therapy and stoma use.  
 
3.3.3 Participant Identification Centres  
 
Invitation letters were sent to 40 NHS Hospital Trusts in the UK. Letters were 
addressed to Consultant Colorectal Surgeons via their work email addresses. PICs 
identified eligible participants using records from colorectal cancer multi-
disciplinary team meetings, audit data from the National Bowel Cancer Audit Project 
or other local prospective databases. Participants were identified by their own direct 
care team only, allowing confidentiality to be maintained. Figure 3.1 lists the PICs 
involved in the study. 
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Figure 3.1 Participant Identification Centres (abbreviations in brackets used in 
subsequent tables) 
 
 
3.3.4 Study population 
 
Adult patients who had undergone anterior resection for rectal cancer at least 12 
months previously were eligible to participate. If they had a defunctioning stoma at 
the time of surgery, this must have been reversed at least 12 months previously.  
 
3.3.5 Inclusion criteria  
 
Inclusion criteria were as follows:  
• Age ≥ 18 years 
• Anterior resection for rectal cancer and ≥ 12 months post surgery 
• If defunctioning stoma used, ≥ 12 months post reversal 
 
• Barking, Havering & Redbridge University Hospitals (BHR) 
• Barts Health NHS Trust (Barts) 
• Brighton and Sussex University Hospitals NHS Trust (Brighton) 
• Colchester Hospital University NHS Foundation Trust (Colchester) 
• Guy’s and St Thomas’ NHS Foundation Trust (GSTT) 
• Homerton University Hospital NHS Foundation Trust (Homerton) 
• London North West Healthcare NHS Trust (St Marks) 
• Maidstone & Tunbridge Wells NHS Trust (M&TW) 
• NHS Fife (Fife) 
• NHS Forth Valley (Forth) 
• NHS Grampian (Grampian) 
• NHS Greater Glasgow and Clyde (Glasgow) 
• NHS Highland (Highland) 
• NHS Lothian (Lothian) 
• NHS Tayside (Tayside) 
• Nottingham University Hospitals NHS Trust (NUH) 
• Royal Devon & Exeter NHS Foundation Trust (RD&E) 
• Royal Free London NHS Foundation Trust (Barnet) 
• United Lincolnshire Hospitals NHS Trust (ULH) 
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3.3.6 Exclusion criteria 
 
Exclusion criteria were as follows: 
• Any inclusion criteria not met 
• Presence of a stoma 
• Local recurrence of cancer 
• Current adjuvant therapy 
• Further rectal surgery after the initial operation  
• Insufficient written English to participate 
 
3.3.7 Data collection 
 
PICs were sent pre-packed and stamped envelopes containing a letter introducing 
the study (Appendix 1), a participant information sheet (Appendix 2); the study 
questionnaire (Appendix 3) and a prepaid envelope in which to return the 
questionnaire. PICs then addressed these using the details of eligible participants 
and sent them out to their home address. Eligible participants completed the 
anonymous questionnaire, which was returned in the prepaid envelope directly to 
the study team at Queen Mary University London. Data were entered into a 
specifically designed database. 5% of the data were rechecked by an independent 
person to ensure accuracy of data entry and no errors were identified. 
 
3.3.8 Questionnaire  
 
Part 1 - Demographic and clinical information  
Questions in part 1 confirmed eligibility to participate and assessed risk factors for 
LARS. The first two questions recorded the participants’ age and gender. Further 
questions were related to eligibility, including confirmation that the patient had 
undergone surgery for rectal cancer, the date of the surgery, stoma formation (if 
applicable) and reversal date, further surgery and ongoing treatment. The remainder 
of the questions were about possible risk factors including: details of neoadjuvant 
and adjuvant therapy, as well as mode of surgery. As this part of the questionnaire 
was unvalidated, it was trialled with members of the public confirming that the 
language was understandable.  
 
 
 
 
 
 120 
Part 2 - LARS questionnaire  
This has five questions about bowel function and scores from 0–42. Results are 
classified into three categories: no LARS (0-20); minor LARS (21-29) and major LARS 
(30-42). Figure 3.2 shows the LARS questionnaire including the scoring method.  
 
Figure 3.2 LARS questionnaire with scoring 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 3 - EORTC QLQ-C30 
Part 3 of the questionnaire was the European Organization for Research and 
Treatment of Cancer (EORTC) generic quality of life questionnaire QLQ-C3030. This 
is a validated, openly available, questionnaire, which asks 30 short questions about 
health to determine quality of life. The scores produce: 
• One global QOL scale 
• Five functional scales: physical functioning, role functioning, emotional 
functioning, cognitive functioning and social functioning 
Q1. Do you ever have occasions when you cannot control your flatus 
(wind)? 
- No, never       0 
- Yes, less than once per week     4 
- Yes, at least once per week     7 
Q2. Do you ever have any accidental leakage of liquid stool? 
- No, never       0 
- Yes, less than once per week     3 
- Yes, at least once per week     3 
Q3. How often do you open your bowels? 
- More than 7 times per day (24 hours)   4 
- 4-7 times per day (24 hours)     2 
- 1-3 times per day (24 hours)     0 
- Less than once per day (24 hours)    5 
Q4. Do you ever have to open your bowels again within one hour of the 
last bowel opening? 
- No, never       0 
- Yes, less than once per week     9 
- Yes, at least once per week     11 
Q5. Do you ever have such a strong urge to open your bowels that you 
have to rush to the toilet? 
- No, never        0 
- Yes, less than once per week     11 
- Yes, at least once per week     16 
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• Nine symptom scales: fatigue, nausea and vomiting, pain, dyspnoea, insomnia, 
appetite loss, constipation, diarrhoea and financial difficulties.  
 
3.3.9 Statistical analysis 
 
The LARS questionnaire was scored according to the published scoring system (see 
Figure 3.2). The QLQ-C30 questionnaire was scored according to the scoring manual 
from EORTC31. Details of scoring for the questionnaires were not seen by the 
participants. 
 
Incomplete questionnaires were not included in the final analysis. Questionnaires 
were counted as incomplete if: 
• More than one part of the clinical details had been left empty 
• More than one part of the LARS questionnaire had been left empty 
• The whole QLQ-C30 questionnaire was empty  
Single missing answers for the QLQ-C30 were scored according to the guidance in 
the scoring manual for dealing with missing answers. Single missing answers for the 
LARS questionnaire were given the minimum score for that category.   
 
Statistical analysis was carried out using Statistical Package for the Social Sciences 
(SPSS Inc. Chicago, USA, version 22.0) and SAS software (SAS Institute, Marlow, UK, 
version 9.4). A two-sided p value of <0.05 was considered statistically significant. 
Descriptive statistics including mean, median, percentages, range, interquartile range 
and odds ratios (OR) with 95% confidence intervals (CI) are reported. No 
adjustments were made for multiplicity of testing. 
 
Risk factors for LARS were treated as dichotomous variables. Age was taken as ≤ or > 
median age. Time since surgery was taken as ≤ or > median years. Similarly, length 
of time with stoma was taken as ≤ or > time in months. Initial analyses (see results 
section) using the Chi-square test showed no difference in outcomes between short-
course radiotherapy (SCRT) and long-course chemoradiotherapy (LCRT). 
Neoadjuvant radiotherapy was therefore dichotomised into none vs. SCRT/LCRT.  
Mode of operation was dichotomised as open/converted to open vs. laparoscopic 
surgery.  
 
Univariable and multivariable analyses were carried out to identify potential risk 
factors for the following binary groups:  
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• No LARS vs. minor/major LARS 
• No LARS/minor LARS vs. major LARS 
• No LARS vs. major LARS 
 
Multivariable analysis was carried out using a forward stepwise approach.  
 
A multivariable ordinal regression model was fitted using no LARS, minor LARS 
and major LARS groups as the response variable. Forward selection was used to 
identify a subset of key significant univariate risk factors. Analyses were carried out 
twice, including questionnaires with one missing LARS score and then excluding 
these questionnaires.   
 
Data from the QLQ-C30 questionnaire are reported using means, as this is standard 
practice32, and compared using the Kruskal-Wallis test as scores have skewed 
distributions33. Values for population data are taken from the EORTC QLQ-C30 
Reference Values document and are the values provided for the general population34. 
Quality of life results for respondents were compared with results for the general 
population using a one-sample T test. QOL results between the different LARS 
categories were analysed using Goodman and Kruskal’s gamma for ordinal data.  
 
3.3.10 Ethical arrangements and research governance 
 
The study was sponsored by Queen Mary University London. The National Research 
Ethics Service (NRES) Committee East Midlands - Derby approved the study on 
07/03/2014 (Reference: 14/EM/0117) (Appendix 4). The study was registered with the 
ClinicalTrials.gov Protocol Registration System on 14/08/2014 (Identifier number: 
NCT02190656). Approval was gained from the Research & Development 
departments at each individual PIC. 
 
Written informed consent was not obtained. The information sheet explained the 
study including that participants were free to choose whether to participate. 
Completion and return of the questionnaire was therefore taken as implicit consent.  
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3.4 Results 
 
3.4.1 Response rates  
 
19 NHS Hospital Trusts (24 hospitals) acted as PICs to identify 2275 eligible 
participants between July 2014 and September 2015. One participant self-identified 
as eligible by contacting the study team directly, she had seen the details of the study 
on the ClinicalTrials.gov website. A total of 1197 replies were received, giving an 
overall response rate of 53%.  
 
The flowchart in Figure 3.3 shows the reasons for ineligibility, 86 respondents were 
categorised as ineligible. A further 18 of the questionnaires were not included as they 
were incomplete. In total, 1093 questionnaires were included in the analysis. Table 
3.1 shows the response rate at each of the PICs. 
 
Figure 3.3 Flowchart showing number of respondents and final numbers included 
in analysis. LARS: low anterior resection syndrome; QOL: quality of life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1197  
Replies 
 
1093  
Included 
 
18 Incomplete 
• Completely empty 2 
• LARS score empty 8 
• QOL score empty 3 
• LARS & QOL scores empty 1 
• Clinical details empty 4 
 
86 Ineligible 
• Stoma 28 
• Stoma closed < 1 year ago 13 
• Chemotherapy 12 
• Surgery not for cancer 10 
• Surgery < 1 year ago 6 
• Further anorectal surgery 6 
• Anastomotic leak 4 
• No surgery 3 
• Local recurrence 2 
• Tumour in transverse colon 1 
• Alzheimer's 1  
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Table 3.1 Response rates by PIC. For full names of PICs see Figure 3.1. 
 
 Sent Responded Response 
rate (%) 
Incomplete Ineligible Included 
BHR 88 43 48.9 0 1 42 
Barts 284 106 37.3 4 4 98 
Brighton 200 107 53.5 0 19 88 
Colchester 50 39 78.0 0 1 38 
GSTT 26 6 23.1 0 1 5 
Homerton 38 14 36.8 0 0 14 
St Marks 147 66 44.9 1 4 61 
M&TW 173 115 66.5 2 1 112 
Fife  91 47 51.6 0 4 43 
Forth 20 12 60.0 1 1 10 
Grampian 54 30 55.6 0 0 30 
Glasgow 66 31 47.0 1 1 29 
Highland 75 51 68.0 0 3 48 
Lothian 490 239 48.8 8 11 220 
Tayside 116 70 60.3 0 13 57 
NUH 113 67 59.3 0 3 64 
RD&E 81 58 71.6 1 5 52 
Barnet 37 17 45.9 0 0 17 
ULH 125 78 62.4 0 14 64 
Patient 1 1 100 0 0 1 
Overall 2275 1197 52.6 18 86 1093 
 
 
3.4.2 Participants  
 
Overall 64% of the respondents were male and 36% female. 31 respondents did not 
provide their age. The median age of the respondents was 65 with an interquartile 
range (IQR) of 59-72 and range of 28-88. Figure 3.4 shows the breakdown of 
respondents into five-year age groups. 
 
The year in which the respondents underwent surgery ranged from 1990 to 2014; 27 
respondents did not answer this question. 90% of respondents had undergone 
surgery in the five years preceding the study. The median number of years since 
surgery was 3 with an IQR of 2-4.  
 
 
 
 125 
Figure 3.4 Number of respondents by age category 
 
 
 
3.4.3 Proportion of participants with defunctioning stoma 
 
559 (51%) respondents had a defunctioning stoma created at the time of surgery. This 
result varied considerably by Trust, with a range of 10-100%. The median length of 
time before closure of a defunctioning stoma was 7 months with an IQR of 5-12 
months. The shortest time to reversal was 2 weeks; the longest was 47 months. Table 
3.2 shows the proportion undergoing defunctioning stoma in each NHS Trust and 
median length of time to closure.  
 
The risk factors for taking longer than median time to stoma closure on multivariable 
analysis were adjuvant chemotherapy OR 6.109 (95% CI 4.047 – 9.221, p = <0.001) and 
neoadjuvant radiotherapy OR 1.764 (95% CI 1.021 – 3.046, p = 0.042). Age, gender, 
neoadjuvant chemotherapy and mode of operation were not significant. The median 
length of time taken to stoma closure in those undergoing adjuvant chemotherapy 
was 11 months compared with 6 months in those not having adjuvant 
chemotherapy.  
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Table 3.2 Use of defunctioning stoma and length of time with stoma by PIC. For 
full names of PICs see Figure 3.1.  
 
The risk factors for stoma formation are shown in Table 3.3 below. Neoadjuvant 
radiotherapy had the highest odds ratio for stoma formation on multivariable 
analysis; the percentage with a stoma was 90% in those having neoadjuvant 
radiotherapy compared with 39% in those who did not.  
 
 
 
 
 
  
 Number with 
stoma 
% with 
stoma 
Median number of 
months with stoma 
IQR months 
with stoma 
BHR 25 59.5 12 7-14 
Barts 63 64.3 9 7-12 
Brighton 25 28.4 12 7-13 
Colchester 30 78.9 4 3-8 
GSTT 4 80.0 5 3-9 
Homerton 10 71.4 12 8-12 
St Marks 37 60.7 7 5-12 
M&TW 71 63.4 6 3-11 
Fife  9 20.9 9 5-12 
Forth 1 10.0 2 - 
Grampian 17 56.7 6 5-9 
Glasgow 25 86.2 5 3-6 
Highland 32 66.7 7 4-10 
Lothian 63 28.6 7 4-9 
Tayside 14 24.6 8 4-9 
NUH 27 42.2 9 6-10 
RD&E 38 73.1 6 5-8 
Barnet 17 100.0 6 5-12 
ULH 51 79.7 12 7-14 
Patient 0 0 - - 
Overall 559 51.1 7 5-12 
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Table 3.3 Risk factors for stoma formation.  
CI: confidence intervals; NS: not significant; lap: laparoscopic.  
 
 
3.4.4 Reoperations and ongoing treatment 
 
240 (22%) of patients had undergone 284 reoperations since their anterior resection; 
206 had 1 subsequent operation; 24 had undergone 2 and 10 patients had 3 
reoperations. Of the 284 reoperations, 24% were for metastatic disease, with 42 liver 
and 26 lung resections. 23% of reoperations were for complications of the anterior 
resection, the details of these are given below. The remaining 53% of reoperations 
were unrelated surgery, the most frequent being groin hernias and joint 
replacements.  
 No 
stoma 
Stoma Univariable 
odds ratio 
(95% CI) 
p-value Multivariable 
odds ratio 
(95% CI) 
p-value 
Gender 
• Female 
• Male 
 
220 
313 
 
174 
385 
 
1 
1.555  
(1.213 – 1.994) 
 
<0.001 
 
1 
1.532  
(1.153 – 2.035) 
 
0.003 
Age 
• ≤65 
• >65 
 
267 
251 
 
274 
270 
 
1 
1.048  
(0.824 – 1.333 
 
0.701 
 
NS 
 
0.122 
Neoadjuvant 
chemotherapy 
• No 
• Yes 
 
 
501 
30 
 
 
388 
165 
 
 
1 
7.102  
(4.709 – 10.712) 
 
 
<0.001 
 
 
NS 
 
 
0.252 
Neoadjuvant 
radiotherapy 
• No 
• Yes 
 
 
507 
24 
 
 
329 
228 
 
 
1 
14.640  
(9.401 – 22.797) 
 
 
<0.001 
 
 
1 
10.908  
(6.245 - 19.054) 
 
 
<0.001 
Mode of 
operation 
• Lap 
• Open/ 
converted 
 
 
249 
283 
 
 
169 
385 
 
 
1 
2.004  
(1.564 – 2.570 
 
 
<0.001 
 
 
1 
1.483  
(1.123 – 1.960) 
 
 
0.005 
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The following reoperations were carried out for complications of anterior resection: 
• 26 incisional hernia repairs 
• 11 stoma site hernia repairs 
• 10 laparotomy for adhesions 
• 9 wound repair/drainage of wound infection 
• 2 drainage of post-operative collection 
• 4 surgery for ileostomy reversal complication 
• 2 excision of scar tissue 
• 2 operations to remove retained swab  
 
3.4.5 Use of neoadjuvant and adjuvant therapy 
 
The proportion of patients undergoing neoadjuvant short-course radiotherapy 
(SCRT) and long-course chemoradiotherapy (LCRT) was variable between different 
Trusts, these results are also shown in Table 3.4. Overall 23.2% underwent 
neoadjuvant radiotherapy of some form.  
 
The likelihood of having neoadjuvant radiotherapy was significantly higher in those 
aged ≤65 years with 26.9% having radiotherapy, compared with 19.9% in those >65 
years (OR 1.475, 95% CI 1.107 – 1.967, p = 0.008). There was no significant difference 
in the proportion undergoing neoadjuvant radiotherapy by gender. The percentage 
specifically undergoing SCRT or LCRT was not dependent on age or gender.  
 
A low percentage of patients, 2.7% underwent neoadjuvant chemotherapy without 
radiotherapy and a much higher percentage, 39.5% had adjuvant chemotherapy. The 
proportion undergoing adjuvant chemotherapy did not depend on gender but was 
dependent on the age of the patient. 46.5% of those aged ≤65 years had adjuvant 
chemotherapy, compared with 31.9% of those >65 (OR 1.858, 95% CI 1.446 – 2.387, p = 
<0.001).  
 
4.5% of respondents had previously undergone radiotherapy for a different 
indication, the majority (43%) had this for breast cancer but others had undergone 
pelvic radiotherapy, particularly for prostate cancer, which may affect bowel 
function.  
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Table 3.4 Use of neoadjuvant and adjuvant therapy by NHS Trust. For full names 
of PICs see Figure 3.1; SCRT: short-course radiotherapy; LCRT: long-course 
chemoradiotherapy. 
 
3.4.6 Mode of surgery 
 
Overall 38.5% of patients had their surgery carried out laparoscopically, as with 
other results this proportion showed wide variation between different NHS Trusts, 
from 7.1 to 75.4%. Table 3.5 shows results for mode of operation for each NHS Trust. 
The rate of conversion from laparoscopic to open surgery also varied widely from 0 – 
21.4%.  
 
NHS Trust Neoadjuvant and adjuvant therapy - % respondents 
 Neoadjuvant therapy  
 Chemotherapy 
alone 
SCRT LCRT 
Adjuvant 
chemotherapy 
BHR 0 12.2 56.1 53.7 
Barts  4.1 6.1 29.6 52.0 
Brighton  5.7 2.3 4.5 19.3 
Colchester  0 0 10.5 28.9 
GSTT 20.0 0 0 60.0 
Homerton  0 14.3 21.4 57.1 
St Marks 4.9 0 8.2 36.1 
M&TW 4.5 11.7 11.7 41.4 
Fife  2.3 7.0 0 34.9 
Forth  10.0 0 0 30.0 
Grampian 6.7 13.3 43.3 46.7 
Glasgow 3.4 0 55.2 17.2 
Highland 0 2.1 29.2 39.6 
Lothian 1.4 7.8 7.3 43.8 
Tayside 1.8 0 0 49.1 
NUH 1.6 7.8 7.8 40.6 
RD&E 0 0 5.8 28.8 
Barnet 0 5.9 35.3 35.3 
ULH  1.6 30.2 31.7 36.5 
Patient  0 0 0 0 
Overall 2.7 7.2 16.0 39.5 
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On multivariable analysis, the only risk factor for open surgery (compared with 
those that started laparoscopically including the converted cases) was having 
undergone neoadjuvant radiotherapy (OR 2.630, 95% CI 1.714 – 4.037, p = <0.001).  
Conversion from laparoscopic to open operation was independent of age, gender 
and neoadjuvant chemotherapy.  
 
Table 3.5 Mode of operation for each NHS Trust. For full PIC names see Figure 3.1. 
 
 
3.4.7 Bowel function and LARS score 
 
Overall 37% of respondents had no LARS, 22% had minor LARS and 41% major 
LARS. The proportion of respondents in each LARS category for the different NHS 
Trusts is shown in Table 3.6. The mean LARS score overall was 24. Only 75 
respondents (7%) had a LARS score of 0.  
NHS Trust  Mode of operation - % respondents 
 Open Converted Laparoscopic 
BHR 52.4 7.1 40.5 
Barts  39.2 12.4 48.5 
Brighton  30.7 14.8 54.5 
Colchester  13.2 18.4 68.4 
GSTT 40.0 0 60.0 
Homerton  71.4 21.4 7.1 
St Marks 18.0 6.6 75.4 
M&TW 50.9 9.8 39.3 
Fife  48.8 16.3 34.9 
Forth  70.0 0 30.0 
Grampian 76.7 10.0 13.3 
Glasgow 71.4 10.7 17.9 
Highland 70.2 8.5 21.3 
Lothian 62.8 8.7 28.4 
Tayside 40.4 8.8 50.9 
NUH 73.4 4.7 21.9 
RD&E 45.1 13.7 41.2 
Barnet 35.3 11.8 52.9 
ULH  65.1 14.3 20.6 
Patient  0 0 100 
Overall 50.9 10.6 38.5 
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69.7% respondents experienced flatus incontinence (19.6% less than once each week 
and 50.1% more than once weekly), compared with 46.5% experiencing liquid 
incontinence (27.9% less than once weekly and 18.6% more than once weekly). 
Clustering was the most frequently occurring symptom, affecting 78.8% of 
respondents. Figure 3.5 shows the breakdown of LARS symptoms for all 
respondents with Figure 3.6 showing each symptom by those in the different LARS 
categories. Figure 3.7 shows the results for frequency of bowel movements, for all 
patients and for each LARS category.  
 
Table 3.6 Respondents in each LARS category for each NHS Trust. For full names 
of PICs see Figure 3.1. LARS: low anterior resection syndrome.  
 
 
 
 
No LARS 
(n) 
No LARS 
(%) 
Minor 
LARS 
(n) 
Minor 
LARS 
(%) 
Major 
LARS 
(n) 
Major 
LARS 
(%) 
BHR 11 26.2 10 23.8 21 50.0 
Barts 35 35.7 13 13.3 50 51.0 
Brighton 42 47.7 17 19.3 29 33.0 
Colchester 7 18.4 11 28.9 20 52.6 
GSTT 1 20.0 3 60.0 1 20.0 
Homerton 4 28.6 5 35.7 5 35.7 
St Marks 20 32.8 12 19.7 29 47.5 
M&TW 51 45.5 20 17.9 41 36.6 
Fife 15 34.9 8 18.6 20 46.5 
Forth 6 60.0 3 30.0 1 10.0 
Grampian 12 40.0 10 33.3 8 26.7 
Glasgow 4 13.8 6 20.7 19 65.5 
Highland 22 45.8 8 16.7 18 37.5 
Lothian 89 40.5 49 22.3 82 37.3 
Tayside 21 36.8 16 28.1 20 35.1 
NUH 29 45.3 13 20.3 22 34.4 
RD&E 17 32.7 16 30.8 19 36.5 
Barnet 4 23.5 3 17.6 10 58.8 
ULH 18 28.1 15 23.4 31 48.4 
Patient 0 0 0 0 1 100.0 
Overall 408 37.3 238 21.8 447 40.9 
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Figure 3.5 Frequency of component symptoms for LARS (all respondents) 
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Figure 3.6 Frequency of component symptoms in the different LARS categories. LARS: low anterior resection syndrome.  
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Figure 3.7 Frequency of bowel movements for all respondents and by LARS category. LARS: low anterior resection syndrome.  
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3.4.8 Risk factors for LARS 
 
There was no difference between those who had undergone SCRT and LCRT in the 
proportion with no LARS, minor LARS or major LARS (χ2 (2) = 0.284; p = 0.868). 
Following this finding, the binary outcome of neoadjuvant radiotherapy (including 
both SCRT and LCRT) was used in further analysis. The risk factors for LARS on 
univariable analysis are shown in Table 3.7. The results for multivariable binary 
logistic regression are shown in Table 3.8 and those for ordinal stepwise logistic 
regression are in Table 3.9. The ordinal regression proportional odds assumption was 
met (χ2 (7) = 8.55; p = 0.286). As shown in Table 3.9, the significant risk factors for 
LARS are: age ≤65 years (OR 1.46, 95% CI 1.16 – 1.84; p = 0.002); defunctioning stoma 
(OR 2.59, 95% CI 2.00 – 3.36; p = 0.001); neoadjuvant radiotherapy (OR 1.67, 95% CI 
1.22 – 2.27, p = 0.002) and female gender (OR 1.54, 95% CI 1.20 – 1.96; p = 0.001).  
 
The same risk factors were found on multivariable binary logistic regression, see 
Table 3.8. There was very little difference between results with missing values 
included and excluded, or between the different binary combinations of LARS 
categories (Table 3.8). The only difference was that for major LARS vs. minor/no 
LARS with missing values excluded, age was no longer a significant risk factor. The 
proportion of those correctly allocated into a LARS category using the risk factors as 
a model was also consistent across the different binary combinations and with or 
without missing values included, ranging from 65.0 to 66.1% 
 
With none of the significant risk factors present, in respondents who are male, >65 
years, with no stoma and no radiotherapy 61.0% have no LARS, 16.3% minor LARS 
and 22.7% major LARS. With all four risk factors present, female, ≤65 years, stoma 
and radiotherapy 15.9% have no LARS, 20.5% minor LARS and 63.6% have major 
LARS. 
 
Figure 3.8 shows box and whisker plots for LARS scores in different groups 
according to the risk factors included in analysis. p-values shown were calculated 
using the Mann Whitney test. The median LARS score for those undergoing 
radiotherapy was 32 compared with 24 in those who did not (p = <0.001); median 
score was 30 in those who had defunctioning stoma vs. 20 in those without (p = 
<0.001).  
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As shown above, neoadjuvant radiotherapy is a risk factor for LARS. 57.5% of those 
undergoing radiotherapy developed major LARS, with 22.2% having minor LARS 
and only 20.2% no LARS, vs. 35.9% major LARS, 21.4% minor LARS and 42.7% no 
LARS in those who did not have radiotherapy. Figure 3.9 and 3.10 show the 
symptom breakdown for those with neoadjuvant radiotherapy and without. Those 
who have had radiotherapy were significantly more likely to experience symptoms 
of LARS: flatus incontinence, faecal incontinence, urgency and clustering were all 
more likely (p = <0.001 for each with Mann Whitney test). Clustering was the most 
frequently experienced symptom by those with and without radiotherapy (90.9 vs. 
75.1%). Only 40.9% of those who had undergone radiotherapy opened their bowels 
1-3 times/day compared with 63.6% of those who had not had radiotherapy. 6 
patients had radiotherapy with no symptoms of LARS (0.6% of all patients and 2.4% 
of those who had radiotherapy), compared with 69 patients (%) who did not have 
radiotherapy (6.3% of all patients and 8.3% of those who did not have radiotherapy).  
 
The likelihood of LARS did not depend on length of time since surgery; no 
significant difference in major LARS vs. no LARS was shown between those who 
were less than, or more than, 3 years since surgery (>3 years OR 0.892, 95% CI 0678 – 
1.173, p-value 0.413). Figure 3.11 shows the breakdown of LARS category for those in 
the first seven years since surgery (further years were not included as there were 
very small numbers in each year).  
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Table 3.7 LARS risk factors on univariable analysis. 95% CI = 95% confidence intervals. * = significant at p <0.05. LARS: low anterior resection syndrome.  
 Major vs. minor/no LARS Major vs. no LARS Major/minor vs. No LARS 
 Missing values included Missing values excluded Missing values included Missing values excluded Missing values included Missing values excluded 
Variables Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Female gender 1.314 
(1.023 - 1.688) 
0.032* 
1.288 
(1.000 - 1.660) 
0.050 
1.333 
(1.008 - 1.764) 
0.044* 
1.315 
(0.990 - 1.747) 
0.059 
1.225 
(0.947 - 1.585) 
0.123 
1.220 
(0.940 - 1.584) 
0.134 
Age category 
≤65 years 
1.321 
(1.034 - 1.688) 
0.026* 
1.291 
(1.007 - 1.655) 
0.044* 
1.552 
(1.181 - 2.040) 
0.002* 
1.514 
(1.148 - 1.996) 
0.003* 
1.553 
(1.209 - 1.994) 
0.001* 
1.525 
(1.185 - 1.964) 
0.001* 
Years since 
operation ≤3 
1.155 
(0.903 - 1.477) 
0.252 
1.149 (0.895 – 
1.475) 
0.275 
1.121 (0.853 – 
1.474) 
0.413 
1.112 
(0.842 – 1.467) 
0.455 
1.048 
(0.816 – 1.346) 
0.712 
1.038 
(0.806 – 1.337) 
0.772 
Stoma 
2.718 
(2.116 - 3.491) 
<0.001* 
2.724 
(2.115 - 3.509) 
<0.001* 
3.682 
(2.775 - 4.885) 
<0.001* 
3.679 
(2.763 - 4.898) 
<0.001* 
3.067 
(2.374 - 3.962) 
<0.001* 
3.053 
(2.357 - 3.957) 
<0.001* 
Neoadjuvant 
radiotherapy 
2.421 
(1.817 - 3.226) 
<0.001* 
2.479 
(1.852 - 3.319) 
<0.001* 
3.383 
(2.374 - 4.821) 
<0.001* 
3.471 
(2.421 - 4.976) 
<0.001* 
2.937 
(2.098 - 4.112) 
<0.001* 
2.991 
(2.124 - 4.213) 
<0.001* 
Neoadjuvant 
chemotherapy 
2.086 
(1.525 - 2.854) 
<0.001* 
2.184 
(1.588 - 3.004) 
<0.001* 
2.662 
(1.820 - 3.893) 
<0.001* 
2.859 
(1.935 - 4.223) 
<0.001* 
2.346 
(1.635 - 3.368) 
<0.001* 
2.505 
(1.728 - 3.632) 
<0.001* 
Adjuvant 
chemotherapy 
1.047 
(0.818 - 1.340) 
0.715 
1.039 
(0.809 - 1.334) 
0.766 
0.958 
(0.729 - 1.259) 
0.757 
0.948 
(0.719 - 1.250) 
0.703 
0.893 
(0.695 - 1.147) 
0.377 
0.884 
(0.687 - 1.139) 
0.342 
Mode: open/ 
converted (vs. 
laparoscopic) 
1.286 
(1.001 - 1.652) 
0.049* 
1.248 
(0.968 - 1.609) 
0.087 
1.344 
(1.018 - 1.774) 
0.037* 
1.314 
(0.992 - 1.741) 
0.057 
1.263 
(0.982 - 1.624) 
0.069 
1.254 
(0.972 - 1.617) 
0.082 
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Table 3.8 LARS risk factors on multivariable binary logistic regression. ns: not significant; 95% CI: confidence intervals; LARS: low anterior resection 
syndrome. * = significant at p <0.05.  
 Major vs. minor/no LARS Major vs. no LARS Major/minor vs. No LARS 
 Missing values included Missing values excluded Missing values included Missing values excluded Missing values included Missing values excluded 
Variables Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Odds ratio 
(95% CI) 
p-value 
Female gender 
1.559 
(1.190 - 2.042) 
0.001* 
1.541 
(1.172 - 2.025) 
0.002* 
1.660 
(1.216 - 2.266) 
0.001* 
1.656 
(1.207 - 2.272) 
0.002* 
1.495 
(1.129 - 1.979) 
0.005* 
1.500 
(1.129 - 1.994) 
0.005* 
Age category 
≤65 years 
1.304 
(1.006 - 1.689) 
0.045* ns ns 
1.530 
(1.138 - 2.058) 
0.005* 
1.504 
(1.115 - 2.031) 
0.008* 
1.569 
(1.203 - 2.047) 
0.001* 
1.549 
(1.184 - 2.026) 
0.001* 
Stoma 
2.475 
(1.862 - 3.289) 
<0.001* 
2.419 
(1.815 - 3.222) 
<0.001* 
3.181 
(2.308 - 4.384) 
<0.001* 
3.160 
(2.284 - 4.372) 
<0.001* 
2.704 
(2.023 - 3.615) 
<0.001* 
2.686 
(2.002 - 3.603) 
<0.001* 
Neoadjuvant 
radiotherapy 
1.664 
(1.198 - 2.311) 
0.002* 
1.757 
(1.262 - 2.444) 
0.001* 
2.132 
(1.417 - 3.207) 
<0.001* 
2.222 
(1.467 - 3.366) 
<0.001* 
1.950 
(1.323 - 2.874) 
0.001* 
2.022 
(1.363 - 3.000) 
<0.001* 
Neoadjuvant 
chemotherapy ns ns ns ns ns ns ns ns ns ns ns ns 
Adjuvant 
chemotherapy ns ns ns ns ns ns ns ns ns ns ns ns 
Years since 
operation >3 ns ns ns ns ns ns ns ns ns ns ns ns 
Mode: open/ 
converted (vs. 
laparoscopic) 
ns ns ns ns ns ns ns ns ns ns ns ns 
Percentage 
correctly 
classified by 
model 
65.0% 65.0% 66.1% 66.1% 65.2% 65.0% 
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Table 3.9 LARS risk factors on multivariable ordinal stepwise logistic regression. 
Missing values were included for this analysis. ns: not significant; CI =  confidence 
intervals; LARS: low anterior resection syndrome. * = significant at p <0.05. 
 
 
 
 
 
 
No 
LARS 
Minor 
LARS 
Major 
LARS 
Multivariable odds 
ratio (95% CI) 
p-value 
Gender 
Missing (n=1) 
Male 
Female 
 
 
272 
135 
 
 
157 
81 
 
 
269 
178 
 
 
Reference 
1.54 (1.20 – 1.96) 
 
 
0.001* 
Age 
Missing (n=31) 
≤ 65 
>65 
 
 
175 
222 
 
 
125 
102 
 
 
241 
197 
 
 
1.46  (1.16 – 1.84) 
Reference 
 
 
0.002* 
Stoma 
Missing (n=0) 
No  
Yes 
 
 
269 
139 
 
 
111 
127 
 
 
154 
293 
 
 
Reference 
2.59 (2.00 – 3.36) 
 
 
0.001* 
Neoadjuvant 
radiotherapy 
Missing (n=5) 
No 
Yes 
 
 
 
357 
51 
 
 
 
179 
56 
 
 
 
300 
145 
 
 
 
Reference 
1.67 (1.22 – 2.27) 
 
 
 
0.002* 
Adjuvant 
chemotherapy 
Missing (n=4) 
No  
Yes 
 
 
 
240 
168 
 
 
 
152 
83 
 
 
 
267 
179 
 
 
 
NS 
 
 
 
NS 
Years since 
operation 
Missing (n=27) 
≤ 3 years 
> 3 years 
 
 
 
220 
178 
 
 
 
122 
107 
 
 
 
255 
184 
 
 
 
NS 
 
 
 
NS 
Mode of surgery 
Missing (n=7) 
Open/converted 
Laparoscopic  
 
 
235 
170 
 
 
145 
93 
 
 
288 
155 
 
 
NS 
 
 
NS 
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Figure 3.8 LARS scores for different risk factors. Box and whisker plots showing differences between 
LARS scores for: age category, gender, stoma, neoadjuvant radiotherapy, adjuvant chemotherapy and 
years since surgery. The middle line in each box represents the median value, with the boundaries of 
the box representing the quartiles and whiskers showing minimum and maximum values. LARS: low 
anterior resection syndrome; op: operation.   
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Figure 3.9 Frequency of component symptoms with and without radiotherapy 
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Figure 3.10 Frequency of bowel opening with and without radiotherapy 
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Figure 3.11 LARS category by year since surgery for those in the first seven years 
since surgery (further years not included as very small numbers in each year). LARS: 
low anterior resection syndrome. 
 
 
 
 
3.4.9 Quality of life results 
 
Quality of life was significantly different between the three groups with a p-value of 
<0.0001 on global health, all five functional scales and all nine symptom scales. These 
results are shown in Tables 3.10 and 3.11 and graphically represented in Figures 3.12 
and 3.13. Despite all the scales showing significant differences between groups, the 
differences in mean scores equate to different clinical relevance35. Social functioning 
showed the greatest difference between groups for the functional scales and 
diarrhoea was the symptom scale with the greatest difference amongst LARS 
categories.  
 
Those with no LARS scored significantly better than the general population for 
global health and all five functional scales, except physical functioning. Respondents 
with major LARS scored significantly worse than the population for global health 
and all scales except emotional functioning, see Table 3.12. Those with minor LARS 
scored significantly better than the population for global health, role functioning and 
emotional functioning, with no difference in the other scales.  
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Table 3.13 shows the results for symptom scales and how the population compare 
with those in the LARS categories. Those with no LARS scored significantly better 
than the population for fatigue, nausea & vomiting, pain, appetite loss, diarrhoea 
and financial difficulties, but they scored significantly worse for constipation. The 
major LARS group scored significantly worse than the population for all symptoms 
except pain. For the group with minor LARS the results were mixed, with scores 
significantly better than the population for fatigue and pain, and significantly worse 
than the population for constipation and diarrhoea; there was no difference for the 
other symptoms.  
 
Tables 3.14 and 3.15 show the quality of life results for those who underwent 
radiotherapy and those who did not. Quality of life was not affected by year since 
operation (p = 0.088). Figure 3.14 shows the mean global health for those in the first 
seven years since surgery (further years were not included as very small numbers in 
each year).  
  
Table 3.16 gives a breakdown of responses to the individual questions from the 
QLQ-C30 questionnaire according to LARS category. The results were significantly 
different across the three LARS categories for all questions (p = <0.001 for all, using 
Goodman and Kruskal’s gamma).  
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Table 3.10 Quality of life results – global health and functional scales (perfect score = 100). p-value shows difference between the three groups using 
Kruskal-Wallis test. Clinical significance of the difference in mean score between no LARS and major LARS. LARS: low anterior resection syndrome. 
 Mean score 
No LARS 
Mean score 
Minor LARS 
Mean score 
Major LARS 
p-value 
Score difference no 
LARS vs. Major LARS 
Clinical 
significance 
Global Health 82.9 79.4 69.1 <0.0001 13.8 Moderate 
Physical functioning  91.3 89.7 81.5 <0.0001 9.8 Minor 
Role functioning  92.6 90.6 75.2 <0.0001 17.5 Moderate 
Emotional functioning  90.6 85.6 76.3 <0.0001 14.3 Moderate 
Cognitive functioning 89.9 87.2 80.3 <0.0001 9.6 Minor 
Social functioning  92.1 85.1 68.2 <0.0001 23.9 Major 
 
Table 3.11 Quality of life results – symptom scales (perfect score = 0). p-value shows difference between the three groups using Kruskal-Wallis test. Clinical 
significance of the difference in mean score between no LARS and major LARS. LARS: low anterior resection syndrome. 
 Mean score 
No LARS 
Mean score 
Minor LARS 
Mean score Major 
LARS 
p-value 
Score difference no 
LARS vs. Major LARS 
Clinical significance 
Fatigue 14.5 18.5 29.5 <0.0001 15.0 Moderate 
Nausea & vomiting  1.5 2.5 7.0 <0.0001 5.5 Minor 
Pain  6.1 9.3 19.2 <0.0001 13.1 Moderate 
Dyspnoea 9.3 11.3 18.0 <0.0001 8.7 Minor 
Insomnia   15.8 22.4 32.7 <0.0001 16.9 Moderate 
Appetite loss 3.3 5.2 10.7 <0.0001 7.4 Minor 
Constipation   14.9 16.2 25.5 <0.0001 10.6 Moderate 
Diarrhoea   3.8 15.4 27.9 <0.0001 24.1 Major 
Financial difficulties  4.8 8.5 16.7 <0.0001 11.9 Moderate 
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Figure 3.12 Quality of life results – global health and functional scales (perfect score = 100) 
Population normal values are shown34. Error bars show the 95% confidence intervals. LARS: 
low anterior resection syndrome. 
 
 
 
Figure 3.13 Quality of life results – symptom scales (perfect score = 0). Population normal 
values are shown34. Error bars show the 95% confidence intervals. LARS: low anterior 
resection syndrome. 
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Table 3.12 Quality of life results – mean scores for global health and functional scales (perfect score = 100). Difference between 
population and LARS groups with one-sample T test. LARS: low anterior resection syndrome. 
 Population norm No LARS p-value Minor LARS p-value Major LARS p-value 
Global Health 71.2 82.9 <0.0001 79.4 <0.0001 69.1 0.0260 
Physical functioning  89.8 91.3 0.0514 89.7 0.8926 81.5 <0.0001 
Role functioning  84.7 92.6 <0.0001 90.6 <0.0001 75.2 <0.0001 
Emotional functioning  76.3 90.6 <0.0001 85.6 <0.0001 76.3 0.9836 
Cognitive functioning 86.1 90.0 <0.0001 87.2 0.3567 80.3 <0.0001 
Social functioning  87.5 92.1 0.0010 85.0 0.0723 68.2 <0.0001 
 
Table 3.13 Quality of life results – mean scores for symptom scales (perfect score = 0). Difference between population and LARS groups with 
one-sample T test. LARS: low anterior resection syndrome. 
 Population norm No LARS p-value Minor LARS p-value Major LARS p-value 
Fatigue 24.1 14.5 <0.0001 18.5 <0.0001 29.5 <0.0001 
Nausea & vomiting  3.7 1.5 <0.0001 2.5 0.0245 7.0 <0.0001 
Pain  20.9 6.1 <0.0001 9.3 <0.0001 19.2 0.1710 
Dyspnoea 11.8 9.3 0.0101 11.3 0.6932 18.0 <0.0001 
Insomnia   21.8 15.8 <0.0001 22.4 0.7354 32.7 <0.0001 
Appetite loss 6.7 3.3 <0.0001 5.2 0.0698 10.7 <0.0001 
Constipation   6.7 14.9 <0.0001 16.2 <0.0001 25.5 <0.0001 
Diarrhoea   7.0 3.8 <0.0001 15.4 <0.0001 27.9 <0.0001 
Financial difficulties  9.5 4.8 <0.0001 8.5 0.4575 16.7 <0.0001 
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Table 3.14 Quality of life results - global health and functional scales (perfect score 
= 100).  QOL with and without radiotherapy. CI: confidence intervals;  NA: 
neoadjuvant. 
 
 
Mean score 
No NA radiotherapy 
(95% CI) 
Mean score 
NA radiotherapy 
(95% CI) 
p-value 
Global Health 76.9 (75.6 – 78.2) 
75.1 
(72.6 – 77.6) 0.241 
Physical functioning  87.7 
(86.5 – 88.9) 
84.3 
(81.5 – 87.0) 
0.237 
Role functioning  86.8 (85.1 – 88.4) 
79.2 
(75.4 – 82.9) <0.001 
Emotional functioning  84.0 (82.6 – 85.4) 
82.3 
(79.5 – 85.1) 0.508 
Cognitive functioning 85.6 (84.3 – 86.9) 
85.1 
(82.6 – 87.5) 0.990 
Social functioning  83.2 (81.5 – 84.8) 
72.9 
(69.2 – 76.6) <0.001 
 
Table 3.15 Quality of life results – symptom scales (perfect score = 0). QOL with 
and without radiotherapy. CI: confidence intervals; NA: neoadjuvant. 
 
 Mean score 
No NA radiotherapy 
(95% CI) 
Mean score 
NA radiotherapy 
(95% CI) 
p-value 
Fatigue 21.2 (19.7 – 22.8) 
22.4 
(19.3 – 25.6) 0.942 
Nausea & vomiting  3.7 (3.0 – 4.5) 
4.8 
(3.1 – 6.5) 0.299 
Pain  11.6 (10.1 – 13.0 
14.2 
(11.2 – 17.2) 0.117 
Dyspnoea 13.1 (11.5 – 14.7) 
13.9 
(10.8 – 17.1) 0.898 
Insomnia   24.0 
(22.0 – 26.0) 
25.3 
(21.6 – 28.9) 
0.510 
Appetite loss 6.5 (5.4 – 7.6) 
7.4 
(5.4 – 9.5) 0.306 
Constipation   19.8 (18.0 – 21.6) 
18.6 
(15.3 – 21.8) 0.470 
Diarrhoea   14.7 (13.1 – 16.3) 
20.8 
(17.4 – 24.2) <0.001 
Financial difficulties  9.6 (8.0 – 11.2) 
13.6 
(10.3 – 16.9) 0.002 
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Figure 3.14 Mean global health by year post-operation for those in the first seven 
years since surgery (further years not included as very small numbers in each year). 
Error bars show the 95% confidence intervals. 
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Table 3.16 Responses to questions on the QLQ-C30 questionnaire by LARS category.  
  
Not at All A Little 
Quite a 
Bit 
Very Much p-value 
N % N % N % N %  
Q1. Do you have any trouble 
doing strenuous activities, like 
carrying a heavy shopping 
bag or suitcase? 
No LARS 
Minor LARS 
Major LARS 
266 
148 
204 
65.4 
62.4 
45.9 
108 
57 
129 
26.5 
24.1 
29.1 
21 
22 
61 
5.2 
9.3 
13.7 
12 
10 
50 
2.9 
4.2 
11.3 
 
<0.001 
Q2. Do you have any trouble 
taking a long walk? 
No LARS 
Minor LARS 
Major LARS 
279 
150 
191 
68.6 
63.6 
43.1 
75 
45 
109 
18.4 
19.1 
24.6 
28 
25 
72 
6.9 
10.6 
16.3 
25 
16 
71 
6.1 
6.8 
16.0 
 
<0.001 
Q3. Do you have any trouble 
taking a short walk outside of 
the house? 
No LARS 
Minor LARS 
Major LARS 
362 
205 
331 
90.0 
87.6 
74.5 
26 
23 
74 
6.5 
9.8 
16.7 
9 
4 
23 
2.2 
1.7 
5.2 
5 
2 
16 
1.2 
0.9 
3.6 
 
<0.001 
Q4. Do you need to stay in 
bed or a chair during the day? 
No LARS 
Minor LARS 
Major LARS 
362 
210 
341 
88.7 
88.6 
76.5 
33 
19 
73 
8.1 
8.0 
16.4 
12 
6 
26 
2.9 
2.5 
5.8 
1 
2 
6 
0.2 
0.8 
1.3 
 
<0.001 
Q5. Do you need help with 
eating, dressing, washing 
yourself or using the toilet? 
No LARS 
Minor LARS 
Major LARS 
397 
228 
410 
97.8 
95.8 
91.7 
4 
5 
20 
1.0 
2.1 
4.5 
2 
3 
14 
0.5 
1.3 
3.1 
3 
2 
3 
0.7 
0.8 
0.7 
 
<0.001 
Q6. Were you limited in doing 
either your work or other 
daily activities? 
No LARS 
Minor LARS 
Major LARS 
346 
192 
248 
84.8 
81.4 
55.7 
46 
33 
118 
11.3 
14.0 
26.5 
8 
6 
44 
2.0 
2.5 
9.9 
8 
5 
35 
2.0 
2.1 
7.9 
 
<0.001 
Q7. Were you limited in 
pursuing your hobbies or 
other leisure time activities? 
No LARS 
Minor LARS 
Major LARS 
343 
182 
232 
84.5 
77.4 
52.1 
45 
42 
120 
11.1 
17.9 
27.0 
8 
4 
49 
2.0 
1.7 
11.0 
10 
7 
44 
2.5 
3.0 
9.9 
 
<0.001 
Q8. Were you short of breath? 
No LARS 
Minor LARS 
Major LARS 
317 
174 
281 
77.7 
73.4 
63.0 
73 
51 
106 
17.9 
21.5
23.8 
13 
7 
42 
3.2 
3.0 
9.4 
5 
5 
17 
1.2 
2.1 
3.8 
 
<0.001 
Q9. Have you had pain? 
No LARS 
Minor LARS 
Major LARS 
339 
165 
255 
83.9 
69.3 
57.3 
45 
60 
119 
11.1 
25.2 
26.7 
14 
10 
48 
3.5 
4.2 
10.8 
6 
3 
23 
1.5 
1.3 
5.2 
 
<0.001 
Q10. Did you need to rest? 
No LARS 
Minor LARS 
Major LARS 
260 
141 
186 
63.9 
59.7 
42.2 
122 
74 
172 
30.0 
31.4 
39.0 
17 
18 
56 
4.2 
7.6 
12.7 
8 
3 
27 
2.0 
1.3 
6.1 
 
<0.001 
 
Q11. Have you had trouble 
sleeping? 
No LARS 
Minor LARS 
Major LARS 
260 
126 
169 
63.7 
52.9 
38.1 
112 
72 
154 
27.5 
30.3 
34.7 
26 
32 
81 
6.4 
13.4 
18.2 
10 
8 
40 
2.5 
3.4 
9.0 
 
<0.001 
Q12. Have you felt weak? 
No LARS 
Minor LARS 
Major LARS 
296 
149 
205 
72.7 
63.1 
46.0 
89 
71 
162 
21.9 
30.1 
36.3 
18 
12 
55 
4.4 
5.1 
12.3 
4 
4 
24 
1.0 
1.7 
5.4 
 
<0.001 
Q13. Have you lacked 
appetite? 
No LARS 
Minor LARS 
Major LARS 
375 
203 
328 
91.9 
85.3 
73.4 
27 
33 
100 
6.6 
13.9 
22.4 
5 
2 
13 
1.2 
0.8 
2.9 
1 
0 
6 
0.2 
0 
1.3 
 
<0.001 
Q14. Have you felt nauseated? 
No LARS 
Minor LARS 
Major LARS 
385 
215 
338 
94.4 
90.3 
75.8 
19 
20 
85 
4.7 
8.4 
19.1 
3 
2 
17 
0.7 
0.8 
3.8 
1 
1 
6 
0.2 
0.4 
1.3 
 
<0.001 
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Not at All A Little 
Quite a 
Bit 
Very Much p-value 
N % N % N % N %  
Q15. Have you vomited? 
No LARS 
Minor LARS 
Major LARS 
402 
230 
407 
98.5 
97.0 
91.1 
4 
6 
31 
1.0 
2.5 
6.9 
2 
1 
7 
0.5 
0.4 
1.6 
0 
0 
2 
0 
0 
0.4 
 
<0.001 
Q16. Have you been 
constipated? 
No LARS 
Minor LARS 
Major LARS 
268 
146 
213 
65.7 
61.6 
47.8 
106 
68 
149 
26.0 
28.7 
33.4 
26 
22 
60 
6.4 
9.3 
13.5 
8 
1 
24 
2.0 
0.4 
5.4 
 
<0.001 
Q17. Have you had diarrhea? 
No LARS 
Minor LARS 
Major LARS 
365 
150 
185 
89.7 
63.0 
41.8 
38 
69 
168 
9.3 
29.0 
37.9 
3 
16 
67 
0.7 
6.7 
15.1 
1 
3 
23 
0.2 
1.3 
5.2 
 
<0.001 
Q18. Were you tired? 
No LARS 
Minor LARS 
Major LARS 
226 
96 
129 
55.9 
40.7 
29.1 
148 
115 
202 
36.6 
48.7 
45.6 
24 
22 
77 
5.9 
9.3 
17.4 
6 
3 
35 
1.5 
1.3 
7.9 
 
<0.001 
Q19. Did pain interfere with 
your daily activities? 
No LARS 
Minor LARS 
Major LARS 
366 
201 
295 
90.1 
84.5 
66.7 
28 
32 
93 
6.9 
13.4 
21.0 
7 
3 
31 
1.7 
1.3 
7.0 
5 
2 
23 
1.2 
0.8 
5.2 
 
<0.001 
Q20. Have you had difficulty 
in concentrating on things like 
reading a newspaper or 
watching television? 
No LARS 
Minor LARS 
Major LARS 
367 
199 
313 
90.0 
84.3 
70.3 
33 
28 
98 
8.1 
11.9 
22.0 
7 
7 
24 
1.7 
3.0 
5.4 
1 
2 
10 
0.2 
0.8 
2.2 
 
<0.001 
Q21. Did you feel tense? 
No LARS 
Minor LARS 
Major LARS 
314 
161 
214 
77.0 
67.6 
48.4 
82 
64 
158 
20.1 
26.9 
35.7 
11 
11 
58 
2.7 
4.6 
13.1 
1 
2 
12 
0.2 
0.8 
2.7 
 
<0.001 
Q22. Did you worry? 
No LARS 
Minor LARS 
Major LARS 
284 
138 
198 
69.6 
58.0 
44.6 
98 
78 
172 
24.0 
32.8 
38.7 
24 
17 
52 
5.9 
7.1 
11.7 
2 
5 
22 
0.5 
2.1 
5.0 
 
<0.001 
Q23. Did you feel irritable? 
No LARS 
Minor LARS 
Major LARS 
315 
152 
213 
77.6 
64.7 
47.8 
79 
72 
156 
19.5 
30.6 
35.0 
10 
8 
61 
2.5 
3.4 
13.7 
2 
3 
16 
0.5 
1.3 
3.6 
 
<0.001 
Q24. Did you feel depressed? 
No LARS 
Minor LARS 
Major LARS 
331 
171 
240 
81.3 
72.2 
54.1 
61 
46 
146 
15.0 
19.4 
32.9 
12 
13 
37 
2.9 
5.5 
8.3 
3 
7 
21 
0.7 
3.0 
4.7 
 
<0.001 
Q25. Have you had difficulty 
remembering things? 
No LARS 
Minor LARS 
Major LARS 
239 
129 
177 
58.7 
55.1 
40.1 
143 
86 
202 
35.1 
36.8 
45.8 
22 
13 
43 
5.4 
5.6 
9.8 
3 
6 
19 
0.7 
2.6 
4.3 
 
<0.001 
Q26. Has your physical 
condition or medical 
treatment interfered with your 
family life? 
No LARS 
Minor LARS 
Major LARS 
336 
1632
04 
82.6 
69.1 
46.0 
56 
53 
138 
13.8 
22.5 
31.2 
9 
17 
66 
2.2 
7.2 
14.9 
6 
3 
35 
1.5 
1.3 
7.9 
 
<0.001 
Q27. Has your physical 
condition or medical 
treatment interfered with your 
social activities? 
No LARS 
Minor LARS 
Major LARS 
329 
147 
152 
80.8 
62.0 
34.2 
58 
68 
162 
14.3 
28.7 
36.4 
17 
18 
82 
4.2 
7.6 
18.4 
3 
4 
49 
0.7 
1.7 
11.0 
 
<0.001 
Q28. Has your physical 
condition or medical 
treatment caused you financial 
difficulties? 
No LARS 
Minor LARS 
Major LARS 
368 
195 
305 
90.4 
82.6 
68.4 
24 
28 
90 
5.9 
11.9 
20.2 
10 
7 
19 
2.5 
3.0 
4.3 
5 
6 
32 
1.2 
2.5 
7.2 
 
<0.001 
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3.4.10 Comments from participants 
 
Along with returning their questionnaire in the post, 23 patients also sent either a 
note or a letter along with it. These responses were uninvited but detail the 
experience of those living with symptoms of LARS. A small selection of these 
responses is included below.  
 
“Difficult to answer some questions as I compare things like quality of life with the 
worst misery and zilch quality of life, and my friends and peers who seem to ‘have a 
life’. I try to measure quality in the things like being able to get to the toilet by 
myself, being actually able to get out for a coffee but I really want to be able to go on 
a holiday or be able to work at a fulfilling or even a decent basic job and stay/visit 
with friends – none of which I can do now.” 
55F, LARS score = 41 (major LARS) 
 
“The first few weeks after the reversal were an absolute nightmare but this 
fortunately soon changed and my bowel settled (if that’s the right word) to a pattern 
of usually producing nothing for two days and then requiring me to make a number 
of visits to the toilet on the third day over a period of about three hours, the first visit 
I usually get a warning of about two or three minutes, subsequent visits can involve 
a more athletic dash (may become a problem with increasing age) after this we settle 
back to the routine. The problem to my work, and social life is never being quite sure 
of the timing and sometimes I can need to go to the toilet on consecutive days and 
although this is unusual it is a frequent worry to my wife and I when travelling or 
when I am attending one of my many meetings, hence my response to the questions 
about worry, stress and depression.” 
66M, LARS score = 42 (major LARS) 
 
“Following reversal my life has changed, I am ruled by my bowels, have to be careful 
about what I eat and drink. Life will never be the same. But what choice did I have? I 
had to go with the treatment good that it was. I am still alive for my family.” 
63M, LARS score = 32 (major LARS) 
 
“Given that my cancer is cured, I accept LARS as the price to pay.” 
79M, LARS score = 41 (major LARS) 
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“You do not ask what changes there have been to the timing, frequency and duration 
of the ‘opening of my bowels’, which are the biggest and most affecting changes to 
my life. Before I went once, first thing in the morning and it took about one minute. 
Now, my ‘active’ time is between 0100hrs and 0700hrs, around three times and each 
one can last half an hour, which interferes with my sleep.” 
72M, LARS score = 30 (major LARS) 
 
“What bothers me most is that I can never predict what a day will bring.” 
70F, LARS score = 37 (major LARS) 
 
“I have to go to the toilet about 6 times a day. I pass about 2 pieces each time. I never 
feel as if I have finished, but cannot pass anymore by staying there. Before I go to the 
toilet it becomes uncomfortable and I must go, where ever I am. I can hold on but 
becomes more uncomfortable the longer I leave it. I have not had any accidents. 
When I go it is normally on the medium to firm side. It is thought that my bowel 
does not expand as it should, to collect more before going to the toilet. I have had far 
more flatus – wind, than before the operation. I have to pass the wind as it makes it 
very uncomfortable, near to pain, in the area of the operation. I cannot control this all 
the time. These are the main problems from the operation. I am in good health and 
try not to get me down, or stop me from doing anything I would normally do. It is 
what it is and I try to get on with my life.” 
62M, LARS score = 36 (major LARS) 
 
 
3.5 Discussion 
 
This study assessed the prevalence of LARS in the UK population for the first time 
following the UK validation of the LARS score. LARS was found to affect a 
considerable proportion of patients following anterior resection, with 41% 
experiencing major LARS and 63% experiencing LARS in some form. The majority of 
patients who have undergone an anterior resection will have to live with bowel 
dysfunction affecting their quality of life. These results are similar to those from the 
UK validation of the LARS questionnaire, which found that 47% of patients had 
major LARS and a further 23% had minor LARS28. The results are also very similar to 
a study of LARS prevalence in Danish patients, which showed 41% major LARS and 
23% minor LARS11. Prior to the development of the LARS score, the lack of 
measurement tool meant that studies were limited to assessment of individual 
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symptoms such as urgency or incontinence, making estimation of the proportion of 
patients who had LARS very difficult21. Previous published reviews about LARS 
quote wide ranging estimates of the proportion affected including: 10-70%36 up to 
60%21, up to 80%37 and up to 90%7. This may partly explain why the proportion 
affected has not been appreciated; one study of Spanish and American surgeons 
found that they have good theoretical knowledge about LARS but underestimate the 
probability of patients suffering from it38.  
 
Clustering was the most frequently experienced symptom in these respondents 
followed by flatus incontinence and urgency. Even the least frequently experienced 
symptom, faecal incontinence, was still experienced by nearly half of respondents. A 
meta-analysis of functional symptoms after anterior resection calculated pooled 
incidence of symptoms and also found clustering to be the most frequently 
experienced, with pooled incidence of 59%21. The results for pooled proportions of 
symptoms from the meta-analysis are lower than the current study for all of the 
symptoms involved21.  
 
Clustering can be defined as “numerous bowel movements occurring within a short 
time period”39, essentially reflecting a sensation of incomplete emptying that requires 
a return to the toilet multiple times40. The term ‘stool fragmentation’ is also used to 
describe the same problem39. It is a symptom that is frequently assessed in studies of 
bowel function37 and one that patients find troublesome as it affects their daily 
activities and quality of life9.  
 
LARS was associated with increased stool frequency; the majority of those with 
major LARS had a frequency of 4-7 times per day. Interestingly, for those with major 
LARS the proportion opening their bowels less than once daily (7.6%) was lower 
than this proportion in those without LARS (11.5%) and in all respondents (8.8%). 
Despite this result, the proportion reporting constipation on the QLQ-C30 
questionnaire was significantly higher for those with LARS. It is possible that what 
these patients are reporting as ‘constipation’ is actually difficulty with rectal 
evacuation or incomplete emptying, both of which are known to be symptoms of 
LARS7.   
 
The risk factors for LARS identified by this study are neoadjuvant radiotherapy, 
defunctioning stoma, female gender and younger age (≤65); these had all been 
identified as risk factors for LARS by previous studies11,41,42. Neoadjuvant 
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radiotherapy is an established risk factor for bowel dysfunction following anterior 
resection41,43. Radiotherapy induces physiological changes including reduced squeeze 
pressures, capacity and rectal distensibility44 with scarring of the anal sphincters, 
possibly due to fibrosis45,46. Defunctioning stoma has also been previously identified 
as a risk factor for LARS42. It is likely that in this study it also acts as a surrogate 
marker for anastomotic height. With the methodology used it was not possible to 
collect this information and confirm this. However, defunctioning stoma has been 
shown to increase risk independently of tumour height42, this may be partly due to 
the effects of diversion colitis on the neorectum47 although the exact mechanism is 
not fully understood.  
 
Studies have shown conflicting results with regard to the effect of gender on 
functional outcomes following anterior resection11,48. It is accepted that bowel 
function in women is potentially made worse by the impact of obstetric factors on 
pelvic floor function but to fully determine whether this is the only factor involved 
would require further studies. Three previous studies using the LARS questionnaire 
have identified younger age as a risk factor for LARS11,13,42 despite baseline bowel 
dysfunction being more prevalent in older people49. One possible explanation for this 
finding is that younger patients have better pre-operative function and therefore a 
greater perceived difference between their function before and after anterior 
resection11. Younger people are more likely to be planning a return to employment 
and the symptoms of LARS can make this very difficult, as mentioned in the 
comments received from respondents. Another possible reason which has been 
suggested for this result, is that those older patients with pre-existing poor function 
may have had an APER or anterior resection with end colostomy rather anastomosis, 
skewing the results42. This would again, require prospective studies, to fully 
understand the contributing factors for this result.  
 
This study did not identify any relationship between the time since surgery and risk 
of LARS. Quality of life was also not dependent on number of years since operation. 
These findings are in keeping with a follow-up study from the Dutch TME trial, 
which showed that even 14 years later, many patients remained symptomatic from 
LARS13. This study excluded patients in the first twelve months post surgery who 
have been previously shown to have worse function than patients at twelve months8. 
These findings have implications for the discussions about function held with 
patients in the first year during surgery and beyond this point.  
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The results from this study confirm that LARS has a detrimental effect on all aspects 
of quality of life, with the greatest effect on social functioning, findings that are in 
keeping with those from previous studies8,12,17. The individual symptoms that 
contribute to LARS have been shown to individually affect QOL so it is no surprise 
that a combination of these problems has an even greater effect. On the individual 
symptom scales, diarrhoea showed the greatest difference between those with and 
without LARS but financial difficulties, insomnia, pain and fatigue were the next 
most clinically relevant scores, showing that LARS affects a number of aspects of 
QOL. Even symptoms seemingly unrelated to LARS such as shortness of breath, 
nausea, weakness and poor appetite were all significantly more frequent in those 
with LARS. Some of the emotional and mental aspects of LARS including feeling 
worried, depressed, tense and irritable, along with difficulties concentrating and 
with memory may be partially the result of problems with sleep but, as one 
respondent mentioned in their comment, these can also relate directly to bowel 
symptoms.  
 
A Cochrane review comparing QOL in patients who have undergone anterior 
resection and APER showed no difference and suggested that LARS accounts for the 
lack of benefit from sphincter preserving surgery50. Cancer survivors have previously 
been shown to have worse QOL than the population51. Interestingly in this study, 
those patients who had undergone anterior resection and did not have LARS 
actually had better QOL than the background population. This could be explained by 
the finding that having cancer can lead to positive adaptations including improved 
life outlook and enhanced relationships52.  
 
Just over half of the respondents underwent a defunctioning stoma at the time of 
surgery, this compares with 57% in the Dutch TME trial53. The UK National Bowel 
Cancer Audit (NBCA) 2018 report shows that between 2013-2016, 77% of anterior 
resections were covered by a stoma29. The proportion of respondents in the current 
study who had a stoma, would be expected to be lower than national data as the 
participants are survivors with good outcomes (see below). The risk factors for stoma 
formation were male gender, open/converted surgery and neoadjuvant radiotherapy. 
These are all known to be risk factors for anastomotic leak54,55 and therefore 
inherently would be potential reasons for stoma formation. Male gender has been 
shown to be a risk for conversion from laparoscopic surgery to open and the 
narrower male pelvis can make rectal cancer surgery technically challenging56. 
Preoperative radiotherapy has been previously shown to increase the likelihood of 
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stoma formation although the same study showed no difference rates of stoma 
between genders57. It is not surprising that adjuvant chemotherapy led to delays with 
closure of stoma, this has been identified by several studies58-60 and is well recognised 
in clinical practice. 
 
In this study, 7.2% underwent neoadjuvant SCRT and 16% LCRT, with increased use 
in younger patients. This compares with national audit data showing 8% of patients 
had SCRT and 26% LCRT; the national audit also found that younger patients were 
more likely to undergo radiotherapy29.  
 
This questionnaire identified highly variable results for rates of defunctioning stoma, 
use of neoadjuvant therapy including short course and long course radiotherapy, use 
of adjuvant therapy, mode of surgery and conversion rates from laparoscopic to 
open surgery across the PICs that took part in the study. This finding reflects the 
complexities involved in the management of rectal cancer treatment but also raises 
several questions about why this variation exists. The use of a defunctioning stoma 
for anterior resection ranged from 10-100% between populations that would be 
expected to be fairly similar in their pathology. The NBCA also reported marked 
variation in rates of stoma use, neoadjuvant therapy, laparoscopic surgery and 
adjuvant chemotherapy29. One of the recommendations of the audit report is a better 
understanding of regional differences in treatment, and the reasons underlying this29. 
The level of variation in practice confirms that complex factors are involved in 
decision-making when treating patients with rectal cancer, and further studies to 
look directly at this would potentially be very useful.  
 
The LARS questionnaire is easily completed and ideally suited to routine use during 
follow-up either in outpatients or via telephone follow-up. It is also ideal as a 
research tool to permit comparison of outcomes with a consistent outcome measure. 
The questionnaire has been designed to be used as a universal international measure 
for measuring LARS27 and has already been translated and validated in several 
languages. Although the questionnaire classifies patients into those with major 
LARS, minor LARS and no LARS, in some regards this is an artificial dichotomy as 
in reality the symptoms are on a spectrum, for example someone scoring 19 and 20 
will probably have very similar experiences. There are also many other symptoms, 
which affect patients and impact on QOL, which are not included in the 
questionnaire, including: urinary incontinence, subfertility, erectile dysfunction, 
neuropathy from chemotherapy, dyspareunia and premature menopause10,61,62. 
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It has previously been shown that surgeons and oncologists do not have a thorough 
understanding of which symptoms are most troublesome to patients63. The results 
from this study indicate a need for careful counselling of patients and discussion of 
this potential side effect through the process of joint decision-making. This can be 
very challenging at the time of cancer diagnosis, particularly in rectal cancer, as the 
treatment options can be complex. Increased use of neoadjuvant therapy has 
improved survival from rectal cancer but this treatment has a long-term impact on 
function and needs to be reserved for those who will benefit from it. There is a need 
to understand more about how to predict response in individual patients and work 
in ongoing, with an online tool to predict bowel dysfunction now available42. 
 
The demographics of the respondents to the questionnaire reflect those of the rectal 
cancer population. Rectal cancer is more common in men, who make up over 60% of 
those with rectal in the UK1. The respondents to the questionnaire are those with 
good outcomes since they have survived beyond twelve months and are not 
receiving ongoing chemotherapy or have local recurrence; this means that the results 
are only applicable to this group. The proportions of all rectal cancer patients 
undergoing defunctioning stoma, neoadjuvant and adjuvant therapy would 
therefore be expected to be higher than those shown in the results. 
 
The response rate to the questionnaire, 53%, is reasonable given that this was an 
uninvited questionnaire which came directly from the study team (and not the 
patient’s usual surgical department) and that the participants were an average of 
three years post surgery, meaning that some would have moved address. A wide 
range of NHS Trusts were included across England and Scotland, including both 
teaching hospitals in cities and district general hospitals in both urban and rural 
areas.   
 
Limitations of the study include that the baseline function / QOL in these patients is 
unclear. Due to the retrospective approach and the methodology used it was not 
possible to guarantee that all potentially eligible participants were included or to 
characterise the non-respondents. In surveys of cancer-related experience, non-
respondents are more likely to be young, non-White and socioeconomically 
deprived64. The sample size was based on feasibility and no power calculation was 
carried out prior to the study. This was partly due to the lack of evidence about the 
expected proportions of patients with LARS at the time the study was designed. It is 
possible that patients may have been inaccurate in their knowledge of their 
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treatment, although this does not seem to be the case as most items were completed 
and many respondents added extra information. It was not possible to collect data 
about some variables including tumour stage, tumour height and anastomotic 
configuration. These variables are often inconsistently recorded and heterogeneous 
in nature21 and this information would be best captured with a prospective approach. 
In hindsight, it would have been interesting to ask participants questions about the 
management of their symptoms, whether they have received support with them and 
how they are coping with their symptoms. These questions would have provided 
additional relevant information but would also have lengthened the questionnaire 
and potentially caused concern or anxiety for participants.    
 
A prospective multi-centre study would not only help to fully understand the risk 
factors and causes of LARS but could also cover a range of other related questions 
including reasons for stoma formation and non-closure, risks for anastomotic leak, 
the effect of post-operative morbidity on long term QOL and comparison in QOL 
with patients having APER. It would be possible to take into account baseline 
function, obstetric injuries, co-morbidities and presenting symptoms, all factors 
which may well play a part in the development of LARS.  
 
The letters and comments received from participants were unexpected but they are 
evidence of the clear need that people with LARS have to talk about the problems 
they are experiencing. Several participants also phoned to discuss their problems in 
more detail, often mentioning that they found it difficult to talk to family or friends 
due to embarrassment. A large number expressed a wish to receive a lay copy of the 
results of this study (which was offered in the participant information sheet). The 
emphasis for these people is on the effect that symptoms have on their daily life and 
ability to carry out activities that other people take for granted, for example going to 
work, going on holiday or visiting friends. These issues have been identified by 
qualitative studies exploring the problems experienced by those with LARS9,65. 
Respondents acknowledged that they have survived cancer and they are grateful for 
this but they surely deserve better recognition and treatment for LARS, a long term 
condition, which is a side effect of treatment and affects so many of them.  
 
Routine use of the LARS questionnaire during follow-up would allow identification 
of patients who might benefit from treatment and referral of these patients. It is only 
through routine assessment, intervention and then structured analysis of 
intervention outcomes that treatment for LARS will be improved10. Given the scale of 
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the problem, more work is needed on treatment strategies including to determine the 
optimal time for treatment and who should oversee this. There is currently no 
specific treatment for LARS and a lack of ownership of these patients outside of 
specialist centres with an interest in functional problems7,66. Colorectal nurse 
specialists, who are primarily responsible for follow-up of rectal cancer patients, are 
usually the first to identify that patients are experiencing symptoms. They may be 
able to provide advice and support depending on their level of experience but 
management is usually symptom based7.  
 
Initial treatment measures for LARS may include dietary advice, laxatives, bulking 
agents, loperamide and suppositories67. Patients who do not improve with these 
measures may be referred to specialist pelvic floor clinics or tertiary units who 
specialise in these problems but this often requires travelling, which can clearly be 
difficult for those with LARS. Further options for therapy may include bowel 
irrigation, biofeedback or sacral nerve stimulation7,67. A systematic review assessing 
the use of pelvic floor rehabilitation, including biofeedback, following anterior 
resection, showed that these therapies can improve functional outcome68. However, 
the studies included were either case control or cohort studies, and there is a lack of 
trials in this area. In addition to physical treatment, these patients are also likely to 
need psychological support69. There have been recent calls for a “holistic, 
multidisciplinary and systematic approach” to treatment for these patients70 but 
surely the first step towards this would be introducing assessment for LARS into 
routine practice when following up patients after anterior resection.  
 
 
3.6 Conclusions 
 
LARS affects a considerable proportion of patients in the UK following anterior 
resection, it is detrimental to quality of life and does not resolve with time. 
Information about LARS needs to be included in patient counselling and consent 
prior to treatments for rectal cancer.  
 
The LARS score should be routinely used in the clinical follow up of all rectal cancer 
patients who have undergone anterior resection, to systematically identify those who 
would benefit from treatment. Rectal cancer patients are usually followed up either 
by their surgical team or a specialist nurse. The LARS questionnaire should be used 
at each patient encounter as a screening tool, completed prior to the appointment if 
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time is limited. This would identify patients who need a more detailed exploration of 
their symptoms and/or any management options, including onward referral for 
specialist management or support groups as appropriate. Focused research studies 
are needed to determine who is best placed to manage LARS – surgeons, specialist 
nurses or specialist gastroenterologists, and whether this management should this be 
provided locally or as a tertiary service in pelvic floor units so that relevant 
investigations and therapeutic options such as biofeedback can be utilised.  
 
This study has confirmed the need for prospective studies to truly understand the 
risk factors for LARS, as there are some variables, for example, baseline function, 
which can only be reliably captured in this way. The prospective approach will be 
the only way to explore the reasons why LARS arises in individual patients. A study 
of this type would also be an ideal opportunity to explore the reasons behind 
variations in decision-making and clinical practice during the treatment of rectal 
cancer.  
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Chapter 4. Diffusion-weighted MRI for the prediction and 
assessment of response to neoadjuvant chemoradiotherapy in 
rectal cancer 
 
4.1 Introduction 
 
Neoadjuvant long-course chemoradiotherapy (LCRT) is used in locally advanced 
rectal cancer to decrease the risk of local recurrence and to facilitate oncologically 
complete resection. In tumours that respond to treatment it leads to downstaging 
and downsizing and can even lead to a complete response (CR), with disappearance 
of the tumour in 11-39% of patients1. Complete response to LCRT is a good 
prognostic indicator with reduced recurrence and improved disease-free survival2. A 
proportion of tumours, however, do not respond to LCRT and continue to progress 
during treatment. Although neoadjuvant LCRT has clear benefits for some patients, 
it is also associated with short-term toxicity and long-term effects on function3. As 
shown in chapter 3, LCRT increases the risk of patients developing low anterior 
resection syndrome (LARS), which has a negative impact on their quality of life. The 
physiological changes underlying LARS are individual and the exact factors leading 
to variations in functional outcome are not yet clear.  
 
Prediction of response to neoadjuvant LCRT, from the time of initial staging, would 
allow therapy to be tailored to individual patients, according to whether or not they 
would benefit from it. This could also allow intensification of treatment with a 
radiotherapy boost or a change of chemotherapy agent, or in patients for whom a 
poor response is predicted, the avoidance of LCRT altogether with expedited 
surgery. This, more rational use of LCRT, would potentially improve functional 
outcomes for those patients who avoid unnecessary LCRT, one of the major risk 
factors for a poor functional outcome4.  
 
At re-staging following LCRT, accurate identification of CR would also be useful, 
allowing selection of an alternative operative approach such as local excision, which 
facilitates preservation of sphincters. In patients with a complete response, a ‘watch 
and wait’ policy has been advocated by some, with intensive surveillance and 
avoidance of surgery altogether for a proportion of patients5. Identification of a tool 
that could predict response would, therefore, be very useful for clinical practice. 
Several imaging and molecular targets, with potential as biomarkers, have been 
investigated.  
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T2-weighted magnetic resonance imaging (MRI) scans are widely and routinely used 
for the diagnosis and initial staging of rectal cancer and have been shown to have 
high sensitivity and specificity for T staging and assessment of circumferential 
margin (CRM) involvement6. However, a study assessing the use of MRI for 
restaging following LCRT showed poor overall accuracy for assessing T-stage (52%); 
identification of CR was also challenging due to difficulty in differentiating between 
areas of residual viable tumour and areas of fibrosis7. The assessment of response to 
LCRT using MRI has been formalised into a grading system, mrTRG (tumour 
regression grade). This imaging marker has been shown to predict disease free and 
overall survival and therefore patient prognosis8, it has recently become an 
established and widely used method for the reassessment of tumours following 
LCRT. Since mrTRG is measured on post treatment scans, it does not, however, have 
any capacity for the prediction of response.  
 
Diffusion-weighted MRI (DWI) is a functional imaging technique, which utilises the 
way in which different tissues affect the dynamics of water molecule diffusion, to 
provide detailed information about tumours and peri-tumoral changes9.  
 
Water molecules are naturally in constant random (Brownian) motion; this permits 
free diffusion where molecules migrate down a concentration gradient10,11. Inside the 
body, within tissues, this motion is affected and restricted by tissue cellularity, 
molecules and cell membranes acting as a barrier to movement10, see Figure 4.1. The 
motion of water molecules can therefore provide information about tissue cellularity 
and whether cell membranes are intact10, factors that can be affected by neoplastic 
processes including cell lysis, oedema, scarring, fibrosis, inflammation or 
infiltration12,13.  
 
DWI assesses the movement of water molecules by ‘labelling’ these molecules in a 
volume of tissue and then resampling the same tissue at time intervals to determine 
the proportion of labelled molecules that remain present13. This is done by using 
radiofrequency to alter the physical properties of protons, in a similar way to 
standard MRI13. This measurement of the movement and restriction of water 
molecules is then quantified as the ‘apparent diffusion coefficient’ (ADC)10.  
 
Measurement of the ADC can facilitate assessment of molecular and metabolic 
changes at a cellular level, before morphological and structural changes even occur 
and therefore before these changes become visible11,14. Assessment of ADC and the 
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signal intensity on DWI can allow differentiation between residual tumour and areas 
of altered tissue cellularity for other reasons including fibrosis, necrosis or 
inflammation15 and allows “inferences to be made about the microstructure of the 
cellular environment”16.  
 
Figure 4.1 Schematic illustrating movement of water molecules  17 
  
A) Water molecules in a 
container outside the body 
move in constant random 
(Brownian) motion. 
B) Highly cellular tissue 
impedes the movement of 
water molecules. These 
tissues may be 
intravascular, intracellular 
or extracellular.  
C) Tissue with low 
cellularity or defective cells 
permits greater water 
molecule movement. 
 
 
DWI has several benefits over other methods of investigation; it is a non-invasive 
technique, which does not require the use of contrast or exposure to radiation18. DWI 
scans are carried out rapidly, taking 5 minutes and can be added onto an existing 
MRI protocol without substantial increase in acquisition time9.  
 
DWI was initially used for the investigation of intracranial pathology including 
epilepsy and dementia10. Subsequent developments in technology facilitated its use 
for extracranial pathology and the potential for evaluation of tumours began to be 
investigated9. Applications of DWI in patients with cancer include tumour detection, 
tumour characterisation, distinguishing between tumours and benign lesions, 
monitoring treatment response and prediction of treatment response10. ADC has 
shown potential as a biomarker to predict and assess efficacy of chemotherapy and 
radiotherapy in a number of other cancers11,19.  
 
In recent years, the use of DWI in rectal cancer has been explored by a number of 
studies. A systematic review of the use of multiparametric MRI in rectal cancer 
found that, although there is some good evidence for the benefit of DWI in the 
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assessment of response to LCRT, the evidence for its usefulness, in terms of 
predicting response, remains unclear15.  
 
 
4.2 Aims 
 
The aim of this study was to determine the potential ability of DWI volumetry and 
ADC measurement to predict and assess response to neoadjuvant LCRT for rectal 
cancer, in comparison with standard T2-weighted MRI volumetry and mrTRG, using 
histopathological response as the gold standard.  
 
 
4.3 Methods  
 
4.3.1 Patients 
 
This was a single institution retrospective cohort study. Consecutive patients 
meeting the eligibility criteria between May 2008 and February 2015 were included. 
Inclusion criteria included 1) patients with biopsy-proven diagnosis of rectal cancer 
2) discussed at colorectal multi-disciplinary team (MDT) meeting 3) undergoing 
neoadjuvant long-course chemoradiotherapy (LCRT) prior to restaging and then 
potential surgical resection 4) routine MRI (including DWI) staging pre- and post-
LCRT. All patients were reviewed at the colorectal cancer MDT as per usual practice. 
 
4.3.2 Treatment 
 
All patients underwent neoadjuvant LCRT. External beam radiotherapy was given as 
45 Gy delivered in 25 fractions (daily dose 1.8 Gy) over a five-week period and all 
patients completed the full course. Concomitant chemotherapy was given as the oral 
5-FU derivative capecitabine at the dose of 825 mg/m2 twice daily. One patient 
developed toxicity (chest pain) after one week and was changed to oxaliplatin, which 
was completed without difficulty. All patients underwent routine DWI as part of 
staging investigations prior to treatment and restaging scans were carried out 6-8 
weeks after completion of neoadjuvant therapy. The surgical approach was decided 
following re-discussion of results at the colorectal MDT and resections were carried 
out according to the principles of total mesorectal excision.  
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4.3.3 Histology 
 
Histology, specifically tumour regression grade (TRG), was used as the gold 
standard against which to compare the value of DWI/ADC as a diagnostic test. 
Tumour Regression Grades had been variably reported previously and therefore the 
TRG for all patients was reassessed. Histological reporting was carried out by an 
experienced Consultant gastrointestinal pathologist (Professor R Feakins) according 
to a standard protocol and TRG was assessed using the Royal College of 
Pathologists’ favoured classification system (as advised by the Association of 
Coloproctologists Guidelines for the Management of Cancer of the Colon, Rectum 
and Anus) shown in Table 4.120. For two patients histology slides were unavailable, 
one was staged post-operatively as T3N0(M1), stage 4 and the other as T3N1, stage 3, 
both were included within the TRG 4 group.  
 
Patients were considered to be responders to treatment if their histology showed a 
TRG 1, indicating a pathological complete response (pCR) to LCRT. Non-responders 
were those classified as TRG 2, 3 or 4. Staging was reported according to the Union 
for International Cancer Control (UICC) staging system 7th edition21.  
 
Table 4.1 Classification of tumour regression grade (TRG) 20 
 
TRG Finding on histology 
TRG 1 No viable tumour cells (fibrosis or mucus lakes only) 
TRG 2 Single cells or scattered small groups of cancer cells 
TRG 3 Residual cancer outgrown by fibrosis 
TRG 4 Minimal or no regression (extensive residual tumour) 
 
4.3.4 MRI protocol 
 
Scans were performed on a 1.5T Philips Achieva scanner (Philips Healthcare, Best, 
The Netherlands, Release 2.6) in conjunction with a sixteen-element body coil array. 
The study site protocol includes T2-weighted Turbo Spin Echo (TSE) axial and 
sagittal with a large field-of-view (FOV), T1-weighted TSE large FOV, DWI and 
oblique small FOV T2-weighted TSE or for larger tumours a 3D VISTA. DW images 
were obtained using a free-breathing multi-slice spin-echo (SE) echoplanar imaging 
(EPI) sequence with the following parameters: repetition time(TR) 5300 - 5800 ms, 
echo time (TE) 62ms, EPI factor 60, three averages, FOV 400 - 450mm, rectangular 
FOV 75%, acquisition matrix 112 ´256, 32 slices, slice thickness 6mm, slice gap 1mm. 
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Six motion probing gradients with b-values of 0, 100, 200, 500, 750 and 1000 s mm-2 
were applied in three orthogonal directions and trace images were synthesised for 
each b-value using the mean of three orthogonal directions. In-vitro reproducibility 
was assessed on this scanner with a coefficient of variation of less than 2%22.  
 
The T2-weighted TSE axial images were obtained using the following acquisition 
parameters: FOV 375-450 mm, TE 100ms TR > 6000ms, TSE factor 15, acquired voxel 
size 1´1.3mm2, acquisition matrix 368´195 reconstructed to 512´512, 6mm slice, 1mm 
gap, 32 slices. No intravenous or oral contrast mediums, rectal distension or bowel 
preparation were used. To limit artefact related to peristalsis, 20mg of hyoscine 
butylbromide (Buscopan, Boehringer Ingelheim, Germany) was routinely given 
intravenously at the start of the scan. 
 
4.3.5 Image evaluation/analysis 
 
Images were analysed using commercially available software OsiriX (Pixmeo SARL, 
Bernex, Switzerland, version 8.5.2)23. T2-weighted and DW images were analysed by 
2 readers (KL/Dr A Parsai) in consensus, using T2-weighted images as a reference 
when interpreting the DWI scans. Both readers were blinded to clinical history, 
histology results and MRI reports. Tumour contours were manually drawn on each 
axial slice and volumes were calculated automatically by the software. For the DWI 
scans, contours were drawn on the b=1000 images. ADC maps were automatically 
generated on the scanner using a mono-exponential fit on a pixel-by-pixel basis; b=0 
was excluded in order to eliminate perfusion effects. ADC regions of interest (ROIs) 
were manually drawn in areas of tumour, corresponding to areas of high signal on 
the b=1000 images, see Figure 4.2. On the post-LCRT scans, where there was no 
residual tumour evident on DWI, ROIs were drawn at the former location of the 
primary tumour. T2-weighted images were used for assessment of mrTRG by a 
single Radiologist (Dr A Parsai). 
 
4.3.6 Statistical analysis 
 
Statistical analysis was carried out using Statistical Package for the Social Sciences 
(SPSS Inc. Chicago, USA, version 22.0) and a two-sided p value of <0.05 was 
considered statistically significant. Fisher’s exact test was used to compare 
proportions for baseline categorical variables. As data is non-parametric, measures of 
location are expressed as median and non-parametric tests of significance were used. 
 
 
 174 
The Mann-Whitney U test was used to compare responders and non-responders and 
the Wilcoxon signed-rank test was used to compare pre and post data for all patients. 
Percentage change between pre- and post-LCRT measurements (Δ) was calculated as 
100´((post-pre)/pre). Spearman correlation analysis was used to assess the 
relationship between mrTRG and histological TRG.   
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Figure 4.2 MR images from a 63-year-old man classified as a non-responder (TRG 3) The white line on figures (a) and (d), and black line on 
figures (b) and (e), indicates the manual ROI drawn for calculation of tumour volume. (a) Pre-LCRT T2-weighted images (b) Pre-LCRT high b-
value DW-MRI images and (c) Pre-LCRT ADC map – demonstrating restricted diffusion (darker areas) within the tumour (indicated by arrow). 
(d) Post-LCRT T2-weighted images (e) Post-LCRT high b-value DW-MRI images – with area of high signal intensity indicating residual tumour 
(f) Post-LCRT ADC map. ROI: region of interest; LCRT: long-course chemoradiotherapy; ADC: apparent diffusion coefficient.  
 
        
 (a)             (b)                        (c)       
         
 
 
 
 
 
 
 
 
 
 
 
 
 
(d)                                                                                         (e)                                                                                        (f)    
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4.4 Results 
 
4.4.1 Patients 
 
48 patients met eligibility criteria between May 2008 and February 2015, see Figure 
4.3. 9 patients were excluded: 6 of these had no operation carried out due to non-
resectable disease, 2 were excluded as they underwent further chemotherapy 
following LCRT and 1 because the rectal cancer was a local recurrence following 
previous high anterior resection. 
 
Figure 4.3 Flow chart showing patient inclusion. 
 
 
 
 
 
 
 
 
 
 
 
4.4.2 Baseline data 
 
39 patients were therefore included in the analysis, 30 men (76.9%) and 9 women 
(23.1%). The median age was 63 years (range 25-78). Staging according to the UICC 
classification, prior to LCRT, is shown in Table 4.2. Three patients were classified as 
stage 4 due to internal iliac nodal involvement in one, a superior rectal node in 
another and liver metastasis (resectable) in the third patient. 17 patients underwent 
an abdomino-perineal excision of rectum (APER), 20 underwent an anterior resection 
(3 with end colostomy) and 1 patient had a local excision.  
 
 
 
 
 
 
 
48 patients met 
eligibility criteria from 
May 2008 – Feb 2015 
39 patients           
included in analysis 
9 patients excluded: 
- 6 no resection 
- 2 further chemotherapy 
prior to resection 
- 1 was local recurrence 
following previous resection 
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Table 4.2 Patient characteristics. The other/none group under operation includes 
three patients with end colostomy (Hartmann’s procedure) all in the non-pCR group. 
IQR: interquartile range; pCR: pathological complete response; LCRT: long-course 
chemoradiotherapy; APER: abdomino-perineal excision of rectum; UICC: Union for 
International Cancer Control staging system.  
 
 
4.4.3 Results of staging and TRG 
 
Comparing pre-LCRT staging with histological staging, 22/39 (56.4%) patients had 
disease downstaged with LCRT. 4 patients had a pathological complete response 
(pCR) following resection. One patient had a clinical and radiological complete 
response on re-staging following LCRT. This patient chose not to undergo surgery 
and has been intensively followed-up for over 5 years with no evidence of 
recurrence. 
 
The patient with the clinical complete response was included with these to give an 
overall pCR rate of 5/39 (12.8%). The remaining 34 patients were classified as ‘non-
pCR’. Table 4.2 shows the characteristics of the two groups.  
 
 pCR group (n = 5) 
Non-pCR group  
(n = 34) 
p-value 
Female : Male 2 : 3 7 : 27 0.572 
Median age (IQR) years 65 (62 – 75) 61 (53 – 72) 0.256 
Pre-LCRT median T2 
tumour volume cm3 
(IQR) 
29.0 (20.1 – 38.6) 29.8 (20.5 – 58.3) 0.674 
Pre-LCRT UICC stage 
   1 
   2 
   3 
   4 
 
1 
0 
3 
1 
 
1 
7 
24 
2 
 
0.171 
Operation 
   APER     
   Anterior resection 
   Other / none 
 
2 
2 
1 
 
15 
15 
4 
 
1.000 
Mucinous  
1 / 4 (25%) 
(1 not applicable) 
10 / 33 (30.3%) 
(1 missing) 
1.000 
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The results for pre- and post-LCRT (histological) staging, as well as histological TRG 
are shown in Table 4.3. The 4 patients with a pCR were classified as TRG 1, of the 
remaining patients 2 were TRG 2, 19 were TRG 3 and 13 were TRG 4. On histological 
staging, in addition to the 5 patients classified as pCR, 12 patients were stage 1, 6 
were stage 2, 15 were stage 3 and 1 was stage 4 (liver metastasis, subsequently 
resected).  
 
Table 4.3 Pre-/post-LCRT UICC staging and TRG. LCRT: long-course 
chemoradiotherapy; UICC: Union for International Cancer Control staging system; 
TRG: tumour regression grade; pCR: pathological complete response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.4 Wilcoxon signed-rank test: pre- and post-LCRT results for all patients 
 
For all patients, there was a significant difference between the T2-weighted tumour 
volume, DWI tumour volume and ADC values on the pre-LCRT scan vs. post-LCRT 
scan (p = <0.001 for each). Volumes measured on DWI were significantly smaller than 
those measured on T2 imaging (p = <0.001). Figure 4.4 illustrates the difference 
between T2 and DWI volume measurements on pre- and post-LCRT imaging, 
indicating a reduction in tumour volume following LCRT.  
 
 
 pCR group (n = 5) Non-pCR group (n=34) 
Pre-LCRT stage 
   1 
   2 
   3 
   4 
 
1 
0 
3 
1 
 
1 
7 
24 
2 
Histological stage 
   pCR 
   1 
   2 
   3 
   4 
 
5 
0 
0 
0 
0 
 
0 
12 
6 
15 
1 
Histological TRG 
   1 
   2 
   3 
   4 
 
5 
0 
0 
0 
 
0 
2 
19 
13 
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Figure 4.4 Pre- and post-LCRT tumour volumes on T2 and DWI imaging for all 
patients. LCRT: long-course chemoradiotherapy.  
 
 
 
4.4.5 Mann Whitney U test: pCR and non-pCR groups pre- and post-LCRT 
 
This analysis was done with the patients grouped into responders and non-
responders according to pCR status. Table 4.4 shows the median values (and 
quartiles) for T2-weighted MRI volume, DWI volume, ADC values and mrTRG for 
three groups: all patients; pCR and non-pCR. Three sets of values are shown: pre-
LCRT; post-LCRT and percentage change between these two measurements (except 
for mrTRG).  
 
The results in Table 4.4 show that for T2-weighted MRI there was no significant 
difference between responders and non-responders on the pre, post or ΔT2 Volume 
%. On DWI there was no significant difference in the pre-LCRT images but 
significant difference between the pCR and non-pCR groups on the post-LCRT scan 
volume (0 vs. 1.8 cm3, p = 0.006) and on ΔDW volume % (-100 vs. -72.3%, p = 0.001), 
see Figure 4.5. Figure 4.5 also illustrates the significant difference in pre-LCRT ADC 
values between responders and non-responders (0.7 vs. 0.8 ´ 10-3 mm2 s-1, p = 0.044). 
There was no significant difference between pCR and non-pCR on post-LCRT ADC 
or ΔADC values.  
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Table 4.4 Median volumes, ADC values and mrTRG for all patients, pCR and non-
pCR groups. * indicates a significant p value. pCR: pathological complete response; 
ADC: apparent diffusion coefficient; mrTRG: MRI tumour regression grade; IQR: 
interquartile range.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All patients n = 39 
median (IQR) 
pCR n = 5 
median (IQR) 
Non-pCR n = 34 
median (IQR) 
p-value 
T2 volume 
Pre (cm3) 
Post (cm3) 
ΔT2 Volume (%)  
 
29.7 (20.5 – 53.9) 
13.1 (8.3 – 24.5) 
-54.6 (-73.5 – -30.9) 
 
29.0 (20.1 – 38.6) 
17.2 (6.5 – 31.5) 
-40.6 (-65.8 – -18.3) 
 
29.8 (20.5 – 58.3) 
12.5 (8.3 – 24.4) 
-57.2 (-74.1 – -31.3) 
 
0.674 
0.705 
0.425 
DWI volume 
Pre (cm3) 
Post (cm3) 
ΔDW Volume (%) 
 
10.8 (3.9 – 25.4) 
1.4 (0.7 – 5.2) 
-78.0 (-93.9 – -37.2) 
 
6.5 (5.1 – 18.1) 
0 (0 – 0.9) 
-100 (-100 – -95.3) 
 
11.2 (3.0 – 27.7) 
1.8 (1.0 – 8.6) 
-72.3 (-89.2 – -28.2) 
 
0.801 
0.006 * 
0.001 * 
ADC  
  Pre (10-3 mm2 s-1) 
  Post (10-3 mm2 s-1) 
  ΔADC (%) 
 
0.8 (0.7 – 0.9) 
1.2 (1.0 – 1.4) 
43.6 (24.2 – 74.2) 
 
0.7 (0.5 – 0.8) 
1.1 (0.9 – 1.4) 
74.7 (43.6 – 113.4) 
 
0.8 (0.7 – 0.9) 
1.2 (1.0 – 1.4) 
36.0 (23.8 – 68.6) 
 
0.044 * 
0.834 
0.078 
mrTRG  
  Post  
 
3 (2 – 4) 
 
1 (1 – 2) 
 
3 (3 – 4) 
 
0.002 * 
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Figure 4.5 Difference in T2-weighted MRI volume, DWI volume and ADC values 
for pCR and non-pCR groups: pre-LCRT; post-LCRT and percentage change 
between these two measurements. The middle line in each box represents the 
median value, with the boundaries of the box representing the quartiles and 
whiskers showing minimum and maximum values. * indicates a significant p value. 
pCR: pathological complete response; LCRT: long-course chemoradiotherapy; ADC: 
apparent diffusion coefficient.  
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4.4.6 Mann Whitney U test: downstaged and non-downstaged groups pre- and post-
LCRT 
 
This analysis was done with the patients grouped into responders and non-
responders according to downstaging following LCRT. Table 4.5 shows the median 
values (and range) for T2-weighted MRI volume, DWI volume and ADC values for 
three groups: all patients; downstaged patients and non-downstaged patients. As 
with the previous table, three sets of values are shown: pre-LCRT; post-LCRT and 
percentage change between these two measurements. There was no difference 
between patients whose tumours had been downstaged following LCRT and those 
whose tumours were not downstaged on any of the parameters measured.  
 
Table 4.5 Median volumes, ADC values and mrTRG for all patients, downstaged 
and non-downstaged groups. IQR: interquartile range; ADC: apparent diffusion 
coefficient; mrTRG: MRI tumour regression grade.  
 
 
4.4.7 Correlation analysis: mrTRG and histological TRG 
 
A Spearman’s rank order correlation run to determine the relationship between 
histological TRG and mrTRG showed a strong positive correlation, which was 
statistically significant, rs = 0.787, p = <0.001. mrTRG showed sensitivity of 80% and 
specificity of 97% for assessment of TRG on post-LCRT images. 
 
All patients n = 39 
median (IQR) 
Downstaged n = 22 
median (IQR) 
Non-downstaged 
n = 17 median (IQR) 
p-value 
T2 volume 
Pre (cm3) 
Post (cm3) 
ΔT2 Volume (%)  
 
29.7 (20.5 – 53.9) 
13.1 (8.3 – 24.5) 
-54.6 (-73.5 – -30.9) 
 
33.9 (24.4 – 47.1) 
13.9 (8.3 – 31.4) 
-55.6 (-78.1 – -35.7) 
 
27.4 (11.1 – 59.1) 
11.9 (8.7 – 20.0) 
-52.1 (-70.2 – -19.9) 
 
0.174 
0.497 
0.308 
DWI volume 
Pre (cm3) 
Post (cm3) 
ΔDW Volume (%) 
 
10.8 (3.9 – 25.4) 
1.4 (0.7 – 5.2) 
-78.0 (-93.9 – -37.2) 
 
15.7 (4.0 – 25.7) 
1.1 (0.3 – 6.8) 
-79.5 (-97.3 – -39.7) 
 
9.0 (2.8 – 25.9) 
2.2 (1.1 – 6.5) 
-72.0 (-89.4 – -19.3) 
 
0.444 
0.328 
0.141 
ADC  
  Pre (10-3 mm2 s-1) 
  Post (10-3 mm2 s-1) 
  ΔADC (%) 
 
0.8 (0.7 – 0.9) 
1.2 (1.0 – 1.4) 
43.6 (24.2 – 74.2) 
 
0.8 (0.7 – 0.8) 
1.1 (1.0 – 1.3) 
44.4 (27.8 – 75.2) 
 
0.9 (0.7 – 1.0) 
1.3 (1.0 – 1.5) 
33.9 (24.1 – 66.4) 
 
0.051 
0.395 
0.497 
mrTRG 
Post 
 
3.0 (2.0 – 4.0) 
 
3.0 (2.0 – 3.3) 
 
3.0 (2.0 – 4.0) 
 
0.386 
 
 
 
 183 
4.4.8 Mann Whitney U: Analysis of clinical and pathological variables  
 
Pre-LCRT ADC values were significantly lower in those with negative nodes on 
histological analysis compared with those with positive nodes or systemic 
metastases, with either UICC stage 3 or 4 disease (0.750 vs. 0.861 10-3 mm2 s-1, p = 
0.030).  
 
Pre-LCRT ADC values were not significantly different in tumours with a mucinous 
subtype on histology vs. those without this subtype (p = 0.379), tumours with and 
without extra-mural venous invasion (p = 0.232) and in patients who had a 
subsequent recurrence of their cancer (p = 0.157). Pre-LCRT ADC values also did not 
depend on gender (p = 0.548) or age (below or above median) (p = 0.077). These 
findings are summarised in Table 4.6.  
 
Table 4.6 Pre-LCRT ADC values and clinicopathological variables. *indicates a 
significant p-value. The patient with a complete clinical response was counted within 
N0 but was not applicable for other pathological variables. ADC: apparent diffusion 
coefficient; T: tumour; N: nodes; M: metastases; EMVI: extra-mural venous invasion.  
Clinico-
pathological 
variable  
Groups 
Number 
of patients 
Median ADC (IQR) 
(10-3 mm2 s-1) 
p-value 
Gender 
Male 
Female 
30 
9 
0.788 (0.697 – 0.870) 
0.774 (0.727 – 0.945) 
0.548 
Age 
<63 (median) 
>/= 63 
19 
20 
0.816 (0.736 – 0.920) 
0.750 (0.686 – 0.840) 
0.077 
Histological  
T stage 
T0-2 
T3-4 
20 
19 
0.755 (0.703 – 0.829) 
0.820 (0.711 – 0.900) 
0.339 
N/M stage 
N/M 0 
N/M 1 
23 
16 
0.750 (0.687 – 0.825) 
0.865 (0.740 – 0.958) 
0.030 * 
Mucinous 
tumour 
Non-mucinous 
Mucinous 
Unknown or n/a 
26 
11 
2 
0.770 (0.709 – 0.870) 
0.787 (0.753 – 0.975) 
- 
0.379 
EMVI 
No EMVI 
EMVI present 
Unknown or n/a 
31 
6 
2 
0.774 (0.710 – 0.840) 
0.917 (0.721 – 1.097) 
- 
0.232 
Recurrence 
No recurrence 
Recurrence 
26 
13 
0.753 (0.697 – 0.825) 
0.846 (0.750 – 0.895) 
0.157 
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4.5 Discussion 
 
DWI volumetry and ADC measurements were evaluated in the prediction and 
assessment of response to neoadjuvant LCRT. The DWI protocol was introduced into 
the routine staging investigations of patients with rectal cancer at this institution. 
Analysis of DWI parameters was carried out without difficulty, although this would 
require some additional time in comparison with a standard MRI report. This 
demonstrates that the use of DWI measures would be feasible in routine clinical 
practice.  
 
Measures derived from DWI show the potential to be useful for the prediction of 
response to LCRT. Pre-LCRT ADC values were lower in the pCR group compared 
with the non-pCR group. This finding is in keeping with several previous 
studies16,18,24,25 and provides further evidence of the potential use of DWI as a tool for 
prediction of response to LCRT. These findings have been replicated in other tumour 
types26-28. Biologically, the explanation for why ADC values should be lower in 
subsequent responders is that the higher ADC in non-responding tumours reflects 
areas of tumour necrosis, which leads to hypoxia-mediated resistance to therapy16,19. 
There remains conflicting evidence in this area, as other studies have shown no 
difference in pre-LCRT ADC values29-31, or even contradictory findings of higher pre-
LCRT ADC values in responders32,33.  
 
This study showed a difference on DWI volumetry between the pCR and non-pCR 
groups on the post-LCRT scan and on ΔDW volume %. Results for T2-weighted 
volumetry were not significant and this is not surprising, as standard T2-weighted 
MRI has previously been found to overestimate tumour volume34 and overstage 
rectal cancers 7. Other studies have found similar results for the improved assessment 
of tumours post-LCRT using DWI volumetry35-37. It has been suggested, however, 
that with increasing experience of the interpreting radiologist, the benefit of DWI 
over T2-weighted MRI is reduced38.  
 
mrTRG showed a high level of sensitivity and specificity in terms of assessing TRG 
on the post-LCRT scans. Unlike DWI, use of mrTRG is inherently limited to the 
assessment of response. It has been shown to be the most reliable current method to 
assess response prior to surgery with potential as a biomarker to stratify treatment38.  
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A systematic review of the role of DWI in rectal cancer, published in 2014, concluded 
that DWI is not yet accurate enough to safely predict complete response with a low 
overall PPV of 54% and accuracy of 68-72% on pre-LCRT imaging14. The authors 
concluded that the major strength of DWI lies in identification of non-responders. 
One of the reasons for this finding was heterogeneity between studies14. Several 
authors have proposed reasons for the discrepancies between the results of 
individual studies. These include variations in the definition of response to 
treatment; technical parameters including MRI protocol and b-values used; study 
populations and ADC measurement techniques including ROI size and 
positioning15,25,40.   
 
A number of studies have compared qualitative assessment of DWI images with 
quantitative measurements and found good results for qualitative interpretation38,41-
43. A pooled analysis of these data showed a specificity of 94% and accuracy of 87%14. 
This could perhaps offer a less time-consuming option for routine practice44.  
 
The use of DWI in rectal cancer imaging is becoming widespread and its routine use 
in assessment following LCRT is now recommended by international guidelines45. 
Other novel imaging techniques have been explored for use in assessing rectal 
cancer, including perfusion or dynamic contrast-enhanced MRI and positron 
emission tomography-computed tomography (PET-CT). These have limitations; it is 
difficult to differentiate between residual tumour and inflammation on PET-CT, it is 
not possible to determine nodal status and extra scans are required with exposure to 
radiation11,46. The applicability of perfusion MRI is limited by the lack of evidence 
and variations in techniques limiting reproducibility15. 
 
Although in this study, as in many others, response was classified into pCR and non-
pCR according to TRG, in reality there is a spectrum of response, with some partial 
responders. Studies assessing DWI have defined response using a number of 
different methods including tumour shrinkage, downstaging, and variations in the 
systems used to assess histological TRG. In this study pCR was used to define 
response because this is the most clinically relevant definition. Patients with pCR are 
those who have gained the greatest benefit from LCRT and could potentially avoid 
surgery altogether if a ‘watch and wait’ policy were followed. The analysis was also 
carried out grouping patients into those with downstaging of their tumour following 
LCRT, and those without downstaging but there was no significant difference found 
between these groups on any of the measures. Downstaging is inherently reliant on 
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the accuracy of pre-LCRT staging, including assessment of nodes, it has less clinical 
relevance than complete response and is a less objective endpoint.  
 
An interesting finding of this study was that ADC values pre LCRT were lower in 
those with negative nodes. This is despite the fact that the pCR and non-pCR groups 
had similar staging pre-LCRT. Two previous studies, which assessed the ADC values 
in responders and non-responders found a conflicting result of lower ADC values 
pre-LCRT in node positive patients33,47. Determination of whether DW-MRI 
measurements can differentiate between favourable and non-favourable histological 
characteristics, beyond just TRG, needs further studies.  
 
Previous studies have investigated the use of interim imaging at various time 
periods during LCRT. Early assessment with a DWI scan a few weeks into treatment 
has shown promising results for stratifying patients into responders and non-
responders24. This remains an area of ongoing study but interim scanning would 
have significant logistical and financial implications for routine practice and might 
add further complexity into the decision-making process. The timing of post-LCRT 
assessment is also important, with recent evidence showing that an increased time 
period of 10-11 weeks can improve response rates compared with the standard 6-8 
weeks48.   
 
Limitations of this study include its single-centre, retrospective nature with fairly 
small numbers although selection bias was avoided by including consecutive eligible 
patients. All patients with rectal cancer who had MRI during this time period also 
had DWI scanning, so this was not a reason for reduced numbers. There were 
multiple other reasons for the low patient numbers achieved in the study. Although 
this is a busy colorectal unit, there were proportionally fewer rectal cancers (vs. 
colorectal cancers) during this time period than expected. Fewer patients underwent 
resection than anticipated, for several reasons, including that patients either had 
inoperable disease or metastatic disease. The unit is a tertiary referral centre, and 
because of this, some patients undergoing resection had their staging investigations 
in a separate NHS Trust. The pCR rate in this patient sample was also slightly lower 
than might be expected (12.8% in this sample vs. 16% in a large published pooled 
analysis2). There were some patients excluded for other reasons, as documented in 
Figure 4.3. In combination, these factors led to smaller sample size and particularly a 
smaller pCR group than would have been desired or ideal. This is likely to lead to 
type II errors and limited subgroup analysis.  
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Other limitations of the study include that scans were carried out pre- and post-
LCRT without an interim scan, this is in keeping with routine clinical practice in the 
UK. This study used two readers in consensus rather than independently, however 
previous studies have shown no significant inter-observer variation with strong 
agreement in measuring tumour volume and ADC values29,36. ADC measurements 
were derived from a sample ROI, which may not be representative of the whole 
tumour sample, especially considering tumour heterogeneity. Sample ROI was used 
to reflect normal practice as outlining of the whole tumour to calculate ADC would 
be inefficient for everyday use35. ADC measurements were not used to assess nodal 
staging as this was beyond the scope of the study; qualitative analysis was also not 
used.  
 
Incorporating DWI measurements into routine clinical decision-making will require 
consensus of MRI protocols24 and standardisation of techniques including hardware, 
software and analysis methods15. These are all factors that affect image quality and 
interpretations. Recent consensus guidelines on the use of DWI have been published 
for the first time19; large multi-centre prospective studies using this guidance will be 
needed to determine consistent threshold values. Use in clinical practice is 
complicated; radiologists need experience interpreting images in order to make an 
efficient assessment. Methods to improve efficiency are being developed, including 
semi-automated techniques for volume calculation49. At present, DWI remains one 
tool amongst many in the assessment of rectal tumours. The ultimate aim, of 
personalised therapy, may well require integration with other tools such as 
molecular biomarkers14.  
 
 
4.6 Conclusion 
 
Incorporating DWI into routine clinical practice is feasible and measures derived 
from DWI show potential as non-invasive biomarkers for predicting and assessing 
response to LCRT in rectal cancer. Specifically, pre-LCRT ADC values calculated 
from DWI scans may be useful for the prediction of response to neoadjuvant LCRT. 
DWI, in terms of post-LCRT volume and ΔDW volume appears superior to T2-
weighted MRI volumetry in assessing whether patients have had a complete 
response to LCRT. Following further research, biomarkers derived from DWI could 
possibly be used to rationalise the use of LCRT, a major risk factor for poor 
functional outcome.  
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Chapter 5. Identifying molecular targets of response to neo-
adjuvant chemoradiotherapy 
 
5.1 Introduction 
 
Traditionally, the complex treatment decision about which patients should undergo 
chemoradiotherapy (CRT) is determined by using a combination of anatomical, 
radiological, functional and patient-specific factors. In the UK, this happens in the 
setting of a colorectal multidisciplinary team (MDT) meeting. Molecular biomarkers, 
which could help to predict and stratify tumour response in the algorithm would 
improve patient selection and help to inform management decisions. These would 
help the move away from protocol-driven care towards individualised cancer 
therapy.  
 
A biomarker for the prediction of response to neoadjuvant CRT would potentially 
allow patients with operable tumours, who were predicted to have a poor response 
to CRT to proceed straight to surgery. Neoadjuvant CRT is a major risk factor for 
poor functional outcome1 and its use would ideally be limited to those patients who 
would benefit from it on an individual level. In a locally advanced tumour where the 
circumferential margin is involved, there is a risk of incomplete resection with 
primary surgery. If it was possible to predict poor response to neoadjuvant therapy 
then potentially early systemic therapy would be of greater benefit to reduce the risk 
of metastatic disease.  
 
In tumours that are sensitive to neoadjuvant therapy, a biomarker predicting this 
response, would introduce the option to increase the dose, aiming for complete 
response and organ preservation. For patients with highly radiosensitive and 
chemosensitive tumours, especially the cohort who particularly wish to avoid 
surgery, there would be an option of intensifying the neoadjuvant regime with the 
aim of avoiding surgical intervention and following a treatment protocol more akin 
to that for anal carcinoma. The effect on sphincter function of an intensified 
radiotherapy dose without subsequent surgery is not fully known but it is likely to 
be superior to that of the combined effect of an anterior resection and CRT.  
 
The introductory chapter discusses a number of molecular biomarkers, which have 
been investigated as markers of response to neoadjuvant therapy in rectal cancer. 
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Those discussed make up a small proportion of the potential markers that have been 
studied. Response to therapy is complex, involving multiple pathways and, as such, 
it is unlikely that any one marker can entirely predict response in all cases2. The first 
step in developing molecular biomarkers is an improved understanding of the 
mechanisms behind response and especially non-response to therapy. This involves 
an improved understanding of which elements of a tumour’s microenvironment and 
metabolism contribute to the resistance to CRT.  
 
Molecular biomarkers that have been investigated have either been present in 
tumour tissue or blood3. Potential biomarkers from within tumour tissues include 
specific gene mutations4; methylation profiles5; combined gene expression profiles6; 
expression of specific proteins or metabolites7; and elements of the tumour immune 
microenvironment2. Biomarkers taken from blood again include expression of 
proteins and metabolites, for example carcinoembryonic antigen (CEA)8; markers of 
the host immune response9, circulating tumour cells10 and nucleic acids11. DNA 
alterations, including chromosomal alterations and instability12, and also single 
nucleotide polymorphisms have also been investigated13.  
 
Hypoxia has been identified as a key factor accounting for the differing sensitivity of 
individual tumours to radiotherapy and chemotherapy14 and is a common cellular 
process linked to many of the biomarkers identified above15. It is present in over 50% 
of rectal cancers and affects the characteristics of the tumour as well as the response 
to therapy16. Hypoxia plays a key role in tumour growth and progression; hypoxic 
tumours are more resistant to radiotherapy since oxygen free radicals are required 
for the generation of DNA damage, such as DNA double strand breaks, caused by 
ionizing radiation17. Hypoxic tumours are also resistant to chemotherapy via a 
number of mechanisms. Some chemotherapeutic agents depend on cellular 
oxygenation for their mechanism of action; others act on tumour cells during DNA 
synthesis and are made less effective by the slow cell cycling occurring as a result of 
hypoxia18. Because of these links between hypoxia and response to CRT, markers of 
hypoxia may be useful as biomarkers of response to CRT.  
 
MicroRNAs are small non-coding RNAs, 18-25 nucleotides in length that act as post-
transcriptional regulators of gene expression19. They have an important functional 
role in cancer as they regulate oncogenes, tumour suppressor genes and genes 
responsible for processes including differentiation, invasion and dissemination20. 
Aberrant expression of microRNAs has been shown in many different types of 
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cancer, including colorectal cancer21. Distinct expression profiles have been linked to 
cancer prognosis or disease progression and can be used to classify cancers22. 
MicroRNAs have shown potential to predict sensitivity to anticancer treatment and 
influence sensitivity to chemotherapy and radiotherapy; this explains their potential 
as both biomarkers and targets for therapy23.  
 
MicroRNAs have been studied in several different diagnostic and prognostic aspects 
of rectal cancer. Their use in diagnosing rectal cancer has been studied in both 
tissue24 and blood samples25. The possibility of using microRNAs to identify specific 
tumour subtypes, for example those that have CpG Island Methylator Phenotype 
positivity or TP53 mutations26 has also been investigated. Gaedcke et al. have shown 
that expression of miR-135b correlates significantly with disease-free and cancer-
specific survival24 and other studies have considered the possibility of diagnosis of 
nodal positivity27, liver metastates28 or the likelihood of recurrent disease29. With 
regard to neoadjuvant therapy, microRNAs have been assessed in monitoring of 
response during CRT30, assessing response following CRT31 and even prediction of 
side-effects to radiotherapy32, including fibrosis of the anal sphincters33. Despite the 
wide range of aspects investigated, compared with similar studies looking at colon 
cancer, there are relatively smaller numbers investigating rectal cancer, with fewer 
patients. Little overlap between identified microRNAs has been found, even in 
studies with similar methodology34.  
 
In rectal cancer, microRNAs have been shown to have potential as predictive 
biomarkers of response to neoadjuvant CRT. A number of studies have conducted 
arrays using pre-treatment tissue from biopsies to identify microRNAs with 
predictive potential35-42. These have shown differing results with little overlap in the 
microRNAs identified. Only four of these studies carried out validation of their 
results on a second group of patients38,39,41,42 and none have used external validation. 
A further group of researchers quantified two specific microRNAs, and found that 
miR-21 predicted good response to therapy and miR-31 predicted poor response43,44. 
The largest study carried out so far identified five microRNAs from the literature 
which they quantified in pre-treatment biopsies from an initial group of 55 patients, 
followed by validation in a further group of 130 patients45.  
 
Three of these studies identified miR-21 as being differentially expressed in 
responders compared with non-responders to neoadjuvant therapy in rectal 
cancer39,43,45. Of these three studies, Lopes-Ramos et al. found it to be overexpressed in 
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responders39, Carames et al. found it to overexpressed in non-responders43 and 
Eriksen et al. found it to be overexpressed in responders in their test cohort and non-
responders in their validation cohort45, so the results are still somewhat conflicting. 
miR-21 has already been identified as a potential diagnostic and therapeutic target in 
colorectal cancer46. It is overexpressed in precancerous adenomas indicating that it 
may be involved in the progression to cancer at an early stage47. miR-21 has been 
previously shown to be involved in adaptations related to hypoxia in tumours48, with 
overexpression allowing cells to avoid apoptosis in hypoxia and inhibition of miR-21 
increasing cellular susceptibility to hypoxia49. Other miRs identified as 
overexpressed in responders in more than one study include miR-63035,38, miR-22338,40 
and miR-124639,40. One study identified eleven microRNAs as upregulated in 
complete responders and two that were down-regulated; the authors found that two 
microRNAs, miR-622 and miR-630 had 100% sensitivity and specificity in identifying 
tumour regression grade (TRG) 1 cases35.  
 
To date, no individual microRNAs or microRNA profiles have been validated for use 
as biomarkers in clinical practice, for the prediction of response to neoadjuvant CRT 
in rectal cancer.  
 
 
5.2 Hypothesis and aims 
 
The hypothesis of this study is that tumours in patients who respond to neoadjuvant 
therapy in rectal cancer express a different microRNA profile to those of non-
responders. 
 
The aim of the study is to identify microRNA targets with potential use as predictive 
biomarkers of response or non-response to neoadjuvant CRT in rectal cancer.  
 
 
5.3 Methods: 
 
5.3.1 Rectal cancer database  
 
This study used data from an established Colorectal Cancer Tissue Bank database, 
which had been collected from 1998 to 2015 (ongoing). This computerised database 
contained prospectively recorded data from over 500 patient-anonymised samples. 
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Samples in the database had initially been collected at the time of operation and were 
paired normal and tumour tissues samples. From 2009 onwards, diagnostic samples 
were also taken at EUA and colonoscopy. All tissue was frozen immediately in liquid 
nitrogen upon resection from the specimen and stored at -80 °C. It was stored in 
compliance with the Human Tissue Act. Ethical approval was granted by the East 
London Research Ethics Committee, reference number: 09/H0703/106. This approval 
included access to the pathology archives at The Royal London Hospital to retrieve 
pathology blocks for these patients.  
 
Using the Colorectal Cancer Tissue Bank database, a new database including all 
rectal cancers was created for this study. This included the data shown in Box 5.1. 
Details of neoadjuvant chemotherapy and radiotherapy were included. 
 
5.3.2 Treatment  
 
Some patients underwent short course 
radiotherapy (SCRT) with external 
beam radiotherapy given as 25Gy 
delivered in 5 fractions (daily dose 
5Gy) over a five-day period. Other 
patients had long-course chemo-
radiotherapy (LCRT) with external 
beam radiotherapy given as 45 Gy 
delivered in 25 fractions (daily dose 
1.8 Gy) over a five-week period and 
concomitant chemotherapy given as 
the oral 5-FU derivative capecitabine 
at the dose of 825 mg/m2 twice daily. All patients subsequently underwent surgical 
resection of the rectal tumour with histological analysis of the specimen. Staging was 
reported according to the Union for International Cancer Control (UICC) staging 
system 7th edition50.  
 
5.3.3 Classification of response 
 
Data for tumour regression grade (TRG) had been variably and inconsistently 
reported previously and therefore the TRG for all patients who had undergone 
neoadjuvant therapy was reassessed. Histological reporting was carried out by an 
Demographics: age, gender 
Date of surgery and type of procedure 
Details of neoadjuvant and adjuvant 
therapy 
Details of imaging carried out 
Pre-operative radiological staging 
Pathological report details:  
• TNM stage 
• Resection margin status 
• Nodal status 
• Extra-mural venous invasion status 
• Histological tumour regression grade  
Local and systemic recurrence 
Disease free and overall survival 
 
Box 5.1. Variables collected for 
database of rectal cancer patients 
 
 
 
 
 198 
experienced Consultant gastrointestinal pathologist (Professor R Feakins) according 
to a standard protocol and TRG was assessed using the Royal College of 
Pathologists’ favoured classification system (as advised by the Association of 
Coloproctologists Guidelines for the Management of Cancer of the Colon, Rectum 
and Anus) shown in Table 5.151.  
 
Table 5.1 Classification of tumour regression grade (TRG)  51 
 
TRG Finding on histology 
TRG 1 No viable tumour cells (fibrosis or mucus lakes only) 
TRG 2 Single cells or scattered small groups of cancer cells 
TRG 3 Residual cancer outgrown by fibrosis 
TRG 4 Minimal or no regression (extensive residual tumour) 
 
A cohort of responders and non-responders was required for the study. All patients 
in the database who had undergone CRT were therefore classified into one of three 
categories:  
• Responders either had a TRG of 1-3 or were downstaged from pre-treatment 
staging to post-operative histological staging 
• Non-responders were TRG 4 and had worsening or no change in their staging  
• Intermediate: Insufficient data to determine response or conflict between TRG 
and change in staging 
 
5.3.4 MiRNA extraction  
 
Pre-treatment biopsy tissue blocks were identified for responders and non-
responders. Tissue from prior to treatment was required as it is likely that 
neoadjuvant chemotherapy and radiotherapy would alter the expression of 
microRNAs in the resection specimen. Formalin fixed paraffin embedded (FFPE) 
tumour tissue sections on haematoxylin and eosin (H&E) stained slides were 
reviewed by a Consultant gastrointestinal pathologist (Professor R Feakins) who 
marked with a thin pen on each slide to show which biopsy contained cancer, an 
example of two slides is shown in Figure 5.1. These images were then used as a 
guide to which biopsy to use when extracting RNA.  
 
Slides were cut and H&E stained by the Pathology Department (Royal London 
Hospital). Ten sections, each of 5 µm were used, giving a final depth of 50 µm 
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(0.05mm), to maximise yield of RNA as recommended by the protocol. The 
miRNeasy FFPE kit (Qiagen, UK) was used to purify total RNA from FFPE sections. 
Xylene was used for deparaffinisation, followed by 100% ethanol to extract residual 
xylene. Samples were then incubated in a lysis buffer containing proteinase K to 
release RNA from the sections. DNase treatment was used to eliminate genomic 
DNA. Ethanol was used to allow total RNA including microRNA to bind to the 
membrane of an RNeasy MinElute spin column and contaminants were washed 
away. RNA was then eluted in 20 µl RNase-free water. A NanoDropTM 
Spectrophotometer (Nano-Drop Technologies, USA) was used to determine the 
concentration of RNA and the ratio of absorbance at 260 nm and 280 nm. Samples 
were stored at -80 °C. 
 
Figure 5.1 Biopsy slides with marked areas of cancer indicated by orange circles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.5 MicroRNA array  
 
MicroRNA array profiling was carried out by Exiqon at Exiqon Services in Denmark. 
28 samples were used, 11 from responders and 17 from non-responders. 325 ng total 
RNA from each sample was labelled with a fluorescent label. These, along with a 
fluorescent labelled reference RNA sample were mixed pair-wise and hybridized to 
the miRCURY LNA™ microRNA Array 7th Gen (Exiqon, Denmark). This array 
contains capture probes targeting all microRNAs in the miRBASE 19.0. 
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Hybridization was performed according to the miRCURY LNA™ microRNA Array 
Instruction manual. The miRCURY LNA™ microRNA array slides were scanned 
using the Agilent G2565BA Microarray Scanner System (Agilent Technologies, Inc., 
USA) and image analysis was carried out using the ImaGene 9.0 software 
(BioDiscovery, Inc., USA). For microRNA array data, normalisation was performed 
based on the average of the assays detected in all samples52.  
 
5.3.6 Technical validation 
 
For technical validation of the results, the same 28 samples were used. In addition, 
samples were sent from 3 rectal cancer cell lines (HT55, SW837 and VACO4s) grown 
under three different oxygen conditions (0.2% oxygen, 1% oxygen and 20.9% oxygen) 
for 48 hours. These samples were provided by Anke Nijhuis, a member of our lab 
group. The rectal cancer cell lines were originally a gift from Professor Ian Tomlinson 
(Wellcome Institute for human genetics, University of Oxford). 
 
Box 5.2 MicroRNAs selected for validation 
* indicates those chosen based on p-values from array results  
Technical validation of microRNA 
expression in pre-treatment 
tumour biopsies was carried out 
using real-time quantitative 
polymerase chain reaction (qPCR). 
A panel of 26 functionally relevant 
microRNAs was selected for 
validation; see Box 5.2 for the list of 
microRNAs selected. The majority of these (indicated by *) were selected based on p-
values from the microRNA array results (see Table 5.5 for p-values) and the 
remainder were selected based on their link to colorectal cancer or response to 
chemo/radiotherapy from the literature, as follows:  
• miR-422a expression levels are reduced in colorectal cancer and have been shown 
to correlate with stage of colorectal cancer53. miR-422a is also associated with 
relapse in gastric54 and hepatocellular cancers55 and linked to response to 
chemotherapy in osteosarcoma56.  
• miR-767-5p is involved in oncogenesis, is expressed in several cancers and has 
functional links to the miR-29 family57 (miR-29b and miR-29c were also included 
in the technical validation). 
miR-574-3p *   miR-92b-3p *    miR-495-5p  
miR-4539 *   miR-330-3p *    miR-221-5p 
miR-4303 *   miR-23c *    miR-192-5p 
miR-212-3p *    miR-215-5p *    miR-146b-5p 
miR-1914-5p *   miR-483-5p *    miR-29c-3p 
miR-4686 *   miR-210-3p    miR-342-5p 
miR-505-5p *    miR-422a    miR-451a 
let-7b-3p *   miR-767-5p    miR-29b-3p 
miR-197-3p *   miR-206 
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• miR-206 is a tumour suppressor, attenuates tumour invasion, proliferation and 
migration in colorectal cancer and has been suggested as a potential therapeutic 
target58,59.  
• miR-495-5p is upregulated in radiotherapy sensitive lung cancer60, and altered 
expression is also associated with multidrug resistance to chemotherapy61. 
• miR-210-3p is upregulated in hypoxia in a number of cancers62. It is also 
increased in hypoxic areas of colorectal cancer tissues and consistently 
upregulated in colorectal cancer cell lines grown in hypoxic conditions63.  
• miR-192-5p influences 5-fluorouracil resistance through cell cycle-mediated 
mechanisms64 and was also shown to be significantly dysregulated in 
chemotherapy resistant oesophageal cancer cell lines65. 
• miR-29b-3p is known to critically affect cancer progression by functioning as a 
tumor suppressor66. Significantly altered expression was identified in non-
responders to neoadjuvant chemoradiotherapy in rectal cancer37. Expression was 
an independent prognostic factor for disease-free survival, lymph node 
metastasis and pathological T stage classification in colorectal cancer67.  
• miR-221-5p is an oncogenic microRNA that is upregulated in several cancers, 
including colorectal68. Anti-miR-221 has been shown to sensitise human 
colorectal carcinoma cells to radiation69 and miR-221 is also involved in 
radiotherapy resistance in glioblastomas70 and chemoresistance in breast cancer71.  
• miR-146b-5p expression shows significant correlation with nodal stage in rectal 
cancer72 and also regulates cell growth, invasion, and metabolism in colorectal 
cancer73. 
• miR-29c-3p expression is significantly decreased during early relapse in stage II 
and III colorectal cancer, and overexpression inhibited cell proliferation and 
migration74. miR-29c also enhances sensitivity to chemotherapy and radiotherapy 
in nasopharyngeal carcinoma75.  
• miR-342-5p has been shown to inhibit colorectal cancer cell proliferation and 
invasion76. Expression in plasma was found to be significantly different in 
responders and non-responders to radiotherapy for rectal cancer77. 
• miR-451a shows decreased expression in non-responders to neoadjuvant CRT in 
rectal cancer40. Expression is also decreased in gastric and colorectal cancer 
versus non-cancerous tissues and overexpression reduces cell proliferation and 
increases sensitivity to radiotherapy78. 
 
microRNA real-time qPCR was carried out by Exiqon at Exiqon Services in 
Denmark. Each RNA sample was reverse transcribed into complementary DNA 
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(cDNA) and run on the miRCURY LNATM Universal RT microRNA PCR Custom 
Panel for the pre-determined microRNAs. Each microRNA was assayed once using 
ExiLENT SYBR® Green master mix. The results were background corrected79 and 
normalised using the quantile normalisation method, which is recommended for this 
type of analysis80. 
 
5.3.7 Statistical analysis 
 
Statistical analysis was carried out using Statistical Package for the Social Sciences 
(SPSS Inc. Chicago, USA, version 22.0). R (version 3.4.4) was used to create 
microRNA heatmaps and XLSTAT (version 14.7) was used to create volcano plots. A 
two-sided p-value of <0.05 was considered statistically significant. Fisher’s exact test 
was used to compare proportions for clinical and pathological categorical variables. 
A moderated independent t-test was used to compare expression values in 
responders and non-responders; the moderation takes into account the variance of 
the whole data set. For microRNA array results p-values were adjusted for multiple 
testing by the Benjamini-Hochberg correction. Fold changes were calculated using 
the 2−ΔΔCT method normalised to endogenous control microRNAs81.  
 
Receiver-operating characteristic (ROC) curves were constructed, with calculation of 
the area under the curve (AUC) and determination of optimal cut-offs (with equal 
weighting to sensitivity and specificity) using the Youden index. These were used to 
determine sensitivity, specificity, negative predictive value (NPV), positive 
predictive value (PPV) and accuracy with Clopper-Pearson exact 95% confidence 
intervals. 
 
Binary logistic regression was used to determine the proportion of responders/non-
responders correctly predicted using selected microRNAs. miRWalk database 
version 3.082 and miRDB83 were used to identify possible target genes. One-way 
ANOVA was used to compare expression levels between the three different oxygen 
tension groups, 0.2% oxygen, 1% oxygen and 20.9% oxygen used for colorectal 
cancer cell line treatments.  
 
 
 
 
 
 
 
 203 
5.4 Results 
 
5.4.1 Patients 
 
The Colorectal Cancer Tissue Bank database was used to create a new database that 
comprised of all patients with rectal cancer; this began in May 1998 and up to the 
point of data collection in May 2015, 162 patients were included. The rectal cancer 
database included 100 male (61.7%) and 62 female (38.3%) patients; the age range 
was from 19 to 91 years with a median age of 67 years (interquartile range 61-73). 
The median age for men and women was similar at 67 and 68 years respectively. 55 
patients underwent neoadjuvant therapy prior to surgical resection of their tumour, 
27 had SCRT, 27 LCRT and 1 had chemotherapy only. The median age of patients 
having neoadjuvant therapy was also 67 years, and 74.5% of patients were male. The 
majority of patients (63.0%) were of White British ethnicity; the second most frequent 
ethnicity was Bengali (9.9%). Anterior resection was the most frequently carried out 
surgical resection (116 patients, 71.6%), 23 of these patients had an end colostomy 
created without anastomosis, APER was the next most frequent operation (21.6%) 
and 4 patients in the database underwent synchronous liver and colonic resection.  
 
There were some difficulties encountered collecting biopsy specimens, as slides from 
the pathology archive at Barts Health NHS Trust are held off-site for all slides 
collected more than five years previously. Figure 5.2 shows patient inclusion and 
reasons for patients being excluded. Table 5.2 shows the details of the cohort of 
responders and non-responders identified. 
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Figure 5.2 Flow chart of patient inclusion 
 
 
 
40 patients with 
biopsies available  
 
15 patients excluded: 
- 2 had duplicate record 
numbers  
- 4 had no cancer in their 
biopsy (only resection 
specimen had cancer) 
- 4 had their biopsy 
carried out in another 
NHS Trust 
- 2 had unavailable 
biopsy slides 
- 3 were having ongoing 
treatments and their 
slides were in use 
 
55 patients underwent 
neoadjuvant therapy 
prior to surgery 
 
162 patients in rectal 
cancer database  
 
11 Responders  
 
12 Intermediate  
 
17 Non-responders  
 
 
 
NA: neoadjuvant, histo: histological; R represents resection margins with R0: complete resection; EMVI: extra-mural venous invasion; SCRT: short-course radiotherapy; LCRT: 
long-course chemoradiotherapy; APER: abdomino-perineal excision of rectum; AR: anterior resection; HP: Hartmann’s procedure (anterior resection with end colostomy); 
Local: local excision; UICC: Union for International Cancer Control; TRG: tumour regression grade.   
Table 5.2 Cohort of responders and non-responders 
Database 
number 
Gender Age Ethnicity Pre TNM 
staging 
Pre UICC 
stage 
NA 
therapy 
Surgery Histo 
TNM 
Histo 
UICC 
R EMVI TRG Recurrence 
 
182 Male 67 White British T3N1 3 SCRT AR T3N0 2 0 - 4 None 
190 Male 74 White British T4N1 3 SCRT APER T3N0 2 0 - 4 None 
264 Male 74 White British T3N1 3 LCRT AR T3N0 2 0 - 4 None 
271 Male 67 White British T3N1 3 LCRT APER T3N0 2 0 - 2 Systemic 
316 Female 64 White British T3N2 3 LCRT AR T3N0 2 1 + 4 None 
352 Male 68 Bangladeshi T3N1 3 SCRT AR T3N0 2 0 - 4 None 
385 Female 29 Bangladeshi T3N0 2 LCRT AR T0N0 0 0 - 1 None 
519 Male 73 White British T2N1 3 SCRT AR T2N0 1 0 - 4 None 
545 Female 63 White British T3N2 3 LCRT APER T0N0 0 0 - 1 None 
629 Male 55 Bangladeshi T3N2 3 LCRT APER T2N0 1 0 - 4 None 
710 Male 63 White British T3N2 3 LCRT AR T1N0 1 0 - 3 None 
 
58 Female 63 White British T2N0 1 SCRT APER T3N1 3 0 + 4 None 
76 Female 70 White British T3N0 2 SCRT AR T3N0 2 0 - 4 None 
105 Male 71 Black Caribbean T3N0 2 SCRT APER T3N0 2 0 - 4 Local 
110 Male 61 White British T3N0 2 SCRT AR T3N2 3 1 + 4 None 
125 Male 84 Unknown T3N0 2 SCRT APER T3N2 3 1 + 4 Local 
126 Female 68 White British T3N1 3 SCRT HP T3N2 3 0 - 4 Systemic 
141 Male 78 White British T3N0 2 SCRT APER T3N1 3 1 - 4 None 
175 Female 76 White British T3N1 3 SCRT APER T3N1 2 1 - 4 None 
178 Male 70 White British T3N1 3 SCRT APER T3N1 3 0 - 4 None 
240 Male 61 Indian T3N1 3 SCRT APER T3N2 3 0 + 4 None 
284 Male 37 Bangladeshi T2N0 1 LCRT AR T3N2 3 0 - 4 Systemic 
321 Female 72 White British T3N1 3 SCRT HP T4N2 3 0 + 4 None 
374 Female 39 Black Caribbean T4N2 3 LCRT HP T3N2 3 2 + 4 Local/systemic 
387 Male 80 Bangladeshi T3N1 3 SCRT HP T4N1 3 0 + 4 Local/systemic 
434 Male 80 White British T3N0 2 SCRT APER T3N0 2 0 - 4 None 
608 Male 68 White & Asian T2N0 1 LCRT Local T2N0 1 0 - 4 None 
637 Female 73 Black Caribbean T3N1 3 SCRT AR T3N2 3 0 + 4 Systemic 
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5.4.2 Baseline data  
 
The baseline characteristics of the responder and non-responder groups are compared in 
Table 5.3. The only significant difference pre-treatment was that more of the non-
responders were node negative. In a similar way to the overall cohort, the majority of 
included patients were male (64.3%), underwent anterior resection (53.5%) and were White 
British (60.7%); the median age was 68 years.  
 
Table 5.3 Baseline Characteristics  IQR: interquartile range; SCRT: short-course 
radiotherapy; LCRT: long-course chemoradiotherapy; APER: abdomino-perineal excision of 
rectum; AR: anterior resection; EMVI: extra-mural venous invasion.  
 Responders 
Number 
Responders 
Percentage 
Non-responders 
Number 
Non-responders 
Percentage 
p-value 
Gender 
• Male 
• Female 
 
8 
3 
 
72.7 
27.3 
 
10 
7 
 
58.8 
41.2 
 
0.689 
Median age 
(IQR) 
67 
(63 – 73) 
- 70 
(62 -  77) 
- 0.220 
Ethnicity 
• White British 
• Other 
• Unknown 
 
8 
3 
0 
 
72.7 
27.3 
0 
 
9 
7 
1 
 
52.9 
41.2 
5.9 
 
 
0.665 
Pre UICC stage 
• 1 
• 2 
• 3 
 
0 
1 
10 
 
0 
9.09 
90.9 
 
3 
6 
8 
 
17.6 
35.3 
47.1 
 
 
0.077 
Pre treatment 
node status 
• Negative 
• Positive 
 
 
1 
10 
 
 
9.09 
90.9 
 
 
9 
8 
 
 
52.9 
47.1 
 
 
0.041* 
Neoadjuvant 
therapy 
• SCRT 
• LCRT 
 
 
4 
7 
 
 
36.4 
63.6 
 
 
14 
3 
 
 
82.4 
17.7 
 
 
0.020* 
Surgery 
• APER 
• AR or other 
 
4 
7 
 
36.4 
63.6 
 
8 
9 
 
47.1 
52.9 
 
0.705 
Histological stage 
• 0 
• 1 
• 2 
• 3 
 
2 
3 
6 
0 
 
18.2 
27.3 
54.5 
0 
 
0 
1 
4 
12 
 
0 
5.9 
23.5 
70.6 
 
 
<0.001* 
R status 
• R0 
• R1 or R2 
 
10 
1 
 
90.9 
9.09 
 
12  
5 
 
70.6 
29.4 
 
0.355 
EMVI 
• No 
• Yes 
 
10 
1 
 
90.9 
9.09 
 
10 
7 
 
58.8 
41.2 
 
0.099 
Recurrence 
• None 
• Recurrence 
 
10 
1 
 
90.9 
9.09 
 
10 
7 
 
58.8 
41.2 
 
0.099 
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5.4.3 Results for miRNA extraction 
 
The method described above for miRNA extraction was used for all samples. Satisfactory 
quantities of RNA were extracted and all samples achieved the 260/280 ratio of >1.6 
required for good quality array. Table 5.4 shows the results for RNA extraction, 260/280 
ratio and 260/230 ratio.  
 
Table 5.4 Results for miRNA extraction 
 
 
 
 
 
 
 
 
5.4.4 MicroRNA array results 
 
The microRNA array contained 3100 capture probes covering 94% of human microRNAs in 
miRBase version 19.083. For each microarray slide, Exiqon calculate the threshold of 
detection as 1.2 times the 25th percentile of the overall signal intensity of the slide. A total of 
1241 probes were discarded by this filtering procedure due to having intensities above 
threshold in less than 20% (or 2) of the samples. 
Responders n = 11 
Number ng/µl 260/280 260/230 
182 197.7 1.91 1.94 
190 334.5 1.88 1.65 
264 64.4 1.95 1.61 
271 74.1 1.79 2.00 
316 199.6 1.93 1.90 
352 107.9 1.63 0.95 
385 55.5 1.83 1.63 
519 180.1 1.88 1.68 
545 437.1 1.97 1.92 
629 142.7 1.72 1.17 
701 64.3 1.97 1.97 
Non-responders n = 17 
Number ng/µl 260/280 260/230 
58 775.2 1.93 1.86 
76 63.8 2.02 2.01 
105 74.5 1.88 1.86 
110 102.5 1.91 1.80 
125 92.3 1.87 1.64 
126 563.8 1.93 2.10 
141 103.9 1.77 1.27 
175 47.2 1.91 1.59 
178 66.8 1.93 1.95 
240 69.5 1.89 1.97 
284 116.6 1.81 1.31 
321 100.0 1.84 1.49 
374 55.6 1.78 1.27 
387 80.6 1.83 1.44 
434 270.0 1.85 1.82 
608 63.7 1.84 1.35 
637 199.3 1.96 1.83 
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The array results showed that thirteen microRNAs were differentially expressed between 
the responder and non-responder groups. Table 5.5 shows the twenty microRNAs with the 
lowest p-value. To facilitate visualisation of the differential expression between responders 
and non-responders, -log10 p-values were plotted against log2 fold change values, see Figure 
5.3. Eleven microRNAs were significantly decreased and two were significantly increased in 
responders vs. non-responders (p<0.05). A heatmap showing the normalised expression 
values of the top fifty microRNAs with the highest standard deviation is shown in Figure 
5.4. 
  
The results shown in Table 5.5 and Figure 5.3 show unadjusted p-values. With adjustment 
for multiple testing, with the Benjamini-Hochberg correction, none of the microRNAs had a 
p-value <0.05. 
 
Table 5.5 MicroRNAs with lowest p-
values in array results. MicroRNAs 
marked with * are those included in the 
technical validation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MicroRNA Fold change p-value 
hsa-miR-574-3p * 0.691 0.002 
hsa-miR-4539 * 0.566 0.003 
hsa-miR-4303 * 0.826 0.016 
hsa-miR-212-3p * 0.856 0.019 
hsa-miR-1914-5p * 0.788 0.019 
hsa-miR-4686 * 0.841 0.020 
hsa-miR-505-5p * 1.151 0.026 
hsa-let-7b-3p * 0.877 0.032 
hsa-miR-197-3p * 0.795 0.037 
hsa-miR-4425 0.768 0.040 
hsa-miR-1255a 1.159 0.044 
hsa-miR-92b-3p * 0.843 0.047 
hsa-miR-330-3p * 0.724 0.048 
hsa-miR-3124-3p 0.780 0.051 
hsa-miR-23c * 0.857 0.055 
hsa-miR-215-5p* 0.854 0.058 
hsa-miR-4491 0.609 0.062 
hsa-miR-4538 0.768 0.064 
hsa-miR-483-5p * 0.779 0.065 
hsa-miR-548t-5p 1.162 0.068 
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Figure 5.3 Volcano plot showing results for all microRNAs identified by the array. The 
blue lines represent p=0.05 and p=0.01 and points above these lines represent statistically 
significant results.  
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Figure 5.4 Heatmap of normalised expression levels in the top fifty microRNAs with the 
highest standard deviation 
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5.4.5 Results of technical validation: Responders vs. Non-responders 
 
MicroRNA real-time qPCR analysis was used to technically validate the findings of the 
microRNA array results. The methods section gives details of the microRNAs chosen for 
validation. These were selected based on array results and/or relevant previous studies 
from the literature (see section 5.3.6 of methods for references). Normalisation for the qPCR 
was based on the average of the assays detected in all the samples as this has been shown to 
be an acceptable method for studies involving numerous assays52.   
 
During qPCR technical validation of the array results, the selected twenty-six microRNAs 
were measured in the 11 responder and 17 non-responder samples. Three of these were 
significantly downregulated in responders (miR-92b-3p, p=0.008; miR-197-3p, p=0.017; miR-
4303, p=0.024). The remaining twenty-three microRNAs were not significantly different 
between the two groups. Five of the microRNAs were detected in too few samples to allow 
comparison between the two groups (miR-23c, miR-422a, miR-767-5p, miR-495-5p and miR-
4686). Table 5.6 and 5.7 show the qPCR results for fold change and p-values. Figure 5.5 
shows a volcano plot created to facilitate easy visualisation of the differential expression 
between responders and non-responders. Figure 5.6 shows results for the three microRNAs 
with significantly different expression between the two groups. A heatmap was constructed 
showing normalised expression levels for the twenty-six microRNAs included in validation 
for all samples, the results of this are shown in Figure 5.7. 
 
Table 5.6 Normalised qPCR results for responders and non-responders: Results for 
microRNAs upregulated in responders. miR-23c was detected in too few samples to 
calculate a p-value.
MicroRNA Non-responder      Responder      Fold change p-value 
miR-215-5p 2.425 3.089 1.585 0.106 
miR-192-5p 3.386 3.979 1.508 0.180 
miR-483-5p -5.174 -3.882 2.448 0.311 
miR-4539 -4.895 -4.430 1.380 0.352 
miR-210-3p -0.390 -0.147 1.183 0.422 
miR-146b-5p -3.656 -3.325 1.258 0.535 
miR-342-5p -6.148 -5.911 1.179 0.619 
miR-29c-3p 0.875 0.983 1.077 0.683 
miR-330-3p -5.474 -5.456 1.012 0.974 
miR-23c -9.727 -7.548 4.529 - 
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Table 5.7 Normalised qPCR results for responders and non-responders: Results for 
microRNAs downregulated in responders. miR-422a, miR-767-5p, miR-495-5p and miR-
4686 were detected in too few samples to calculate p-values.
MicroRNA Non-responder       Responder    Fold change p-value 
miR-92b-3p -2.368 -3.324 0.515 0.008 
miR-197-3p -0.621 -1.315 0.618 0.017 
miR-4303 -6.538 -8.251 0.305 0.024 
miR-451a 2.323 1.099 0.428 0.067 
miR-505-5p -5.459 -6.210 0.594 0.092 
miR-574-3p 0.636 0.225 0.753 0.207 
miR-206 -7.431 -8.207 0.584 0.242 
let-7b-3p -2.362 -2.779 0.749 0.278 
miR-221-5p -5.282 -5.942 0.633 0.414 
miR-1914-5p -4.348 -5.118 0.586 0.776 
miR-212-3p -4.660 -4.731 0.952 0.887 
miR-29b-3p 0.951 0.941 0.993 0.970 
miR-422a -8.058 -8.101 0.970 - 
miR-495-5p -6.523 -8.433 0.266 - 
miR-4686 -7.017 -9.525 0.176 - 
miR-767-5p -7.614 - - - 
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Figure 5.5 Volcano plot for responder and non-responder samples for the twenty-six 
microRNAs included in validation. The blue lines represent p=0.05 and p=0.01 and points 
above these lines represent statistically significant results.  
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Figure 5.6 Expression levels of three microRNAs with significantly different expression 
between responders and non-responders. Large dark blue square represents mean 
expression.  
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ROC curves, comparing the three microRNAs with significantly different expression 
between responders and non-responders, are shown in Figure 5.8. A ROC curve was also 
constructed for the combination of the three microRNAs into one test and this is also 
included in Figure 5.8.  
 
The highest AUC for an individual microRNA was 0.775 (95% CI 0.599 – 0.952) for miR-197-
3p, this produced an optimal cut-off of 1.012 which showed 82% sensitivity, 73% specificity 
and 79% accuracy for detection of non-responders. The combination of the three 
microRNAs showed an even higher AUC of 0.913 (95% CI 0.797 – 1.000). Table 5.8 shows 
the optimal cut-off points derived from each ROC curve and the sensitivity, specificity, 
PPV, NPV and accuracy for each measure.  
 
Using binary logistic regression with miR-92b-3p, miR-197-3p and miR-4303 combined, 
correctly predicted 70% of responders and 93.8% of non-responders, with overall 84.6% of 
samples correctly predicted using these three microRNAs.  
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Figure 5.7 Heatmap of normalised expression levels for the twenty-six microRNAs 
included in the validation 
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Figure 5.8 ROC curves demonstrating the ability of the microRNAs to act as diagnostic tests to differentiate between responders and non-
responders. ROC: receiver-operating characteristic; AUC: area under the curve; 95% CI: 95% confidence intervals. 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      AUC value  
miR-92b-3p 0.754  
(95% CI  0.563 – 0.945) 
Reference line 
      AUC value 
miR-197-3p 0.775 
(95% CI 0.599 – 0.952) 
Reference line 
 
 
 
 218 
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(95% CI 0.551 – 0.949) 
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       AUC value 
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Table 5.8 Sensitivity, specificity, PPV, NPV and accuracy of the three microRNAs, and the combination of all three, when used as diagnostic 
tests for differentiating non-responders from responders. Values in brackets are 95% confidence intervals. ROC: Receiver-operating 
characteristic; PPV: positive predictive value; NPV: negative predictive value.  
 
 
 
 
 
Cut-off derived 
from ROC 
curve 
Sensitivity % Specificity % 
Positive predictive 
value % 
Negative 
predictive value % 
Accuracy % 
miR-92b-3p -3.441 100 (84 – 100) 45 (17 – 77) 74 (52 – 90) 100 (55 – 100) 79 (59 – 92) 
 miR-197-3p -1.012 82 (57 – 96) 73 (39 – 94) 82 (57 – 96) 73 (39 – 94) 79 (59 – 92) 
 miR-4303 -8.236 88 (62 – 98) 80 (44 – 97) 88 (62 – 98) 80 (44 – 97) 81 (61 – 93) 
Combined 0.556 94 (70 – 100) 80 (44 – 97) 88 (64 – 99) 89 (52 – 100) 88 (70 – 98) 
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MicroRNA target prediction databases miRWalk database version 3.082 and miRDB83 
were used to identify possible target genes for the three microRNAs showing 
significantly different expression between responders and non-responders. The list 
of genes was then reviewed with reference to the relevant literature and a list of 
putative targets derived. These are shown in Table 5.9. The target genes identified 
are examined in more detail in the discussion section below.  
 
Table 5.9 Putative target genes predicted using miRWalk, miRDB and with 
reference to literature. FBXW7: F-box and WD-40 domain protein 7; NLK: Nemo-like 
Kinase; DKK3: Dickkopf-3 gene; BCL2L11: Bcl-2-like protein 11; PER2: period 
circadian regulator 2; PTEN: Phosphatase and tensin homolog; SMAD3: Mothers 
against decapentaplegic homolog 3; ITGA6: Integrin α6; DAB2IP: Disabled homolog 
2-interacting protein; CKS1B: cyclin-dependent kinase CDC28 protein kinase 
regulatory subunit 1B; STAT3: Signal transducer and activator of transcription 3; Bcl-
2: B-cell lymphoma 2; MCL1: Myeloid cell Leukemia 1.  
 
 
5.4.6 Results of technical validation: Hypoxia samples 
 
Along with the 28 responder and non-responder samples, the twenty-six microRNAs 
selected for technical validation were also measured in samples from three rectal 
cancer cell lines (HT55, SW837 and VACO4s), grown under three different oxygen 
conditions (0.2% oxygen, 1% oxygen and 20.9% oxygen) for 48 hours. The only 
microRNA which showed a significant difference in expression between the oxygen 
tensions was miR-210-3p (ANOVA between oxygen tensions p = 0.019; T-test for 
MicroRNA MicroRNA sequence Putative targets 
miR-92b-3p UAUUGCACUCGUCCCGGCCUCC 
FBXW784, NLK85,  
DKK386, BCL2L1187, PER288, 
PTEN89, SMAD390, ITGA691, 
Rab2392, DAB2IP93  
miR-197-3p UUCACCACCUUCUCCACCCAGC 
p5394, NLK95, CKS1B96, 
STAT396, Bcl-296, MCL197 
miR-4303 UUCUGAGCUGAGGACAG - 
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normoxia to 0.2% oxygen p = 0.002). There was no significant difference identified 
between oxygen tensions for any of the other microRNAs including miR-92b-3p, 
miR-197-3p and miR-4303.  
 
 
5.5 Discussion 
 
The management of patients with rectal cancer has improved considerably in recent 
years, partly due to improvements in staging and the use of neoadjuvant therapy98. 
Despite this, the individual tailoring of therapy remains one of the major challenges 
facing clinicians who treat rectal cancer98. New technology has the potential to 
identify prognostic molecular biomarkers that could enable this goal. A lack of 
response to neoadjuvant therapy is associated with poor prognosis in terms of 
poorer disease-free survival99 and tumour regression grade has been shown to be a 
better prognostic factor than downstaging100. 5-year survival is over 90% for patients 
with a histological complete response (TRG 1) following neoadjuvant therapy and 
these patients have a 3.3-fold advantage in overall survival compared with 
incomplete responders101.  
 
A biomarker for the prediction of response to neoadjuvant CRT would allow 
tailoring of therapy on an individualised level, rationalising the use of CRT, which is 
known to have a negative impact on functional outcome1. As outlined in the 
introduction above, it could also facilitate avoidance of surgery altogether in those 
patients predicted to respond well to CRT who opted to follow an intensified regime 
aiming from the outset to avoid surgery if possible. Even without a predictive 
biomarker stratifying use, an intensified neoadjuvant CRT regime has been shown to 
achieve up to 49% early complete clinical response of the tumour102 indicating that a 
sizeable group of patients could potentially benefit from this strategy.   
 
This exploratory study has confirmed that extraction of microRNAs from pre-
treatment rectal biopsy tissue blocks is feasible and can yield sufficient RNA to 
facilitate array profiling. The results have identified that expression of microRNAs 
potentially differs between responders and non-responders to neoadjuvant CRT 
showing that microRNAs have potential as predictive biomarkers. There is some 
overlap between the methodology used in this study and previous similar studies 
but this study has identified further microRNA targets, which could form the basis 
for future research to validate and build on these initial findings.  
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For two of the microRNAs identified, miR-92b-3p and miR-197-3p, there are 
established links to response to chemo/radiotherapy in several cancers and studies 
from the literature potentially explain the mechanisms of chemoresistance which 
could be linked to altered expression84,96,103-109.  
 
miR-4303 was identified in 2009, based on deep sequencing110 and is predicted to be a 
microRNA based on its sequence but it has not yet been functionally validated111. It is 
relatively unknown in the literature and the only previously reported association 
with cancer is that expression was found to be downregulated in gastric cancer112. 
 
miR-92b-3p is known to be an oncogenic microRNA103 with increased expression 
previously identified in several cancer types, including colorectal cancer84, 
glioblastoma103, lung cancer104, sarcoma113, nasopharyngeal carcinoma90, oral 
squamous cell carcinoma114, oesophageal squamous cell carcinoma91, hepatocellular 
carcinoma115, cholangiocarcinoma87, bladder cancer93 and osteosarcoma88. MicroRNA 
array analysis has shown that is it upregulated in metastatic colorectal cancer 
tissues84 and further studies have shown that miR-92b-3p promotes proliferation, 
migration and invasion in colorectal cancer84. It has been shown to play a similar role 
in the proliferation of glioblastomas103. miR-92b functions as an oncogene in non 
small cell lung cancer regulating cell growth and is also upregulated in cisplatin 
chemotherapy resistant cells104. As well as a role in proliferation and resistance to 
therapy, it also has a potential role in recurrent disease, it was highly expressed in 
patients who developed recurrence following curative surgery and adjuvant 
chemotherapy for gastric cancer116.  
 
Several putative target genes were identified for miR-92b-3p. F-box and WD-40 
domain protein 7 (FBXW7) is a tumour suppressor gene associated with resistance to 
chemotherapy105. miR-92b-3p has been shown to inhibit FBXW7 in vitro and thereby 
promote colorectal cancer development84. Nemo-like Kinase (NLK) is also a tumour 
suppressor gene, identified to play a role in colorectal cancer117. NLK is a direct target 
of miR-92b-3p and elevated levels affect glioma proliferation through NLKs effects 
on the Wnt/beta-catenin signalling85. Dickkopf-3 gene (DKK3) is a further target gene 
of miR-92b, which acts as an antagonist of the same Wnt/beta-catenin signalling 
pathway118. miR-92b inhibits the expression of DKK3 and can thereby regulate cell 
proliferation and apoptosis in gliomas86.  
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Bcl-2-like protein 11 (BCL2L11) is part of the Bcl-2 (B-cell lymphoma 2) family of 
proteins, and is a downstream gene of the Wnt/beta-catenin signalling pathway119. 
The period circadian regulator 2 (PER2) gene plays a potential role in tumor 
suppression through regulation of DNA-damage-responsive pathways120, it is also 
partly regulated by beta-catenin121. BCL2L11 and PER2 have both previously been 
identified as potential targets of miR-92b in cholangiocarcinoma87.  
 
MicroRNA miR-197 is known to function as an oncoMIR, playing several key roles in 
cancer progression including effects on proliferation, differentiation, metastasis, 
invasion, apoptosis and drug resistance106,107. Altered expression has been identified 
in many types of cancer including colorectal cancer108, lung cancer94, breast cancer122, 
ovarian cancer95, hepatocellular carcinoma123, thyroid cancer124, pancreatic cancer125 
and osteosarcoma126. miR-197 was shown to be downregulated in colorectal cancer 
cell lines following 5-fluorouracil (5-FU) chemotherapy109 and a further study by the 
same group showed that miR-197 mediated resistance to 5-FU via regulation of 
thymidylate synthase expression108. Similarly, miR-197 was significantly increased in 
ovarian cancer cells showing resistance to Taxol chemotherapy and expression of 
miR-197 promoted Taxol resistance, proliferation, and invasion95. In non-small cell 
lung cancer, miR-197 is downregulated in platinum chemotherapy-resistant 
specimens and regulates drug resistance and tumour progression96. miR-197-3p has 
been identified as a possible therapeutic target in thyroid cancer as overexpression 
promotes migration and invasion124. Similarly, miR-197 overexpression has been 
shown to promote invasion in pancreatic cancer125 and bladder cancer127.  
 
As with miR-92b-3p, several putative target genes were identified for miR-197-3p. 
p53 is one of the best known tumour suppressor genes and is frequently mutated in 
human cancers128. In lung cancer cells, downregulation of miR-197 was shown to 
induce p53-dependent lung cancer cell apoptosis with down-modulation of miR-197 
leading to significant upregulation of the p53 pathway94. Another tumour suppressor 
gene, NLK, which is also a direct target of miR-92b-3p (see above), is also 
downregulated by miR-197, promoting drug resistance in ovarian cancer cells95.  
 
As outlined in the introduction, hypoxia is known to play a key role in response to 
both chemotherapy and radiotherapy14. The samples from rectal cancer cell lines 
grown in normoxia and hypoxic conditions, showed significant differences in 
expression of miR-210-3p. The other microRNAs, including the three identified as 
linked to response to neoadjuvant therapy, did not show any difference in 
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expression between the different oxygen tensions, indicating that mechanisms other 
than hypoxia are probably more important for these microRNAs. 
  
The finding that miR-210 is increased in hypoxia, is expected, as miR-210 is known to 
be a master hypoxamir, induced under hypoxic conditions129 and was included in the 
validation set of microRNAs for this reason. miR-210 is upregulated in most solid 
tumours, high levels are linked to hypoxia and are associated with poor prognosis in 
terms of clinical outcomes62. When hypoxia is present in a tumour, hypoxia inducible 
factors (HIF) are activated129. These control cellular responses to hypoxia including 
metabolism, proliferation and invasion. miR-210 is a known target of both HIF1α 
and HIF2α130. miR-210 is specifically increased in hypoxic regions of colorectal 
cancers and has been suggested as a potential biomarker for hypoxia in these 
cancers63. 
 
There are an extensive number of studies attempting to identify predictive molecular 
biomarkers for response to neoadjuvant therapy in rectal cancer. As outlined in the 
introduction, few of the markers identified have subsequently been verified by 
external validation or independent studies. Biomarkers for routine clinical use would 
need to show accuracy and consistency, as well as applicability to relevant patient 
groups and, so far, none have achieved this sufficiently to be adopted. Establishment 
of the mechanistic links between biomarkers and tumour biology are crucial to their 
use and there are other considerations including cost-effectiveness3. It is likely that a 
single marker may not be able to meet these challenges and instead, a panel, or 
combination of molecular biomarkers could be used to stratify risk. A combination of 
three molecular biomarkers, c-MYC, PCNA and TIMP1 has been previously used in 
an attempt to predict outcome in rectal cancer, in order to improve predictive 
accuracy compared with single markers alone131. The same study went on to combine 
this molecular panel with MRI-detected extramural venous invasion, an imaging 
biomarker, and was able to improve categorisation of patients into prognostic groups 
(p <0.01) 131.  
 
Currently none of the predictive molecular markers used in rectal cancer are in 
routine clinical use. This contrasts with other cancers, in particular breast cancer, 
where biomarkers play an essential role, both in diagnosis and in predicting 
outcome132. Multigene panels are used for breast cancer patients in clinical practice, 
to provide prognostic information about disease free survival and assist decision-
making about chemotherapy132.  
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The comparison of baseline characteristics between the responder and non-
responder groups show that they are well matched with the only pre-treatment 
difference being a higher proportion of responders having nodal involvement. There 
was no difference in pre-treatment staging but as would be expected, histological 
stage was significantly lower in responders to neoadjuvant therapy.  
 
The two groups were not exactly matched in terms of the neoadjuvant therapy 
received, more of the non-responders had short course radiotherapy, while more of 
the responders had long course chemoradiotherapy. This lack of matching between 
the two groups is one of the limitations of the study. It would also have been 
preferable to have defined response purely in terms of tissue regression grade with 
only those with TRG 1 or even TRG 1 or 2 in the responder group. Relying on 
downstaging as a marker of response, inherently relies on the accuracy of MRI for 
staging rectal cancer pre-treatment, the limitations of which have been discussed in a 
previous chapter. The decision to include downstaging as well as TRG in defining 
response was down to limitations on the number of samples available.  
 
The sample size was limited by several factors. The study could only include patients 
within the Colorectal Cancer Tissue Bank database as these patients had given ethical 
approval, including for retrieval and use of their pathology blocks. There were 55 
patients in the database that had neoadjuvant therapy for rectal cancer. A proportion 
of these were excluded (see Figure 5.2), firstly it was not possible to retrieve biopsy 
slides for all patients, as these were stored off-site for historical slides. As this unit is 
a tertiary centre some patients underwent their biopsy in a separate NHS Trust and 
further patients did not have cancer present in their biopsy slides. A few patients 
were having ongoing treatment and their pathology slides were in use and 2 patients 
had duplicate numbers in the database and unfortunately had to be excluded. This 
left 40 eligible patients. Of these, 12 patients were not clearly responders or non-
responders, they had mixed results, for example, worsening of their stage from pre 
treatment staging to histological stage but TRG 2. This resulted in the overall sample 
of 28 patients and the smaller sample size limited subgroup analysis and may have 
lead to type II errors.  
 
Further limitations of the study are that not all characteristics of the tumours were 
not known, including height of the tumour from the anal verge, one tumour related 
factor that can affect outcome133; however, this is unlikely to have had much impact, 
as the proportion undergoing abdominoperineal excision rectum (APER) was not 
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significantly different between the two groups. No independent validation group 
was used to verify the results and this is obviously still required, but again was 
limited by available numbers.  
 
There are some limitations associated with the methodology of this type of study. 
The use of pre-treatment biopsies is required to ensure that the microRNAs have not 
been altered by therapy received, and because this is the tissue that would be used in 
the real world to measure any predictive biomarker which could be established. 
However, the biopsies taken are usually from the surface of the tumour, and marked 
heterogeneity within cancers may mean that these may not be representative134, this 
is however, a limitation of all diagnostic methods using biopsies.  
 
Further work to build on these results would need to start with validation in 
independent sample cohorts, ideally via collaboration with other clinical centres and 
laboratories using standardised methodologies. The validation set should ideally 
have larger numbers, with clear definition of response and non-response to achieve 
more homogenous groups. Work to try and achieve this is ongoing and 
unfortunately was not completed within the timescale of this thesis. The next step 
would be work to identify targets and further develop the possible mechanisms 
involved, this would be based on findings from previous studies outlined above and 
the list of putative targets identified. As described above, consideration would need 
to be given as to whether the microRNAs identified could be used alone, as a 
combination, or in combination with another modality, such as diffusion weighted 
MRI. 
 
 
5.6 Conclusions 
 
This exploratory study has confirmed that analysis of microRNA expression in pre-
treatment rectal biopsies is feasible. Expression of microRNAs potentially differs 
between responders and non-responders to neoadjuvant CRT. MicroRNA targets 
therefore have potential as predictive biomarkers for response to neoadjuvant 
therapy in rectal cancer. This study has identified three possible targets for future 
validation studies. Further research into the development of molecular biomarkers 
will require a more sophisticated understanding of the mechanisms behind response 
and non-response to therapy.  
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Chapter 6. Assessment of anal sphincter function following 
anterior resection using high-resolution anorectal manometry  
 
6.1 Introduction 
 
As detailed in chapter 3, low anterior resection syndrome (LARS) affects a large 
proportion of patients undergoing treatment for rectal cancer. Although risk factors 
have been identified, it is still unclear why the incidence varies even within the low 
and high-risk groups. The changes in anal sphincter structure and function that 
ultimately lead to LARS are not well understood and predicting which individual 
patients might develop problems remains a challenge. A better understanding of the 
pathophysiology underlying poor functional outcomes will be the only way to 
determine how we can improve the management of rectal cancer, with the overall 
treatment aim of preserving functioning sphincters.  
 
LARS is a multifactorial condition with a contribution from several different 
mechanisms1. Figure 6.1 illustrates some of these contributory factors. Autonomic 
nerve disruption, with division of the inferior mesenteric ganglia and the 
hypogastric plexus during surgery, has long been thought to contribute to poor post-
operative function2, this is one of the few mechanisms believed to be partly 
preventable. During anterior resection, the rectum is replaced with the sigmoid or 
descending colon, this has thinner, weaker muscle, that does not contract as strongly 
and is relatively denervated compared with the rectum3. The neorectum also has 
altered motility, loss of the normal propagation of contraction and spastic waves 
have been demonstrated and these were shown to correlate with urgency and 
clustering3. Several studies have identified altered sensitivity following anterior 
resection4-6, the reduction in reservoir size4 and altered compliance7 are thought to 
contribute to this.  
 
It is clear that neoadjuvant chemoradiotherapy is a risk factor for LARS, but this 
effect has mostly been studied in combination with subsequent surgery and there is 
very little evidence about the effect of chemoradiotherapy alone on anorectal 
function. A better understanding of the effects of CRT separate to those of surgery 
would be useful to help minimise negative effects and also when counselling 
patients about the risks and benefits of different aspects of rectal cancer therapy.  The 
effect of CRT can be difficult to study in rectal cancer patients as most of these 
patients undergo surgery following CRT. Increasingly some patients with a clinical 
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complete response to CRT are following a watch and wait protocol12 rather than 
undergoing surgery. The functional outcomes of this newer treatment protocol are 
not known, and this patient group may be ideal for studying the effect of CRT alone 
on functional outcome13.  
 
Figure 6.1 Mechanisms contributing to LARS 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Functional outcomes following treatment for rectal cancer have been poorly assessed 
in comparison to oncological outcomes14. As discussed in chapter 3, it is important 
that the routine assessment of functional outcome becomes normal practice, in order 
to identify symptomatic patients and refer them for treatment. However, it is equally 
important that we give consideration to the ways in which post treatment 
dysfunction can be minimised or prevented. This can only be achieved with 
improved understanding of pathophysiology. 
 
Anorectal manometry is the most commonly used investigation to assess anorectal 
function15. Studies have shown that anorectal manometry results can influence the 
diagnosis, management and outcome for patients with faecal incontinence and 
constipation16,17. It is therefore likely that it would be a very useful tool in the 
assessment of pre and post treatment function in rectal cancer patients. Despite the 
widespread use of manometry, there are acknowledged limitations of this 
assessment. The main difficulty in interpreting results is the variation in equipment 
and methodology between units15. This prohibits comparisons between different 
units and has led to lack of agreement about normal values and reference ranges15. 
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Standard anorectal manometry utilises either a solid-state or water-perfused probe 
with transducers at 1cm intervals arranged radially18. This is then withdrawn 1cm at 
a time and repeated measurements taken. High-resolution manometry differs from 
traditional manometry as the catheter uses multiple transducers, closely spaced 
together, which simultaneously measure circumferential pressures15, see Figure 6.2. 
The transducers are close enough together to allow intraluminal pressure to be 
measured as a continuum19. Software can then be used to convert the manometry 
readings into colour contour pressure topography plots, which allow appreciation of 
the anorectum as a functional unit and can also be used to show dynamic changes19. 
Examples of these colour contour plots are shown in Figure 6.3 and Figure 6.4.  
 
Figure 6.2 UniTip HRAM catheter 20 
 
 
The initial use of high-resolution manometry was for investigation of oesophageal 
function and it has now been widely adopted for this assessment in preference to 
standard manometry21. In contrast to standard manometry there has been a focus on 
standardisation of techniques for anorectal assessment, with published definitions 
and protocols for the methods used22. The reference ranges for the normal population 
have also been provided by studies carried out on healthy volunteers22,23. High-
resolution anorectal manometry (HRAM) using a standardised protocol is an 
objective and repeatable measure, ideal for use in rectal cancer patients with 
interacting factors affecting sphincter morphology and function.  
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Figure 6.3 HRAM colour contour display at rest. The pressure scale is shown to the 
left of the colour plot and the diagram to the far left demonstrates the manometry 
catheter position within the anal canal and rectum. On the colour plot, the functional 
anal canal length is displayed by the green band (measured by black arrow), low 
pressure (indicated by light blue band) is seen in the rectum.   
 
 
Figure 6.4 Representative HRAM 
colour contour displays at rest and 
during endurance squeeze 
manoeuvre. The red and yellow 
stripes in the anal canal during 
resting indicate the presence of 
normal slow wave activity. The rise 
in pressure in the anal canal during 
squeeze is due to the contraction of 
the external anal sphincter.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 242 
There is limited evidence about the link between LARS, or the component symptoms 
of LARS, and specific abnormalities on manometry testing5. This is partly due to a 
lack of studies considering this question. The studies that have been carried out have 
shown conflicting results, some show correlation between LARS and altered 
parameters including resting pressure, compliance and capacity measures5 with 
others showing no difference in manometry results between patients with and 
without symptoms24.  
 
The advantages of HRAM over conventional manometry give it the potential to be a 
useful tool to better understand the physiological changes that underlie functional 
problems and determine whether treatment for rectal cancer can be improved in any 
way to better preserve function. It may also be a useful tool for the assessment of 
symptomatic patients. Although standard manometry has been studied in patients 
who have had an anterior resection, very few studies have used HRAM in rectal 
cancer patients, or compared findings at pre and post treatment timepoints. This 
provides an opportunity for an exploratory study to establish the use of HRAM as an 
investigative tool in these patients and build a basis for future studies into this 
important topic.  
 
 
6.2 Aims 
 
The primary aim of this study is to define the changes in anal sphincter function 
following anterior resection and chemoradiotherapy using HRAM (compared with 
normal values and pre-treatment values). 
The secondary aims are to correlate values for HRAM parameters following 
treatment with clinical variables, and with the presence of minor and major LARS. 
 
 
6.3 Methods 
 
6.3.1 Patients 
 
This was a single institution prospective cohort study. A change in clinical practice 
was introduced in August 2014 with all rectal cancer patients undergoing routine 
anorectal manometry as part of their pre-treatment planning. The aim of this was to 
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assess sphincter function prior to CRT or surgery. Patients were also sent for post-
treatment testing as part of assessment of their functional outcomes. Figure 6.5 
shows the flow of patients between pre treatment and post treatment testing. 
 
As this was an exploratory study, the inclusion criteria were deliberately broad. 
Inclusion criteria included 1) Patients aged >18 years with biopsy-proven diagnosis 
of rectal cancer 2) Treatment plan from colorectal multidisciplinary team meeting 
(MDT) for patient to undergo chemoradiotherapy (CRT) or surgical resection 3) Able 
to provide informed consent to manometry. All patients were reviewed at the 
colorectal cancer MDT as per usual practice. 
 
Figure 6.5 Flow of patients through pre treatment testing, treatment for rectal 
cancer, followed by post treatment testing. MDT: multidisciplinary team meeting; GI: 
gastrointestinal; HRAM: high-resolution anorectal manometry.  
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Exclusion criteria were limited in order to capture data from as many patients as 
possible at multiple time points. Exclusion criteria included permanent stoma 
creation, recurrent cancer and inability to tolerate manometry evaluation.  
 
6.3.2 Treatment  
 
Some patients who were discussed at MDT and had obstructive or difficult to 
manage symptoms underwent defunctioning sigmoid or transverse loop colostomy 
prior to the start of treatment.  
 
Rectal cancer patients underwent a CRT regime with external beam radiotherapy 
given as 45 Gy delivered in 25 fractions over 5 weeks (daily dose 1.8 Gy) and 
concomitant chemotherapy given as the oral 5-FU derivative capecitabine.  
 
For patients who subsequently underwent resection of the rectal tumour, anterior 
resection was carried out according to the principles of total mesorectal excision, 
with histological analysis of the specimen. Defunctioning ileostomy was carried out 
selectively with the decision made intra-operatively by the surgeon depending 
mainly on the height of the tumour.  
 
6.3.3 Manometry protocol  
 
High-resolution anorectal manometry was carried out using standardised 
techniques18 in accordance with a published protocol for HRAM at the 
Gastrointestinal (GI) Physiology Unit at The Royal London Hospital22 shown in 
Figure 6.6. HRAM was performed using a solid-state catheter (UniTip: UniSensor 
AG, Attikon, Switzerland), of external diameter 12F. Data processing and analysis 
was carried out using a commercially available manometric system (Solar GI HRM 
v9.1; Medical Measurement Systems (MMS), Enschede, The Netherlands). HRAM 
assessment included measurement of functional anal canal length in cm, defined as: 
length of anal canal (cm) in which pressure exceeded rectal pressure by >5 mmHg22.  
 
Four measurements were used to report results; the definitions are taken from the 
paper defining normal values and measures used in HRAM by Carrington et al22.  
1. Average anal resting pressure defined as: average maximum pressure (mmHg) 
over the functional anal canal length (FACL) during the 1 min period of rest. 
2. Maximum incremental anal squeeze pressure defined as: maximum recorded  
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Figure 6.6 HRAM protocol 22 
during voluntary squeeze, minus 
the mean maximum resting 
pressure prior to the manoeuvre 
(over 5 seconds). 
3. Average incremental anal squeeze 
pressure defined as: mean 
maximum pressure (mmHg) 
sustained over the duration of the 5 
second squeeze manoeuvre minus 
the mean maximum resting 
pressure prior to the manoeuvre 
(over 5 seconds). 
4. Endurance squeeze index: FACL 
x average incremental anal squeeze 
pressure x 30 (seconds). 
 
Physiology reporting was done as per standard department protocol. A written 
consent form was signed at the time of attending for manometry (as for all other 
patients undergoing this investigation). Manometry was carried out with the patient 
in the left lateral position; no bowel preparation was used prior to examination. 
 
Following manometry, rectal volumes were assessed using a balloon attached to a 
Foley catheter introduced into the rectum. Three measurements were taken: first 
rectal sensation; then defaecatory desire volume and maximum tolerated volume (all 
in ml). Endoanal ultrasound was then used to assess the structural integrity of the 
anal sphincters.  These additional tests are routinely used for patients undergoing 
HRAM testing within the GI Physiology Unit.  
 
6.3.4 Questionnaires 
  
The LARS questionnaire has been described in chapter 3. The LARS score includes 
five questions about bowel function and scores from 0–4225. Results were classified 
into three categories: no LARS (0-20); minor LARS (21-29) and major LARS (30-42). 
This questionnaire was used at the time of anorectal manometry, pre-treatment to 
record baseline data and post-treatment in order to assess functional outcomes.  
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Patients also underwent scoring with the St Marks Incontinence Score (SMIS), also 
known as the Vaizey score26 (Appendix 5). This validated questionnaire includes 
seven questions in total, three related to the frequency of incontinence for solid stool, 
liquid stool and flatus, one relating to the frequency of bowel symptoms affecting 
lifestyle and three further yes/no questions about urgency and use of pads or 
constipating medication. Patients also completed the Cleveland Clinic Constipation 
Score (CCCS)27 questionnaire (Appendix 6). This validated questionnaire includes 
eight questions about various aspects of constipation including frequency of bowel 
movements and the presence of abdominal pain.  
 
The SMIS and CCCS questionnaires were included as they are routinely used prior to 
testing for all patients attending the GI Physiology Unit.  
 
6.3.5 Statistical analysis 
 
Statistical analysis was carried out using Statistical Package for the Social Sciences 
(SPSS Inc. Chicago, USA, version 22.0) and a two-sided p-value of <0.05 was 
considered statistically significant. Fisher’s exact test was used to compare 
proportions for baseline categorical variables. This was an exploratory single centre 
study and therefore no sample size calculation was carried out. The sample size of 50 
participants was determined as being a feasible sample size and a sample that would 
give meaningful results. Descriptive statistics including mean, median, percentages, 
range, interquartile range and odds ratios (OR) with 95% confidence intervals (CI) 
are reported. No adjustments were made for multiplicity of testing. 
 
Scoring of the LARS questionnaire was carried out according to the original source of 
the score and patients were classified into three groups: no LARS, minor LARS, 
major LARS. Scoring of the SMIS and CCCS questionnaires was also carried out 
according to the sources of these scores. Values for post-treatment HRAM 
parameters were compared against pre-treatment values using the independent-
samples T test and against values for the normal population using a one-sample T 
test. Results for patients from group B, who all underwent testing pre and post 
treatment (see below and Figure 6.7) were compared using a paired-samples T test. 
Chemoradiotherapy was treated as a dichotomous variable: no treatment vs. 
treatment. Age was treated as a continuous variable and dichotomised to above or 
below the median age of the respondents. Binary logistic regression was used to 
assess the impact of clinical and pathological variables on manometry parameters.  
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6.4 Results 
 
6.4.1 Patients 
 
52 patients met the inclusion criteria and were referred for HRAM between August 
2014 and March 2018. 1 patient, with a low rectal cancer, which was a large tumour 
invading the sphincter complex, was not able to tolerate the tests. Therefore in total 
51 patients were included in the analysis. Due to the fact that this protocol was newly 
introduced to the department, not all patients were referred for testing at each 
relevant time point. 32 underwent testing at diagnosis only, 8 underwent tests both 
pre-treatment and post-treatment and a further 11 patients only had tests following 
treatment. These three groups of patients were labelled groups A, B and C in order to 
clarify the results of analysis, see Figure 6.7. There were no complications arising 
from manometry testing.  
 
Figure 6.7 Division of patients into three groups according to which set or sets of 
tests they underwent  
 
 
 
Pre  
treatment 
testing 
 
 
 
 
 
 
Post  
treatment 
testing 
 
 
 
 
 
6.4.2 Baseline data 
 
51 patients were included in the analysis, 30 men (59%) and 21 women (41%). The 
median age was 66 years (range 28-88). Table 6.1 shows that the different groups 
were matched for baseline characteristics, except for the proportion with a stoma.  
 
Group A  
(pre only) 
32 patients 
 
 
Group C  
(post only) 
11 patients 
 
 
Group B  
(pre and post) 
8 patients 
 
 
Group B  
(pre and post) 
8 patients 
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Table 6.1 Patient characteristics for groups A, B and C. IQR: interquartile range, 
CRT: chemoradiotherapy, LAR: low anterior resection. 
 
 
Group A 
(n = 32) 
Group B 
(n = 8) 
Group C 
(n = 11) 
p-value 
Female : Male 13 : 19 4 : 4 4 : 7 0.845 
Median age (IQR) years 67 (58-71) 55 (37-63) 68 (51-72) 0.252 
CRT : LAR  
n/a all pre 
treatment 
3 : 5 9 : 2 0.074 
Stoma : no stoma 
at post treatment testing 
n/a all pre 
treatment 
5 : 3 1 : 10 0.041 
 
 
6.4.3 Treatment  
 
In total, 19 patients underwent HRAM testing following treatment. 12 patients had 
chemoradiotherapy as their primary treatment, only 1 of these had creation of a 
colostomy prior to therapy and still had their colostomy at post-treatment testing. 7 
patients with rectal cancer had a low anterior resection (LAR) as their primary 
treatment for cancer, 5 of these still had their ileostomy at the time of post-treatment 
testing and 2 had undergone closure of ileostomy. These groups are summarised in 
Figure 6.8.   
 
Figure 6.8 Diagram showing number of patients undergoing each treatment. CRT: 
chemoradiotherapy; LAR: low anterior resection.  
 
 
 
 
 
 
 
6.4.4 Results for functional anal canal length   
 
The results for functional anal canal length (FACL) showed greater change in women 
than in men. For female patients, post treatment measurements were significantly 
lower than the normal population values, p = 0.023. For men, there was no significant 
Pre-treatment 
11 post 
CRT 
1 post CRT + 
colostomy 
 
5 post LAR + 
ileostomy 
 
2 post LAR 
+ ileostomy 
reversal 
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difference between any group and the normal population. These results are shown in 
Figure 6.9.  
 
Figure 6.9 Functional anal canal length in the normal population (error bars for 
normal population demonstrate range) and in other groups vs. the normal 
population (error bars show 95% confidence intervals). CRT: chemoradiotherapy; 
LAR: low anterior resection.  
 
 
 
 
There was no significant change in FACL between pre and post treatment 
measurements in either male or female patients. In men pre treatment mean was 
3.9cm (95% CI 3.5 – 4.4cm) and post treatment mean 4.0cm (95% CI 3.3 – 4.6cm), p = 
0.882. In women pre treatment mean was 3.2cm (95% CI 2.7 – 3.6cm) and post 
treatment 2.7cm (95% CI 2.1 – 3.4cm), p = 0.226. There was also no difference in 
FACL following CRT or LAR compared with pre treatment values, in either men or 
women.  
 
 
6.4.5 Results for average anal resting pressure 
 
There was no significant difference between the average anal resting pressure in all 
groups, either pre or post treatment when compared with normal population data, in 
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men or women. There was also no difference found on comparison between pre and 
post treatment testing results.  
 
6.4.6 Results for maximum incremental anal squeeze pressure 
 
The results for comparison with normal values for maximum incremental anal 
squeeze pressure show that for female patients, post treatment measurements were 
significantly lower than the normal population values in all patients post treatment, 
post CRT and post LAR groups. However, in contrast with FACL, the values for 
maximum incremental anal squeeze pressure prior to treatment in women were also 
significantly lower than normal values. For men, there were no significant 
differences between normal values and any group. These results are shown in Table 
6.2.  
 
Table 6.2 Results for maximum incremental anal squeeze pressure in different 
groups compared with population normal data22. 95% CI: confidence intervals; CRT: 
chemoradiotherapy; LAR: low anterior resection.  
 
 Mean value  
(mmHg) male 
patients 
(95% CI) 
p-value 
vs. 
normal 
Mean value 
(mmHg) female 
patients 
(95% CI) 
p-value 
vs. 
normal 
Normal population 219 (range 61 – 525) - 
164  
(range 45 – 324) - 
Pre treatment  
(groups A & B) 
180 
(134 – 226) 0.091 
114 
(80 – 148) 0.006 
Post treatment  
(groups B & C) 
251 
(163 – 340) 0.433 
98 
(78 – 118) <0.001 
All post CRT 266 (154 – 378) 0.442 
92 
(68 – 116) 0.004 
All post LAR  226 (63 – 388) 0.907 
108 
(69 – 147) 0.025 
 
There was no significant difference in either men or women when comparing pre 
treatment and post treatment results. 
 
6.4.7 Results for average incremental anal squeeze pressure 
 
The results for comparison with normal values for average incremental anal squeeze 
pressure showed a similar pattern to those seen above. For female patients, pre-
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treatment values were significantly lower than the normal population as were 
measurements in all patients post treatment and the post CRT group. For men, there 
were no significant differences between normal values and any group. These results 
are shown in Table 6.3.  
 
Table 6.3 Results for average incremental anal squeeze pressure in different 
groups compared with population normal data22. 95% CI: confidence intervals; CRT: 
chemoradiotherapy; LAR: low anterior resection.  
 
 Mean value 
(mmHg) male 
patients 
(95% CI) 
p-value 
vs. 
normal 
Mean value 
(mmHg) female 
patients 
(95% CI) 
p-value 
vs. 
normal 
Normal population 144 (range 40 – 366) - 
113 
(range 29 – 235) - 
Pre treatment  
(groups A & B) 
122 
(89 – 154) 0.170 
70 
(48 – 91) 0.001 
Post treatment  
(groups B & C) 
187 
(120 – 254) 0.180 
74 
(52 – 95) 0.003 
All post CRT 201 (118 – 284) 0.227 
66 
(45 – 87) 0.013 
All post LAR  164 (33 – 294) 0.668 
86 
(23 – 149) 0.209 
 
On comparison between pre treatment and post treatment values, there was no 
significant difference in men and women for the majority of groups. In male patients 
there was a trend towards measurements being higher in the post treatment groups 
than on the pre treatment measurement. This was the case for all patients, post CRT 
and post LAR patients but was only significant in the rectal cancer patients with a 
pre treatment mean value of 122mmHg (95% CI 89 – 154) compared with 187mmHg 
(95% CI 120 – 254) following treatment, p = 0.040.  
 
6.4.8 Results for endurance squeeze index 
 
The results for endurance squeeze index were similar to those for maximum and 
average incremental anal squeeze pressures. For female patients, pre treatment 
measurements were significantly lower than the normal populations (p = <0.001), as 
were post treatment measurements for all patients (p = <0.001) and post CRT groups 
(p = 0.001). For men, pre treatment (p = <0.001) values were significantly lower than 
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those for the normal population but there was no difference between post treatment 
values and the normal population.  
 
As for average incremental anal squeeze pressure, in male patients there was a trend 
towards measurements being higher in the post treatment groups than on the pre 
treatment measurement. This was significantly different for the overall patient group 
with a pre treatment mean value of 2239mmHg/s (95% CI 1396 – 3081) compared 
with 3781mmHg/s (95% CI 2766 – 4796) following treatment, p = 0.028. This pattern 
was not repeated in female patients. 
 
6.4.9 Results for sensitivity testing 
 
Testing for rectal sensation included three measurements, first rectal sensation, 
defaecatory desire volume and maximum tolerated volume. The results for all three 
measurements showed similar patterns. In both male and female patients post 
treatment measurements were significantly lower than the normal population values 
in all patients, post CRT and post LAR groups. This is consistent with rectal 
hypersensitivity. In men the pre treatment values were normal but in women, the pre 
treatment test results also showed values significantly lower than normal. These 
results are shown in Figures 6.10 and 6.11.  
 
There was no significant difference between pre treatment values and post treatment 
values for rectal sensation in male or female patients across the three different 
measurements used. 
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Figure 6.10 Rectal sensation (ml) for men in the normal population and in other 
groups vs. the normal population. CRT: chemoradiotherapy; LAR: low anterior 
resection.  
 
 
 
Figure 6.11 Rectal sensation (ml) for women in the normal population and in other 
groups vs. the normal population. CRT: chemoradiotherapy; LAR: low anterior 
resection.  
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6.4.10 Results for endoanal ultrasound  
 
33 patients underwent pre treatment ultrasound, 20 men and 13 women. 18 patients 
had an ultrasound following their treatment, 11 of these were male. The majority of 
rectal cancer patients had normal sphincter morphology on ultrasound. These 
figures are shown in Table 6.4.  
 
Table 6.4 Pre and post treatment endoanal ultrasound findings. USS: ultrasound.  
 Normal n (%) 
Abnormal 
n (%) 
Pre treatment USS:  
External sphincter 25 (75.8%) 8 (24.2%) 
Internal sphincter 20 (60.6%) 13 (39.4%) 
Post treatment USS:  
External sphincter 14 (77.8%) 4 (22.2%) 
Internal sphincter 12 (66.7%) 6 (33.3%) 
 
Of those with an abnormal pre treatment USS, the majority had defects or distortion 
directly due to tumour. On post treatment USS, 50% of abnormalities were described 
as being directly due to tumour with the remainder being characterised as simple 
defects or due to atrophy, scarring or fibrosis.  
 
Between male and female patients there was no difference in the numbers with 
abnormal pre or post treatment USS. Female gender was a risk factor for abnormal 
external sphincter on USS pre treatment with an odds ratio of 7.714 (95% CI 1.246 to 
47.754, p = 0.028) and was also a risk factor for abnormal external sphincter on USS 
post treatment with an odds ratio of 6.000 (95% CI 1.172 – 30.725, p = 0.032). There 
was no difference identified in the number of patients with abnormal post treatment 
ultrasound in patient groups that underwent CRT or LAR.  
 
6.4.11 Questionnaire results  
 
27/51 patients completed the SMIS questionnaire prior to their treatment. The most 
frequent score was 0 (37.0%), with a median score of 3 (IQR 0 - 5). Only 2 patients 
scored ≥12 indicating moderate incontinence. Following treatment, 9/51 (only 17.6% 
of the total cohort) completed the SMIS questionnaire. The median score was 2 (IQR 
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0 - 13). The maximum score was 17 and 3 (33.3%) of the patients scored ≥12. On 
statistical testing there was no difference between pre and post treatment scores (p = 
0.236).  
 
On pre treatment testing, patients with SMIS ≥12 did not have significantly different 
manometry measurements from those with SMIS scores <12. In patients with SMIS 
≥12 post treatment, the average anal resting pressure was significantly reduced 
compared with those with SMIS <12 (44 mmHg vs. 72 mmHg, p = 0.018, there was no 
difference seen in other manometry variables. There was no statistically significant 
difference in FACL or sensitivity measurements between those with high or low 
SMIS scores.  
 
27/51 patients completed the CCCS questionnaire prior to treatment. For these 
patients, the median score was 2 (IQR 2 - 4). No patients in this cohort scored ≥15, a 
score that indicates moderate constipation. Following treatment 9 patients completed 
this questionnaire. The median score was 4 (IQR 2 - 7). The maximum score was 10 
and again no patients scored ≥15.  
 
There was no difference between pre and post treatment CCCS scores p = 0.432. 
Scores were dichotomised to above and below the median score of 3 (as no patients 
scored ≥15 this could not be used to dichotomise). In patients with above and below 
median scores there was no difference in pre or post treatment FACL, manometry 
measurements or sensitivity.  
 
22/51 patients (43.1%) completed the LARS score pre treatment. The median score 
was 15 (IQR 5-20). The majority of patients, 18 (81.8%) had no LARS; 2 (9.1%) had 
minor LARS and 2 (9.1%) had major LARS prior to treatment. Only 6 (11.8%) 
completed the questionnaire following their treatment. The median score was 
increased to 25 (IQR 14 - 26). 2 (33.3%) patients had no LARS, a further 3 (50%) had 
minor LARS and 1 (16.7%) had major LARS.  
 
Although the LARS scores were increased post treatment when compared with pre 
treatment values, this difference was not significant (p = 0.101). This is illustrated in 
Figure 6.12. With scores dichotomised to no LARS or minor/major LARS, there was 
no difference between groups in pre or post treatment FACL, manometry 
measurements, sensitivity or proportion with abnormal USS.  
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Figure 6.12 Difference between LARS score pre and post treatment. The middle 
line in each box represents the median value, with the boundaries of the box 
representing the quartiles and whiskers showing minimum and maximum values. 
LARS: low anterior resection syndrome.  
 
 
For all three questionnaires used, 
scores prior to treatment were 
not dependent on gender and 
scores following treatment were 
not dependent on gender, use of 
CRT or whether patients had 
undergone LAR.  
 
 
 
 
 
 
 
 
 
 
6.5 Discussion 
 
This study showed that in a department where HRAM is accessible it is easily 
incorporated into pre and post treatment assessment for patients with rectal cancer. 
These tests were widely accepted; no patients refused to have testing carried out and 
only two patients did not tolerate testing. No complications arose as a result of these 
tests. There are several benefits of HRAM. It is intuitive and easy to learn, its 
reproducible and objective nature make it an ideal tool for research and to measure 
changes pre and post intervention. The visual output is easy for patients to 
understand and follow, meaning it can be used for biofeedback and it is also easily 
understood by healthcare professionals who do not have specific knowledge of 
HRAM.  
 
This exploratory study has established the feasibility and application of HRAM as a 
tool to assess functional changes following treatment for rectal cancer. This is a novel 
area of research as, despite the advantages of HRAM outlined above, there are very 
few studies that have used HRAM to assess physiological changes in rectal cancer 
patients. There is also a lack of studies demonstrating the clinical utility and potential 
p	=
	0.
10
1
0
5
10
15
20
25
30
35
40
Pre treatment Post treatment
LA
R
S 
sc
or
e
Treatment group
 
 
 
 257 
benefits of HRAM when compared with standard manometry28. Even conventional 
anorectal manometry has a lack of evidence for clinical benefit and conflicting 
evidence about how well it correlates with symptoms5,24. One study has successfully 
used HRAM to assess the effect of radiotherapy and anterior resection in rectal 
cancer patients and found that functional outcomes were worse in patients who had 
undergone both CRT and LAR with HRAM showing low resting pressures, reduced 
capacity and compliance in these patients29.  
 
Functional anal canal length correlates with both resting and squeeze pressures and 
is a measurement that can therefore reflect anal sphincter function30. It has also been 
shown to correlate with incontinence scores31 and improvement following sphincter 
repair predicts improvement in continence32. Average FACL is known to be shorter 
in women than in men22. The current study has demonstrated that in women with 
rectal cancer, post treatment FACL is below normal. FACL was also reduced 
following CRT and LAR, although not significantly, and this shortening may be a 
potential mechanism by which these treatments impact on sphincter function.  
 
This study did not show any difference in anal resting pressure following treatment 
for rectal cancer. There was also no difference found when comparing the groups in 
the study with normal population data. There was a possible reduction in resting 
pressures in men post LAR but insufficient numbers to really draw any conclusions 
regarding this. Previous studies have shown conflicting results in this area. 
Decreased resting pressures have been shown in patients with LARS and those with 
incontinence2,5. Other studies have shown no difference in resting pressures 
following anterior resection6. Reduced anal resting pressures were identified in 
patients scoring highly on the SMIS questionnaire and therefore experiencing 
incontinence. This would be expected, as resting pressure is essentially a measure of 
internal anal sphincter function, a crucial mechanism for controlling continence33.   
 
On HRAM measures of squeeze there were again some differences identified 
between genders which have not previously been reported. The average and 
maximum incremental anal squeeze in women showed that pre and post values 
were both lower than normal but no difference was seen between pre and post 
measurements. Men essentially had normal results for these two measures. Both 
genders showed lower than normal results for endurance squeeze index prior to 
treatment, with women also showing low values post treatment. This is in keeping 
with previous studies, which have shown decreased squeeze pressures following 
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anterior resection2 and coloanal anastomosis34. Some interesting patterns were seen 
with some of the measures for squeeze having higher post treatment values in men 
when compared with pre treatment values. This may be due to the effect of the 
tumour during pre treatment testing but other unknown mechanisms may also be 
involved. Larger studies would be required to clarify these patterns.  
 
Marked abnormalities of rectal sensation were seen following treatment with both 
CRT and LAR, with low sensory thresholds, indicating rectal hypersensitivity. This 
could clearly account for urgency, which is one of the most troublesome symptoms 
following treatment for rectal or anal cancer. There is good evidence from previous 
studies showing that altered rectal sensation plays a part in dysfunction following 
anterior resection5,10,35,36,49. This altered sensitivity persists over time and may account 
for the lack of improvement in symptoms beyond one year post anterior resection10.  
 
Rectal hypersensitivity is likely to result from a combination of reduced rectal 
reservoir, and also altered compliance of the neorectum5. Rectal compliance is 
defined as “change in volume or cross-sectional area divided by the change in 
pressure”37. It cannot be measured using manometry alone; it has traditionally been 
assessed using a barostat38 but can also be measured using balloon distension of the 
rectum with concurrent pressure measurement29. Creation of a colonic pouch with 
side to end anastomosis at anterior resection leads to a temporary improvement in 
post-operative symptoms when compared with end to end anastomosis39 and this is 
believed to be partly due to better capacity and compliance39.  
 
Although altered reservoir and compliance may partly explain changes in sensitivity 
following anterior resection, these mechanisms cannot account for abnormalities 
following CRT alone. Similar findings of rectal hypersensitivity have been previously 
shown following CRT40. The pathophysiology behind the detrimental effect of 
radiotherapy on anorectal function is not fully understood41. Radiotherapy is known 
to induce fibrosis and scarring within the sphincters42. Reduced compliance is 
believed to be one of the main mechanisms by which radiotherapy alters anorectal 
function, causing rectal wall stiffness and poor distension with reduced capacity43. 
For patients who undergo CRT followed by anterior resection, the neoadjuvant 
radiotherapy can make their surgery more challenging due to fibrosis41. Patients 
undergoing both radiotherapy and surgery for rectal cancer have been shown to 
have significantly lower anal resting and squeeze pressures29,42 and one study of 13 
patients undergoing CRT alone, in the context of anal cancer, showed similar 
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findings44. However, in the current study no significant change in resting or squeeze 
pressures was seen following CRT. 
 
The results of this study showed that the majority of abnormalities seen on endoanal 
ultrasound were directly due to tumour, although these findings have to be 
interpreted in light of the fact that the assessor was aware of the patient’s clinical 
presentation. Female gender was identified as a risk factor for abnormal ultrasound 
post treatment. Although gender differences in endoanal ultrasound findings have 
been shown previously45, this specific finding has not previously been reported.  
 
The results from all three pre treatment questionnaires indicate that patients had 
good overall function prior to treatment, even though, for women particularly, many 
of the pre treatment manometry results were significantly different from the normal 
population. The small number of patients that completed the LARS questionnaire 
post treatment limited the ability to meet the stated aim of correlating LARS with 
manometry findings. With a larger cohort, the hypothesis that those with LARS have 
hypersensitivity and lower resting and squeeze pressures on HRAM than patients 
with no LARS could be tested. The results did suggest that there was an increase in 
the LARS score following treatment, but this did not reach significance. It would not 
be an unexpected finding, especially since most patients underwent testing only a 
short time following their treatment. Two studies have previously explored the 
relationship between LARS score and manometry results. The first of these included 
65 patients and demonstrated decreased resting anal sphincter pressures, decreased 
rectal volume tolerability and decreased rectal compliance in patients with major 
LARS compared with those with no/minor LARS5. A further study of 28 patients also 
found that resting anal pressure in those with major LARS was significantly lower 
than no LARS group, maximum squeeze pressure was also reduced46.  
 
Although outside of the remit of this study, one of the potential uses for HRAM will 
be in the assessment of patients who develop LARS following anterior resection. 
Investigation with HRAM including sensitivity testing and endoanal ultrasound, in 
individual patients, is an ideal tool for highlighting specific pathology, which may be 
amenable to therapy. Pelvic floor rehabilitation including biofeedback has been 
shown to be an effective treatment for LARS47. One Chinese study has used HRAM 
as a tool to assess the effectiveness of biofeedback as therapy for LARS48 but so far, 
no studies have used HRAM as a tool to guide choice of therapy for LARS. A further 
systematic review of the literature on the treatment of LARS concluded that current 
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treatment is based on weak evidence with low quality studies, and that well 
conducted multicentre randomised trials are urgently needed in this area18.  
 
The demographics of the cohort reflect those of the population of rectal cancer 
patients50. This study does, however, have several major limitations. Due to the 
exploratory nature of the study, it was conducted at a single centre. As the testing 
protocol was newly introduced into the department, many patients did not undergo 
testing at all relevant timepoints. This was partly because not all of the clinical staff 
were familiar with the protocol and patients were not referred at all time points 
when they should have been. It is also likely that some eligible patients were not 
referred at all. Particularly around the time of diagnosis, the management of the 
cancer itself may understandably have taken priority for clinicians and not allowed 
time for patients to attend for manometry prior to starting treatment, this problem 
would be likely to affect any study of this type. Not all patients attended their 
appointment as some were concerned about the nature of the tests and had not been 
given sufficient information. Due to the protocol being newly introduced, some 
patients had already undergone their treatment at this point and only underwent 
post treatment tests. The end date of the study was dictated by the constraints of the 
timeframe of the thesis and some patients had only undergone pre treatment testing 
at this point.  
  
The LARS, SMIS and CCCS questionnaires were unfortunately only completed by 
limited numbers of patients rather than the whole cohort. This was due to some 
confusion amongst physiology staff who were carrying out the testing about whether 
the new protocol included the questionnaires or not, as well as lack of familiarity 
with the LARS score which was newly introduced to the department.  
 
As a result of these difficulties, the cohort was heterogeneous, and made up of 
patients at different time points, undergoing different therapies. This led to small 
numbers in some of the patient groups, which raises the possibility of type II errors 
and also limited the analysis. It was not possible to carry out some analysis that 
would have been interesting, for example the effect of a defunctioning stoma on 
manometry results, about which little is known. No patients underwent CRT 
followed by LAR and then testing, so it was not possible to examine the cumulative 
effect of CRT and LAR. Assessors carrying out physiology testing were aware of the 
patient’s clinical history and whether they had undergone treatment or not, which 
may introduce unconscious bias into reporting of results. Testing post treatment was 
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carried out at varying lengths of time following treatment and this was not 
standardised in any way. As discussed in chapter 3, it is known that function 
following anterior resection is most troublesome during the initial 12-month period51 
and the results of post treatment testing may well have been different if carried out 
after the first year.  
 
This study has noted some interesting patterns with abnormalities identified both 
prior to and following treatment. Some of these are consistent with findings from the 
literature as outlined above. In order to examine in more detail, the effect of anterior 
resection specifically, patients would need to be tested prior to treatment, following 
neoadjuvant chemoradiotherapy and following anterior resection, after a suitable 
time period. These patients could also have their manometry and other test results 
correlated with their LARS score and specific symptoms including urgency. Patients 
with LARS could undergo biofeedback or retraining using HRAM as an assessment 
method for this. The aim of such a study would be to use HRAM specifically to 
better understand LARS and find potential targets for biofeedback therapy. HRAM is 
not widely or routinely used yet in the UK, and is only available at tertiary centres. 
At the current time, therefore, it would be difficult to introduce it as a routine part of 
care for rectal cancer patients and this limits the applicability of research in this area. 
However, patients who develop significant problems with LARS following anterior 
resection can be referred into tertiary centres to undergo assessment and treatment 
and HRAM results are easily presented in a format that is understandable to the 
team at the referring centre.  
 
Clinicians caring for patients with rectal cancer need to understand the potential 
impact that therapies can have on anorectal function and continue work to 
understand the pathophysiological mechanisms involved. Measures to limit and 
prevent dysfunction should be taken wherever possible, including tailoring of 
radiotherapy fields, careful surgery to limit nerve damage and minimising direct 
injury to sphincters. It remains to be seen how developments in rectal surgery, 
including transanal approaches, will impact functional outcomes in the future. Direct 
visualisation of the pelvic nerves may be improved but prolonged instrumentation 
may have unforeseen effects.  
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6.6 Conclusions 
 
HRAM is an ideal tool for the routine pre and post treatment assessment of sphincter 
function in patients with rectal cancer. This exploratory study has established the 
feasibility of this investigative technique for studying functional changes following 
treatment for rectal cancer. 
 
Patients undergoing treatment for rectal cancer have likely abnormalities on testing 
of functional anal canal length, HRAM, rectal sensitivity and endoanal ultrasound 
but correlation of these findings with symptoms is crucial and requires further study. 
Large-scale multicentre prospective studies, carefully designed to answer specific 
questions, are needed and these should incorporate HRAM both as a means of 
assessment and as a research tool to assess the effectiveness of interventions for 
LARS.  
 
HRAM has the potential to help us better understand functional changes following 
treatment for rectal cancer and how these functional changes are linked to the 
symptoms that patients experience, an understanding that could ultimately help to 
achieve the aim of preserving sphincter function during treatment for rectal cancer.  
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Chapter 7. Conclusions  
 
The assessment and management of rectal cancer is complex, requiring consideration 
of multiple interacting factors and coordinated care from several specialities. The 
range of available therapeutic options is broad, and expanding. Surgical techniques 
continue to evolve and these developments will require ongoing research to guide 
decision-making. Our selection of neoadjuvant therapy is dependent on the accuracy 
of the investigative tools we have available and currently remains an imperfect 
science.  
 
Oncological outcomes for rectal cancer are improving and, as a result, over the last 
few years there has been a clear shift in the paradigm of care. The focus is no longer 
necessarily on sphincter preservation, but on the preservation of acceptable anorectal 
function. This is an important factor in determining the long-term quality of life of 
survivors. This thesis therefore aimed to discover what determines the ability to 
preserve functioning sphincters during the management of low rectal cancer.  
 
The questionnaire study in chapter 3 has confirmed that our current management 
leads to morbidity for many patients. Low Anterior Resection Syndrome (LARS), 
with disordered bowel function, affects a considerable proportion of patients in the 
UK following anterior resection, it is detrimental to quality of life and does not 
resolve with time. The risk factors identified for LARS in this study are neoadjuvant 
radiotherapy, female gender, younger age and defunctioning stoma. The assessment 
of functional outcomes must become a routine part of follow-up to ensure that we 
avoid doing a disservice to those who could benefit from treatment for LARS.  
 
There has been improvement in rectal cancer care but the next step forward will be 
tailored delivery of care for the individual, based on patient factors and tumour 
biology. Along with ensuring the best possible oncological outcome, personalisation 
of care should be a specific aim of the multi-disciplinary team. Response to 
neoadjuvant chemoradiotherapy is variable, and it is not currently possible to predict 
tumour response on an individual level. As shown in chapter 3, neoadjuvant 
radiotherapy is a risk factor for poor functional outcome. Tools to predict response to 
neoadjuvant therapy would rationalise its use, thereby improving functional 
outcomes for those patients who would avoid radiotherapy that would not be of 
benefit to them. This targeting of therapy will need reliable biomarkers, for use either 
individually or as part of a panel allowing stratification of patients.  
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Difficulties interpreting the effects of chemoradiotherapy on a tumour and its 
surrounding tissues have led to innovation in imaging techniques. Some of these, 
including diffusion weighted MRI (DWI), are functional imaging techniques, with 
the ability to go beyond assessing anatomy, to defining the metabolic characteristics 
of a tumour. It is likely that the use of such technology will continue to grow and 
become increasingly important in the initial planning of therapy and prediction of 
response to neoadjuvant therapy. The results of the imaging study in chapter 4 show 
that use of DWI is feasible and that measures derived from DWI have potential as 
biomarkers, not just to assess, but also to predict, response to neoadjuvant therapy. 
Following improved standardisation of techniques and reporting, combined with 
validation, these measurements could be incorporated in multi-disciplinary decision-
making. 
 
The use of molecular biomarkers will be one of the most important developments 
across cancer care in the coming years. The laboratory study in chapter 5 has 
demonstrated that analysis of microRNA expression from pre-treatment rectal 
biopsies is feasible and that the expression of microRNAs potentially differs between 
responders and non-responders to neoadjuvant therapy. MicroRNA targets therefore 
have potential as predictive biomarkers for response to neoadjuvant therapy in rectal 
cancer. The study identified three possible microRNA biomarkers. Following further 
validation studies, these could in the future be combined with other molecular or 
imaging biomarkers. Breast cancer patients already benefit from a panel of 
biomarkers used to assess the likely response of their tumour to chemotherapy and a 
similar stratification for neoadjuvant therapy in rectal cancer would benefit patients.  
 
With the focus on preservation of anorectal function, the option of organ 
preservation for selected patients with rectal cancer, with avoidance of surgery 
altogether, is being increasingly explored and studied. Questions remain about the 
long-term oncological outcomes and the most appropriate surveillance schedule, and 
anterior resection remains the current gold standard. We need to understand more 
about the impact of chemoradiotherapy, when used in isolation, on sphincter 
physiology and functional outcomes in order to better counsel and advise patients 
about the options available.  
 
The findings in Chapter 6 outline the potential of high-resolution anorectal 
manometry (HRAM) to further our understanding of the factors underlying 
dysfunction following chemoradiotherapy and anterior resection. This exploratory 
 
 
 
 269 
study has established the feasibility of this investigative technique for studying 
functional changes following treatment for rectal cancer. Studies utilising HRAM 
would also have the potential to help us understand how functional changes are 
linked to the symptoms that patients’ experience, an understanding that could 
ultimately help to achieve the aim of preserving sphincter function during treatment 
for rectal cancer. HRAM is an ideal tool for the routine pre and post treatment 
assessment of sphincter function in patients with rectal cancer and is also ideal for 
use as a research tool to assess the effectiveness of interventions for LARS.  
 
Variations in the management of rectal cancer across the UK reflect gaps in our 
knowledge about the ‘best’ care for each patient; further research is undoubtedly 
needed in many areas. Better understanding of decision making by individual 
clinicians, and at team level, is one challenging but important aspect of this research. 
An ideal way to study the many facets of rectal cancer care would be a large 
prospective multicentre cohort study of patients with rectal cancer. Following their 
course from diagnosis through investigation and treatment, with appropriate 
functional, imaging, laboratory and manometry results would allow improved 
interpretation of complex interacting factors, decision-making, outcomes following 
treatment for rectal cancer as well as a more sophisticated understanding of the 
factors which affect these outcomes.  
 
It remains the responsibility of individual clinicians to continue to challenge the lack 
of understanding, to ask questions and to demand better evidence in order to ensure 
that we continue to improve outcomes for all rectal cancer patients.  
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Appendix 1. Invitation Letter  
                                      
 
 
 
 
 
 
 
 
 
 
INVITATION LETTER 
 
Anterior resection syndrome following sphincter-preserving surgery 
 
Chief Investigator: Mr Mohamed Thaha 
 
Ethics Committee Reference: 14/EM/0117 
 
Dear Sir or Madam 
 
We would like to invite you to participate in a research study. This letter has been sent 
to you by your surgical team who are working with us on this study, they have access 
to your name and address but they have not sent any of these details to us. If you 
decide that you do not want to participate in the study simply do not return the 
enclosed questionnaire.  
 
This study is looking at symptoms and quality of life following surgery to remove 
part of the bowel. Taking part in the study will involve completing one questionnaire 
and returning it to us in a pre-paid envelope.  
 
We have enclosed a Participant Information Sheet which explains why we are doing 
this study, why you have been invited and other details about the study.  
 
If you have any questions then please get in touch with us via the contact details 
above. Thank you for considering taking part in our study. 
 
 
Yours sincerely 
 
 
Kathryn Lynes 
Colorectal Research Fellow  
National Centre for Bowel Research and Surgical Innovation 
 
 
 
 271 
Appendix 2. Participant Information Sheet       
 
 
 
 
 
 
 
 
INFORMATION SHEET 
 
 
Project: Anterior resection syndrome following sphincter-preserving surgery 
 
We would like to invite you to take part in a research study. Before you make your decision 
you need to understand why the research is being done and what it would involve. Please take 
time to read the following information carefully. Talk to others about the study if you wish.  
 
What is the purpose of the study? 
After an operation to all, or part of, the rectum (the lower part of the large bowel), patients 
can sometimes have difficulties controlling their bowels. This can include symptoms such as 
urgency (uncontrollable urge to open your bowels) and faecal incontinence (inability to hold 
in stool resulting in soiling).  Currently there is a lack of understanding of the exact cause of 
these symptoms.  
Gaining information from patients who have already had these operations will allow us to 
further understand how many patients develop these problems, the impact they have on 
quality of life and how they vary according to different risk factors. This improved 
understanding will allow us to better predict when patients will experience these problems 
and help us tailor their treatment accordingly. 
 
Why have I been invited?  
You have been invited as your surgical team have identified that you have previously had 
surgery to remove all, or part of, your rectum.  
 
Do I have to take part? 
It is up to you whether you want to take part or not. If you do not want to be involved that is 
not a problem and will not affect any of your care in the future.  
 
What will participation in the research involve in practical terms? 
If you agree to participate in the study you will need to complete a questionnaire, which will 
take around 30 minutes. A pre-paid envelope is included for you to return the questionnaire to 
 
Miss Kathryn Lynes MBBS MSc MRCS 
Colorectal Research Fellow 
T: 020 7882 2638 
E-mail: k.lynes@qmul.ac.uk 
 
Blizard Institute 
Centre for Digestive Diseases 
Barts and The London School of 
Medicine and Dentistry 
 
National Centre for Bowel 
Research and Surgical 
Innovation 
1st Floor, Abernethy Building 
2 Newark Street 
London E1 2AT 
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us. If you complete and return the questionnaire, we will assume this means you have given 
us your consent to take part in the study. 
 
What are the possible benefits of taking part?  
You will not gain any personal benefit from being involved in the study.  However, the 
information we get from this study will hopefully help improve the understanding of patients 
with these problems by determining how many patients are affected. The results will also help 
us to understand why some patients develop these symptoms and the impact that they can 
have on quality of life. This will help develop and test new treatments for these problems.  
 
How will your confidentiality be protected? 
This letter has been sent to you by your surgical team who are working with us to carry out 
this study. They have not provided us with your name, address or any other personal or 
medical information about you. The information from the questionnaire will be stored 
securely and confidentially. Your name will not be used or identified in the analysis of the 
information generated by this study.  
 
How can I find out the results of the study?  
If you would like to find out the results of the study then please contact us via the details below 
and we will be happy to provide a summary once the study is completed.  
 
What happens if you are worried? 
If answering the questionnaire makes you concerned about your symptoms then you should 
contact your medical team to discuss them. This may be your GP, your Colorectal Surgeon or 
your Colorectal Specialist Nurse.  
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (see contact details above).  
 
What happens if there is a problem? 
We understand that some of the questions are personal in nature and ask about private 
information on your bowel habit and daily activities. The questions are important in order to 
find out about symptoms that patients experience. If you do not feel comfortable to answer 
the questions, either leave them blank or do not complete the questionnaire.  
If you wish to complain or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms should be available to you. Please contact the Patient Advisory 
Liaison Service (PALS) if you have any concerns regarding the care you have received, or as 
an initial point of contact if you have a complaint.  You can find your nearest PALS office on 
the NHS Choices website at www.nhs.uk.  
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. 
Derby Research Ethics Committee has reviewed this study.  
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Appendix 3. Study Questionnaire 
 
 
 
 
 
 
   
 
QUESTIONNAIRE 
 
Anterior resection syndrome following sphincter-preserving surgery 
 
 
This questionnaire has three parts.  
 
The first part asks details about your treatment, as background information to confirm 
for us that this study applies to you and help us interpret the results.  
 
The second part asks about bowel function.  
 
The third part asks general questions about your health and daily activities.  
 
We would be grateful if you could complete all parts of the questionnaire but if there 
are any questions you do not feel happy to answer, then please leave them blank. 
There are no ‘right’ or ‘wrong’ answers. The information that you provide will remain 
strictly confidential.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blizard Institute 
Centre for Digestive Diseases 
Barts and The London School of 
Medicine and Dentistry 
 
National Centre for Bowel 
Research and Surgical 
Innovation 
1st Floor, Abernethy Building 
2 Newark Street 
London E1 2AT 
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Part 1 Background Information 
What is your gender:     Male   □   Female □     
Please provide your age: ____________ 
 
Have you had surgery to remove all or part of your lower large bowel (rectum)?   
Yes  □    No □     
If so, when was this surgery carried out   ______________________  
 
If you answered no, and you have not had this surgery then please do not complete the 
questionnaire as it does not apply to you, we apologise that you have been sent this 
questionnaire in error. 
 
At the time of your surgery did you have a stoma created?  Yes  □  No □     
If you answered yes, has this now been closed/reversed?   Yes  □  No □     
If your stoma has been closed/reversed, when was this done ______________ 
 
 
Following your original surgery have you had any other further operation (apart from 
stoma closure/reversal)   Yes  □  No □     
If you answered yes, please provide details ___________________________ 
                             
          _____________________________________________________________ 
 
 
Other than monitoring your progress, are you still having any treatment for your 
cancer?    
Yes  □  No □     
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If you answered yes, please provide details  _____________________________ 
         
     ________________________________________________________________ 
 
Prior to surgery did you have treatment with:  
 Chemotherapy: Yes  □  No □     
 Radiotherapy:   Yes  □  No □     
If you had radiotherapy, how many days was this for?    __________________ 
 
 
After your surgery did you have treatment with: 
 
Chemotherapy: Yes  □  No □     
Radiotherapy:   Yes  □  No □     
 
Have you ever had radiotherapy for any other reason?  Yes  □  No □     
If you answered yes, please provide details  _________________________ 
 
            _____________________________________________________________ 
 
 
How was your surgery carried out?  
Laparoscopically (keyhole surgery)  □   
Open surgery  □   
Planned laparoscopically, but converted to open during the operation  □ 
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Part 2 Bowel Function Questionnaire  
 
Please tick only one box for each question. It may be difficult to select only one answer, as we 
know that for some patients symptoms vary from day to day. We would kindly ask you to choose 
one answer which best describes your daily life. If you have recently had an infection affecting 
your bowel function, please do not take this into account and focus on answering questions to 
reflect your usual daily bowel function.  
 
1: Do you ever have occasions when you cannot control your flatus (wind)? 
□  No, never 
□  Yes, less than once per week 
□  Yes, at least once per week  
 
2: Do you ever have any accidental leakage of liquid stool? 
□  No, never 
□  Yes, less than once per week 
□  Yes, at least once per week  
 
3: How often do you open your bowels? 
□  More than 7 times per day (24 hours) 
□  4-7 times per day (24 hours) 
□  1-3 times per day (24 hours) 
□  Less than once per day (24 hours) 
 
4: Do you ever have to open your bowels again within one hour of the last bowel opening? 
□  No, never 
□  Yes, less than once per week 
□  Yes, at least once per week  
 
5: Do you ever have such a strong urge to open your bowels that you have to rush to the toilet?  
□  No, never 
□  Yes, less than once per week 
□  Yes, at least once per week 
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Part 3 Questions about your health 
 
Please answer all of the questions by circling the number that best applies to you. 
 
  Not at 
All 
 
A  
Little 
Quite  
a Bit 
Very 
Much 
1.  Do you have any trouble doing strenuous 
activities, like carrying a heavy shopping 
bag or suitcase? 
 
1 2 3 4 
2. Do you have any trouble taking a long 
walk? 
 
1 2 3 4 
3. Do you have any trouble taking a short 
walk outside of the house? 
 
1 2 3 4 
4. Do you need to stay in bed or a chair 
during the day? 
 
1 2 3 4 
5. Do you need help with eating, dressing, 
washing yourself or using the toilet? 
 
1 2 3 4 
 
 
During the past week: 
Not at 
All 
 
A  
Little 
Quite  
a Bit 
Very 
Much 
6. Were you limited in doing either your 
work or other daily activities? 
 
1 2 3 4 
7. Were you limited in pursuing your 
hobbies or other leisure time activities? 
 
1 2 3 4 
8. Were you short of breath? 
 
1 2 3 4 
9. Have you had pain? 
 
1 2 3 4 
10. Did you need to rest? 
 
1 2 3 4 
11. Have you had trouble sleeping? 
 
1 2 3 4 
12. Have you felt weak? 
 
1 2 3 4 
13. Have you lacked appetite? 
 
1 2 3 4 
14. Have you felt nauseated? 
 
1 2 3 4 
15. Have you vomited? 
 
1 2 3 4 
16. Have you been constipated?       1        2          3  4 
 
 
 
 278 
 
During the past week: 
Not at 
All 
 
A  
Little 
Quite  
a Bit 
Very 
Much 
17. Have you had diarrhea? 
 
1 2 3 4 
18. Were you tired? 
 
1 2 3 4 
19. Did pain interfere with your daily 
activities? 
 
1 2 3 4 
20. Have you had difficulty in 
concentrating on things like reading a 
newspaper or watching television? 
 
1 2 3 4 
21.. Did you feel tense? 
 
1 2 3 4 
22. Did you worry? 
 
1 2 3 4 
23. Did you feel irritable? 
 
1 2 3 4 
24. Did you feel depressed? 
 
1 2 3 4 
25. Have you had difficulty remembering 
things? 
 
1 2 3 4 
26. Has your physical condition or 
medical treatment interfered with your 
family life? 
 
1 2 3 4 
27. Has your physical condition or 
medical treatment interfered with your 
social activities? 
 
1 2 3 4 
28. Has your physical condition or 
medical treatment caused you 
financial difficulties? 
 
1 2 3 4 
For the following questions please circle the number between 1 and 7 that best 
applies to you 
 
29. How would you rate your overall health during the past week? 
 
 1 2 3 4 5 6 7 
  Very poor    Excellent 
 
30. How would you rate your overall quality of life during the past week? 
 
 1 2 3 4 5 6 7 
  Very poor    Excellent 
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Appendix 4. Ethics Approval Letter 
 
 
 
N
RES Committee East Midlands - 
Derby 
Research Ethics Office 
The Old Chapel Royal Standard Place 
Nottingham NG1 6FS 
 
Telephone: 0115 8839390 
07 March 2014 
 
Mr Mohamed Thaha 
Senior Lecturer & Honorary Consultant in 
Colorectal Surgery Queen Mary, University 
of London 
National Centre for Bowel Research & Surgical Innovation 
1st Floor, Abernethy Building, 2 Newark Street 
London 
E1 2AT 
 
Dear Mr Thaha 
 
Study title: Anterior resection syndrome following 
sphincter-preserving surgery 
REC reference: 14/EM/0117 
IRAS project ID: 143889 
 
The Proportionate Review Sub-committee of the NRES Committee East Midlands - 
Derby reviewed the above application on 06 March 2014. 
 
We plan to publish your research summary wording for the above study on the NRES 
website, together with your contact details, unless you expressly withhold permission to 
do so. 
Publication will be no earlier than three months from the date of this favourable opinion 
letter. Should you wish to provide a substitute contact point, require further information, 
or wish to withhold permission to publish, please contact the REC Manager Ms Tracy 
Leavesley, NRESCommittee.EastMidlands-Derby@nhs.net. 
 
Ethical opinion 
 
• The sub-committee commented this is completely anonymised research. 
 
• The sub-committee noted this is a study looking at the experiences of patients who 
undergo rectal resection following bowel cancer surgery. 
 
• The sub-committee commented they view this as important research and expressed 
they are pleased it is now being undertaken. The sub-committee also agreed the 
research is valuable because it could help flag up problems participants are 
having following resection surgery and encourage them to speak to their GP. 
• The sub-committee commented the study is essentially sound. 
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• The sub-committee commented the study is questionnaire based comprising of a 
series of questions regarding patients experiences post rectal resection. 
 
• The sub-committee commented the target sample for this study is eight hundred 
people, although it is not stated how many people they expect to respond. 
 
• The sub-committee highlighted the lack of consent form but also commented that 
consent is implied by completion and return of the questionnaire. The sub-
committee did however comment that some participants may be confused by this. 
 
On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the 
above research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see “Conditions of the favourable opinion” below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior 
to the start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites (“participant identification centre”), guidance should 
be sought from the R&D office on the information it requires to give permission for this 
activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees). 
 
 
 
 281 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g when submitting an amendment. We will audit the registration details as part of the 
annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but for 
non clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS. 
 
1. The sub-committee would like a sentence adding to the Participant Information Sheet clarifying 
that consent is implied by completion and return of the questionnaire, to avoid any ambiguity or 
confusion. 
2. The sub-committee would like clarification on the number of people the researcher envisages 
returning the questionnaires. 
 
You should notify the REC in writing once all conditions have been met (except for site 
approvals from host organisations) and provide copies of any revised documentation with 
updated version numbers. The REC will acknowledge receipt and provide a final list of the 
approved documentation for the study, which can be made available to host organisations 
to facilitate their permission for the study. Failure to provide the final versions to the REC 
may cause delay in obtaining permissions. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The documents reviewed and approved were: 
 
Document Version Date 
Covering Letter Signed by Kathryn 
Lynes 
24 February 2014 
Evidence of insurance or indemnity Arthur J Gallagher 29 July 2013 
Investigator CV Mohamed A Thaha 13 December 2013 
Investigator CV Kathryn Lynes 17 December 2013 
Letter from Sponsor Signed by Gerry 
Leonard 
14 February 2014 
Letter of invitation to participant 1 02 December 2013 
Participant Information Sheet 1 02 December 2013 
Protocol 1 02 December 2013 
Questionnaire 1 02 December 2013 
REC application 143889/570415/1/908 21 February 2014 
Referees or other scientific critique report Signed by Bijendra 
Patel 
07 February 2014 
Referees or other scientific critique report Mr Shafi Ahmed 09 February 2014 
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Membership of the Proportionate Review Sub-Committee 
 
The members of the Sub-Committee who took part in the review are listed on the 
attached sheet. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure. If you wish to make 
your views known please use the feedback form available on the website. 
information is available at National Research Ethics Service website > After Review 
 
14/EM/0117 Please quote this number on all correspondence 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
Mr Peter Korczak (Chair) 
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Appendix 5. St Mark’s Incontinence Score  
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Appendix 6. Cleveland Clinic Constipation Score 
 
 
 
 
 
